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ABSTRACT 
Recent advances in the derivation of functional cells from pluripotent stem cells have 
raised hope for cell therapy to treat liver ailments. They have enhanced the prospects of 
developing reliable in vitro models for liver diseases and drug toxicity screening. A 
differentiation protocol mimicking key signaling cues of embryonic development was 
developed to direct stem cells (ES) towards the hepatic fate and express key hepatic 
markers and functions. While these results are encouraging, most directed differentiations 
from stem cells to the target cell types are hampered by lack of functional maturity, cell 
heterogeneity and low cell yields limiting their translation to the clinic. These cells are 
therefore refereed to hepatocyte-like cells (HLCs). 
An integrative strategy was employed including both experimental techniques as well 
as a systems-based analysis towards enhancing the product quality and yields of HLCs. 
Functional maturity was enhanced by initiating three dimensional spheroid formation 
upon differentiation. Enrichment of hepatic cells using selective medium conditions was 
performed to obtain higher fraction of cells with the desired properties. Cell expansion 
was incorporated during differentiation to improve cell yields. Several additional 
strategies have been used to increase hepatocyte maturity in literature including co-
culture and transfection with transcription factors. These methods including ours have 
shown improvement, however a universal gap to maturation is still present when 
compared to primary hepatocytes. 
Comparison of transcriptome data of differentiation to embryonic liver development 
can elucidate the genetic roadblocks preventing ES cells from reaching the functional 
maturity of their tissue counterparts. Transcriptome data was compiled from various 
depositories for mouse fetal liver development (from E8.5 to post-natal). Transcriptome 
data was obtained during the time course of our human hepatic differentiation protocol 
and was augmented with human in vitro hepatic differentiation data in the public 
depository. Interestingly, majority of the HLCs are similar irrespective of the cell source 
and protocol. The entire cohort of HLCs clustered separately from the primary 
hepatocytes and adult liver indicating an inherent roadblock to maturation. The 
transcriptome data of human ES hepatic differentiations was then integrated with mouse 
liver development using a unique approach. This allowed us to identify the corresponding 
development stage at which the in vitro stem cell differentiation is blocked. The analysis 
uncovered a pivotal gene set with contrasting profiles in ES differentiation and mouse 
liver development that merit combinatorial genetic intervention to enhance maturation of 
ES derived hepatocytes. Thus, one can envision the availability of stem cell based liver 
therapies in the not so distant future. 
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1. INTRODUCTION 
 Introduction  1.1
The liver is the largest internal organ in an adult organism. It performs many important 
functions that sustain the organism’s vitality. Liver metabolizes nutrients from ingested 
food and regulates glucose levels by converting excess glucose to glycogen for storage 
and releasing it when the blood glucose level is low. It detoxifies xenobiotics and harmful 
metabolites, and synthesizes many proteins in the blood [7]. Most of these functions are 
provided by the parenchymal cell type, hepatocytes, that comprise approximately 70% of 
the adult liver mass.  
Liver failure may arise from many causes, including cirrhosis, viral infections and drug 
overdoses.  Typically, the liver has a tremendous regenerative capacity to repair itself.  
After partial hepatectomy to remove two-thirds of the liver surgically, it is capable of 
regaining its original mass over time. However, liver disorders can compromise its 
inherent regenerative capacity and result in complete liver failure leading to death.  
Although treatment of the symptoms can alleviate the severity of liver failure, organ 
transplantation is the only curative treatment. However, a severe shortage of donors has 
limited the access of liver transplants for many patients. As of 2012, there are 
approximately 17,000 people on the waitlist for liver transplantation in the United States 
alone, while only half the number of transplantations were performed annually because of 
the shortage of donor organs (United Network for Organ Sharing: 
http://optn.transplant.hrsa.gov ).      
Extracorporeal liver devices have been explored as a treatment to sustain patients until 
successful liver regeneration, or until a donor organ becomes available. These 
extracorporeal devices comprise of hepatocytes from a variety of cell source (porcine, 
human, etc.) as well as mechanical components to provide temporary assistance [8].  The 
mechanical components of the device employ filtration, adsorption or dialysis to remove 
small molecular weight toxic metabolites from the patient’s blood, while hepatic cells 
provide the bio-transformative and biosynthetic functions [8,9]. Other approaches of liver 
failure treatments include transplantation of dissociated hepatocytes from organs and 
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implantation of tissue engineered liver analogues to augment liver’s regenerative capacity 
for liver recovery [10-12].  
For applications involving liver cells such as extracorporeal devices, cell transplantation 
and tissue engineering, primary human hepatocytes have been the preferred cell source 
because of its low risk of immunogenicity. The use of isolated liver cells can potentially 
expand the pool of donor organs, as even organs unsuitable for transplantation may be 
suitable for use in hepatocytes transplant.  However, difficulties in expanding and 
maintaining primary hepatocytes in culture remain a major hurdle in this field. Even with 
expanded pools of donor organs as the source of hepatocytes, the need still exceeds the 
availability of hepatocytes. Furthermore, functional capabilities decrease rapidly during 
in vitro culture [10].  In addition to maintaining our desired cell type, we must also 
address the need for large quantities of primary cells are needed for the treatment of even 
a single patient.  
Hepatocytes isolated from other species, primarily porcine, may provide an alternative 
source, however, these cells also suffer from rapid decrease of functional activities when 
cultured in vitro similar to primary human hepatocytes.  Moreover, the differences in 
their drug metabolism and other hepatic functions with human hepatocytes, along with 
potential immunogenic concerns, render these xenogeneic hepatocytes less than desirable 
compared to human sources [9]. 
For future medical applications of liver cells, including cell therapy and extracorporeal 
liver assist devices, in vitro cultivation is most likely to be employed to expand the 
supply of human cells. These expanded cell population can then be guided to differentiate 
to the desired cell type for specific applications. In the past few years, stem cell research 
has made significant advances; stem cells and progenitors cells can now be isolated from 
various sources, and expanded and differentiated towards the liver lineage.  This has 
brightened the prospect of generating large numbers of functional hepatocytes for 
applications in hepatic cell transplantation, extracorporeal liver-assist devices and liver 
tissue engineering.   
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 Research Objectives 1.2
The aim of this study is to develop a platform for the robust generation of stem cell 
derived hepatocytes for clinical applications. The key objectives towards this goal are: 
 
Objective 1: To improve the process technology for stem cell differentiations to 
hepatocytes, focusing on increasing cell yields and homogeneity to enable clinical 
transition 
 
Objective 2: To perform systems-based informatics analysis of transcriptome data, 
comparing stem cell differentiations across the state of the art with embryonic liver 
development to elucidate universal roadblocks in hepatic differentiation. 
 
 Scope of Thesis 1.3
 
A detailed literature review is presented in Chapter 2 adapted from published review 
articles [5,6,13Raju, 2013 #21] 
The first part consists of an introduction to stem cells and a description of their clinical 
applications. A detailed description of in vivo embryonic liver development is provided 
followed by different strategies used in generating hepatocyte-like cells. The last part 
focuses on how the knowledge of conventional bioprocess development for protein 
production can be adapted for translation of stem cell research into a robust bioprocess. 
This knowhow will be essential to develop strategies for stem cell processes to satisfy 
clinical demands in the near future. 
Chapter 3 contains information about the materials and methods used in this study. 
Chapter 4 describes how product yields can be improved by utilizing endodermal cell 
expansion, where the product refers to stem cell derived hepatocytes. Chapter 5 focuses 
on improving product quality through increased cell homogeneity using surface marker 
and selective medium-based techniques. 
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Chapter 6 and 7 represent a comprehensive systems analysis of in vitro differentiation 
and in vivo liver developments. Details on sample collection, data integration across 
platforms and species, analysis for identification of genes that are responsible for the 
universal gap to maturation and their regulators are included. Finally, in Chapter 8, a 
summary of findings and their relevance is presented, and potential topics for future 
investigation are discussed. 
2. BACKGROUND 
 Introduction to Stem Cells 2.1
Stem cells have the ability to propagate in a self-renewing manner, while possessing the 
potential to differentiate into more specialized cell types in response to molecular cues 
[14,15]. These special intrinsic characteristics have engendered much interest in using 
them not only for clinical applications such as regenerative therapy but also for 
facilitating research by providing better in vitro models of diseases for developing novel 
small molecules of biologics drugs, and drug toxicity testing. 
 The stem cell nomenclature is often derived from the developmental stage at which they 
are sampled or from the tissue from which they are isolated. Embryonic stem cells 
(ESCs) are derived from a specific stage of the developing mammalian embryo [14]. 
These cells have the potential to differentiate into all three germ layers. Adult stem cells, 
on the other hand, are derived from post-natal organisms, and are often sub-classified on 
the basis of the tissue of isolation. These cells are believed to be responsible for tissue 
homeostasis or repair/regeneration following an injury, and have been found in many 
tissues such as bone marrow [16], digestive tract [17], heart [18] and kidney [19] amongst 
others. Hematopoietic stem cells (HSCs) continue to be the best characterized and most 
clinically relevant adult stem cells to this date [20]. These latter cells are able to 
differentiate into a variety of specialized hematopoietic cells such as lymphocytes, nature 
killer cells, and megakaryocytes [21]. Notably, hematopoietic stem cells do not represent 
the only adult stem cell type that has been isolated from the bone marrow. Mesenchymal 
stem cells (MSCs), endothelial progenitor cells and other types of progenitor cells also 
have been isolated. Moreover, multiple neural precursor cells have been isolated from the 
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adult nervous systems, such as neural stem cells, neuronal progenitor and glial progenitor 
cells [22].  
Stem cells originated from different sources have vastly different properties, the most 
fundamental of which being the ability to differentiate into various types of specialized 
cells. Particularly, embryonic stem cells, given their ability to differentiate into cell types 
characteristic of all three germ layers, namely, mesoderm, endoderm and endoderm, are 
pluripotent [14],Martin [15] as seen in Figure 2-1.  
 
Figure 2-1: Developmental stages in the mouse embryo. The development of the 
different layers from the inner cell mass  (ICM) of the early blastocyst and the 
subsequent formation of the pluripotent primitive ectoderm (PrEct) is seen The 
PrEct contains pluripotent cells that differentiate to all three germ layers  [23].  
 
 Unique properties of stem cells 2.2
 
2.2.1 Self-renewal 
Stem cells are not prone to cellular aging like somatic cells after a certain number of cell 
divisions (Hayflick limit). This phenomenon is due to the presence of the enzyme 
telomerase, which prevents the shortening of the telomeres with cell division. The self-
renewal potential of embryonic stem cells derived from the blastocyst is different from 
that of adult stem cells derived from adult tissues. Understanding the reasons for this 
behavior of the respective stem cells and the factors regulating this process is necessary 
when expanding large numbers of undifferentiated cells for long term clinical 
applications [23] 
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2.2.2 Potency 
Potency is defined by the ability of the stem cells to differentiate towards specific cell 
lineages. A pluripotent cell can generate all the three germ layers: the ectoderm, 
mesoderm and endoderm while a multipotent cell can differentiate to more restricted cell 
lineages. Similarly, a unipotent cell, in spite of its self-renewal capacity, can differentiate 
into only one specific cell type. A typical example of pluripotent cells are embryonic 
stem cells. Adult stem cells are defined as multipotent as they can differentiate to organ 
specific cell types like neural stem cells or hematopoietic cells. Unipotent cells reside in 
adult tissues, undergo self-renewal and differentiate into a specific cell type during injury 
or wear and tear. Understanding the control mechanisms that maintain these different 
types of stem cells in a proliferative yet undifferentiated state are critical especially when 
the large scale expansion of these cells is desired for clinical trials. 
Stem cells can remain uncommitted to any lineage for long periods of time. Several 
transcription factors play an important role in maintaining the undifferentiated state of a 
stem cell along with chromatin-modifying enzymes, regulatory RNA molecules, and 
signal-transduction pathways [3]. The most common TF’s implicated in this role are the 
POU-domain transcription factor Oct4, the homeodomain transcription factor Nanog and 
the high mobility group protein Sox2 [23].These TF’s enhance their own expression by 
binding to their promoters via auto-regulatory loops. They maintain pluripotency by 
activating related genes involved as well as silencing the genes that promote 
differentiation. Gene silencing occurs with the recruitment of Polycomb group proteins 
which induce epigenetic modifications such as histone methylation that condense the 
chromatin structure making it inaccessible for modifications [3] as seen in  
Stem cells can proliferate for extended periods of time but when provided with the right 
cues they can differentiate into specific cell lineages. The Polycomb machinery is 
accordingly modified and cell lineage specific genes are activated while the remaining 
genes are silenced. It is still unclear how these Polycomb group proteins are recruited and 
how they regulate the cells transformation from a pluripotent state to a differentiated 
state. 
  23 
 
 
 Stem Cell Applications 2.3
2.3.1 Stem Cells in Regenerative Therapy  
 
As briefly discussed above, the properties of human embryonic stem cells (ESCs) have 
allowed their use in various clinical applications such as regenerative therapy and 
transplantation [14]. Their potential is being evaluated through clinical trials to treat 
diseases in which the function of impaired tissues or organs can be restored by the 
replenishment of desired cell types. The first clinical trial involving human embryonic 
stem cells sanctioned by the US FDA in 2009 used a 42-day long differentiation protocol 
to obtain oligodendrocyte progenitor cells (OPCs) [24]. These human ESC-derived 
OPCs, which were developed by Geron Corporation for the treatment of spinal cord 
injury, were found to be 95% positive for oligodendroglial markers such as RIP and GalC 
[24,25]. In another clinical trial, human ESC-derived retinal pigment epithelium (RPE) 
cells were evaluated for the treatment of Stargardts’s macular dystrophy (SMD) and Age-
 
Figure 2-2: Circuit for maintaining pluripotency of ES cells  [3] 
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related Macular Degeneration (AMD) based on the long term rescue observed in 
preclinical studies [26-29] 
Embryonic stem cells give rise to teratomas consisting of cell types of all three germ 
layers in immunocompromised mice [30]. The potential of teratoma formation poses risk 
when differentiated cells derived from hESCs are used clinically. Therefore, the presence 
of even a small quantity of undifferentiated cells in an hESC transplant is a cause for 
great concern as exemplified by Geron’s Phase I clinical trial application to the FDA in 
2010 (http://cell-therapies.geron.com/grnopc1). A very robust differentiation protocol 
with a strong quality control and quality assurance procedures must be present to assure 
the absence of hESCs in the final therapeutic cell dose. Notably, since the final product 
consists of live cells and thus cannot be sterilized, ideally all manufacturing operations 
are conducted in a closed system to minimize, as much as possible, the risk of 
contaminations with infectious agents with all primary raw materials also being subjected 
to extensive tests to ensure the absence of infectious agents. In contrast, the use of 
mesenchymal stem cells (MSCs) generates a lower safety concern on the tumorigenic 
potential given their much more limited differentiation properties and the years of 
practice of bone marrow transplantation. As a result, the therapeutic potential of MSCs is 
currently explored through various clinical trial, comprising Phase I, Phase II, and Phase 
III trials,  by several companies including Mesoblast, Angioblast, TCA Cellular Therapy 
or Osiris (http://www.mesoblast.com/clinical-trials/overview), 
(http://www.tcacellulartherapy.com/fda _clinical_trials.html), 
(http://www.osiris.com/clinical.php).  Notably, the differentiation potential of MSCs is 
not limited to the mesodermal lineage since these cells can also differentiate into 
neuroectodermic and endodermic lineages [31-33]. Importantly, MSCs can be readily 
expanded in vitro, thus facilitating their industrial scale manufacturing [34]. Given their 
immune privilege status, MSCs are used allogeneically in clinical trials for a large variety 
of indications comprising myocardial and limb ischemia [35], myocardial infarction [36], 
spinal cord injury [37], Crohn’s disease [38], and bone marrow regeneration [39],[40]. 
2.3.2 Liver support systems 
 
  25 
An extracorporeal liver support device may be solely mechanical relying on filtration or 
adsorption mechanisms to remove toxins in the blood, or a cell-based device designed to 
perform bio-transformative and homeostasis sustaining functions [9].  A cell based 
extracorporeal liver support, or bio-artificial liver (BAL) aims to not only remove toxic 
substances, but also carry out bio-transformative and homeostasis maintaining functions.  
Depending on the membrane employed and the flux across the membrane, the device 
may also provide different levels of other excretory and synthetic liver functions, such as 
urea and albumin synthesis. Some BALs are used in conjunction with an adsorption 
column (charcoal or ion exchanger). All employ an oxygenator to increase the oxygen 
content of the blood stream before it enters the cell chamber or bioreactor.  As the 
circulating blood is the only source of oxygen for cells in the bioreactor, such a practice 
is essential for sustaining cell viability and function.  All bioartificial liver devices 
invariably employ a membrane separating patient’s blood or plasma from cells in the 
device. Such membrane separation of blood stream and cell bioreactor minimizes the 
cross-over of patient’s complement into the cell chamber and the introduction of excreted 
molecules or lysis products from the cells to the patient.  All BAL devices employ hollow 
fiber bioreactors for use as the cell chamber. [41] 
The main challenges BAL devices face include the source and quantity of cells, and 
means to sustain their viability and functions. An adult liver consists of about 10
11
 
hepatocytes, or about 100 g gross wet weight of cells. Most BAL designs thus aim to 
supply about 10
10 
cells for each treatment of a few hours to over ten hours.  With the 
scarcity of human liver for hepatocyte isolation, researchers have resorted to continuous 
cell lines derived from human hepatomas such as HepG2-C3A or porcine primary 
hepatocytes as the source. The devices that underwent large-scale clinical trials include 
the HepatAssist [42] which used cryopreserved porcine hepatocytes as a cell source and 
the Extracorporeal Liver Assist Device (ELAD)[43] that employs the HepG2-C3A cell 
line. The advances over the last few decades in bioartificial liver support along with 
detailed review of the above devices has been presented in [8,9,44] 
Recently, the liver of immunocompromised Frg/Rag2 mutant mice with 
fumarylacetoacetate hydrolase deficiency (Fah), causing liver death upon withdrawal of 
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2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), have been used to 
achieve a 150-fold  proliferation of human hepatocytes. Both cryopreserved and primary 
sources of hepatocytes were able to engraft and exhibit Fah enzyme activity [45] Similar 
efforts are being made in generating mutant Fah-deficient pigs for large scale human 
hepatocyte proliferation which may prove to be a suitable for use in drug testing and in 
BAL devices [46]. 
The cells employed in BAL devices all lack the capability of further proliferation in 
culture and require surface attachment for survival and function.  To sustain their 
viability during BAL applications porcine hepatocytes have been cultivated on 
microcarriers (Cytodex 3), which are microbeads of about 200 µm diameter with external 
surface suitable for cell attachment.  Collagen gel entrapment of porcine hepatocytes has 
also been used to provide cell anchorage [47].  Another approach is to allow hepatocytes 
to self agglomerate and form spheroids by using either a stirred bioreactor or a rocking 
pan [48]. These spheroids develop organized and polarized structures resembling 
hepatocytes in liver tissue, and have a prolonged viability and functional activities [49].  
A design challenge in BAL is the very high loading cell density in the bioreactor. The 
bioreactor volume is constrained by the total volume in the blood circulating loop 
external to the patient.  The maximum size of the cell chamber is limited; to maximize 
the biological activities of the BAL, hepatocyte loading in the cell chamber should also 
be maximized while not causing oxygen diffusion limitations and decreased in cell 
viability.  The use of microcarriers or alginate beads in the cell chamber may result in the 
loss of cell loading volume. In the past two decades clinical trials have been performed 
with a number of BAL systems. Improvements in the patient status have been reported; 
however, overall clinical betterment has not been fully demonstrated.   
BAL technologies are critically dependent on reliable supply of hepatocytes with 
consistent quality and in sufficient quantities.  The hepatoma lines such as HepG2-C3A 
exhibit altered bio-transformative and metabolic profiles, such as cytochrome P450 and 
ureagenesis activities [9]. Even primary hepatocytes have substantially lower transcript 
levels of key phase I and phase II biotransformation enzymes when compared to adult 
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liver.  The lower activities, coupled with the limited amount of cells that can be loaded 
for patient treatment may have contributed to the elusiveness of better clinical outcomes. 
2.3.3 Disease model and drug metabolism testing 
 
Stem cell derived hepatocytes have great potential as in vitro models for studying liver 
disease mechanisms and drug metabolism. The primary tools to date for such studies are 
animals and primary human hepatocytes; the former are not ideal model for human 
disease while the latter is constrained by cell availability and representation of genetic 
diversity. As experimentation on animal models faces increasing ethical challenges, 
hepatocytes generated from cultured stem cells are becoming even more attractive. 
Furthermore, with iPSC and iHep, the investigation can be performed using derived 
hepatocytes of different genetic backgrounds.   
A notable example of a cell-based liver model is the replication of hepatitis C using 
hepatocyte-like cells derived from stem cells [50-53]. The model should facilitate the 
screening of inhibitors of HepC virus replication pathways. Given the influence of host 
genotypes on hepatitis C virus entry, assembly and replication, cell based models 
representing diverse genetic background will be a welcoming development.  Another 
example is the use of hepatocyte-like cells obtained from iPSCs derived from patients 
with familial hypercholesterolemia. These cells with a mutation in the low density 
lipoprotein receptor serve as a model of the deficiency in LDL-cholesterol uptake [54].  
Such in vitro applications as a liver analogue for disease studies and drug screenings 
require the reproduction of biological functions or even the structure. Like other in vitro 
applications the maturity of the derived hepatocytes will still need to be enhanced 
substantially. 
 Embryonic Liver Development- the guide for in vitro culture 2.4
processes 
In this section, we will describe the development of mouse liver, as an example of 
mammalian development, being cognizant that the development in mouse and man 
differs in certain aspects.  
In early embryo development, the blastocyst consists of an inner cell mass and an outer 
layer of trophoblast cells.  As the primitive blastocysts become polarized and exposed to 
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a number of signaling pathway cues, they will give rise to the inner cell mass [55,56]. 
During this developmental stage, embryonic stem cells can be isolated from the inner cell 
mass which can give rise to all three germ layers. The inner cell mass will further 
differentiate to two specialized cell type, hypoblast and epiblast cells [57]. Hypoblast 
cells will give rise to extraembryonic tissues, while epiblast cells will make up all the 
tissues in an adult by first differentiating to ectoderm and mesoendoderm [58].  During 
this time, the formation of the primitive streak will set in place the bilateral symmetry and 
anterior-posterior axis indicating the start of gastrulation [59]. This event marks the 
beginning of the delineation between the three germ layers, ectoderm, endoderm, and 
mesoderm, leading up to organogenesis shown in Figure 2-3 
The differentiation of the intermediate stage, mesoendoderm, is driven primarily by 
Nodal signaling, a member of the transforming growth factor (TGF- β ) family, as 
demonstrated in an explant model [60-62]. The Nodal protein acts as a morphogen; high 
levels promote endoderm formation and low levels promote mesoderm formation.  In the 
developing mouse embryo, NODAL is produced at the anterior region of the primitive 
streak where it can exert its effect through a number of downstream transcription factors, 
including FOXA2, SOX17, GATA4-6, MIXL1 and EOMESODERMIN [63]. The 
expression level of the genes regulated by these transcription factors delineates the 
difference between endoderm and mesoderm. The importance of Nodal signaling for 
endoderm commitment was demonstrated in multiple transplantation studies that showed 
ectopic regions expressing Nodal signaling can induce cells to express endoderm markers 
and differentiate further into endodermal derivatives [64,65].  
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The epithelial layer of endoderm, in close contact with a thick layer of mesenchymal cells 
called the septum transversum, will give rise to the digestive and respiratory organs, 
including the liver. The processes by which cells undergo a massive transformation into a 
multi-layered group of cells from the blastula are regulated by several signaling 
pathways. The most widely studied pathway, FGF signaling, causes cells to undergo an 
epithelial to mesenchymal (EMT) transition by decreasing the amount of cell-cell 
adhesion [66,67]. The decrease allows cells to expand and spread out to form new layers. 
The initial stage of gastrulation involves the invagination of the epithelium which results 
in the cell movement to subdivide the gut tube into foregut, midgut and hind gut regions. 
In the ventral region of foregut, the cardiogenic mesenchymal cells adjacent to the 
endoderm secrete several fibroblast growth factors (FGFs), in conjunction with bone 
morphogenic proteins (BMP)(also members of TGF-superfamily) produced by septum 
transversum mesenchyme (STM) cells, to induce hepatic specification [68-72]. Fast 
Figure 2-3: Delineation of Liver Development [4] 
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proliferating hepatoblasts then emerge and commit this segment of endoderm to develop 
into the liver bud. 
Hepatic endoderm cells or hepatoblasts are bi-potential and can undergo differentiation to 
hepatocytes or biliary epithelial cells that line the lumen of the intrahepatic bile ducts. 
Hepatoblasts are capable of proliferating extensively and invading the surrounding 
septum transversum.  Endothelial cells then interact with these hepatoblasts by providing 
specific growth factors needed for hepatoblasts maintenance and proliferation [73]. 
Between E10-15 in mice, the formation of the liver bud undergoes rapid growth and 
vascularization. By day E14-15, the liver bud is a highly vascularized tissue. During this 
stage of liver development, the STM continues to provide BMP, and additionally 
expresses hepatocyte growth factor (HGF), while the hepatoblasts express c-Met, the 
HGF receptor [74]. HGF acts as a suppressor for the apoptosis of hepatoblasts by 
promoting hepatoblasts proliferation through Wnt3a [75]. It has been speculated that both 
HGF and BMP provide growth signals, perhaps through parallel pathways. In addition to 
HGF, Oncostatin is released by the hematopoietic cells which promotes hepatocyte 
differentiation and maturation by the JAK/Stat3 signaling pathway through activation of 
the gp130 receptor [76]. The importance of this finding will be illustrated in sections 
below when we discuss the selective growth factors for in vitro differentiation. 
The functional cells slowly undergo maturation and the biliary network is formed as the 
liver attains the appropriate tissue architecture and functional capability [4,7,77]. An 
overview of liver development is shown in Figure 2-4.The detailed mechanisms behind 
liver bud development and subsequent maturation of the hepatocytes have been  
investigated further using microarray analysis on samples taken through various 
timepoints of mouse embryonic development [78]. 
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Figure 2-4: Overview of Mouse Liver Development[1] 
 
 Different Types of Stem Cells 2.5
2.5.1 Pluripotent Stem Cells 
 
ESCs were first derived by Evans and Kaufman from mouse embryos by culturing mouse 
blastocysts on layer of STO fibroblasts [30]. The ‘pluripotential’ cells, derived from the 
outgrowth of the inner cell mass, not only differentiated in vitro into cell types 
representing multiple tissues, but also formed teratocarcinomas upon subcutaneous 
injection into syngenic male mice [30]. Human embryonic stem cells were derived 
several years later from human blastocysts by Thomson et al [14]. The seminal 
observation of this latter work was that these human cells are similar to their mouse 
counterparts in many ways: (1) as high nucleus to cytoplasm ratio, (2) expression of 
surface antigen SSEA-1, and (3) differentiation into the three germ lineages in vivo and in 
vitro. 
Adult stem cells are generally more restricted in their potency [16,18,79] in line with 
their suggested role of maintaining homeostasis in the native tissue or organ and initiating 
proliferation or differentiation only when repairing the tissue or otherwise necessary [80].  
It has recently been shown that the potency of stem cells as well as somatic cells is 
subject to change through a process called ‘cellular reprogramming’ [81]. Expression of a 
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combination of exogenous key transcription factors, along with modification of culture 
conditions, enables the conversion of somatic cells to pluripotent stem cells. Shinya 
Yamanaka et al. have shown that adult somatic cells from mice can be reprogrammed to a 
pluripotent, stem cell-like fate by exogenous induction of four transcription factors: Oct4, 
Sox2, Klf4 and c-Myc [81]. In these experiments, 24 candidate genes that are expressed 
at high levels in mouse ESCs were screened, leading to the discovery that the expression 
of these four genes, often referred as OSKM or Yamanaka factors, is sufficient to kick-
start a cellular program that remodels the epigenome of the somatic cells such that they 
become what are now known as induced pluripotent stem cells or iPSCs [81]. These cells 
are morphologically similar to ESCs, display highly similar gene expression profile, and 
they differentiate in vivo, as well as in vitro, into the three germ layers [81-83]. The 
derivation of iPSCs has opened the possibility of deriving autologous pluripotent stem 
cells from adult somatic cells. Such autologous, pluripotent cells can in turn be 
differentiated into specific cell types for transplantation, possibly with minimal risk of 
immune response. To demonstrate this therapeutic concept, Hanna et al. have derived 
iPSCs from the fibroblasts of humanized sickle cell anemia model of mouse, corrected 
their genetic defect by gene targeting, and rescued the mice by using iPSC-derived 
hematopoietic progenitors [84].  
With the prospect of clinical application of stem cells, there is thus a heightened interest 
in developing technology that would permit their large scale bioprocessing at the lowest 
cost possible and with the highest quality possible. A number of large-scale efforts are 
underway for bringing about this bench to the bedside transition. 
2.5.2 Fetal Liver Stem Cells 
Progenitor cells derived from the fetal liver may be a promising source of hepatocytes for 
liver cell based therapy. In embryonic liver development, hepatoblasts, a common liver 
lineage committed cell type, can give rise to both hepatocytes and cholangiocytes. These 
hepatoblasts exhibit a very much larger proliferative potential compared to primary 
hepatocytes because of its less differentiated state. Furthermore, they are less prone to 
rapid de-differentiation in culture than primary hepatocytes and are more suitable for 
transplantation [85]. Thus there has been a long sustained interest in their isolation and in 
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vitro cultivation. However, because these cells are isolated from fetal livers, their study 
has mostly been performed in animal models.  
Hepatic progenitor cells have been isolated from fetal rodent livers around E11 to 14.5 by 
flow cytometry or magnetic activated sorting of dissociated liver cells based on the 
expression of one or a combination of surface markers. Early cell sorting studies used the 
absence of CD45 and TER119 along with low c-kit expression to sort for these types of 
early progenitor cells [86,87]. Later, Delta-like protein 1 (DLK1), which begins its 
expression in the mouse liver bud around E10.5, was used as a surface marker to enrich 
for hepatoblasts from rat [88] and mouse fetal livers [89,90]. E-cadherin, a cell adhesion 
protein [91] and epithelial cell adhesion molecule (EPCAM), a cell surface glycoprotein 
[92] have also been used to isolate hepatoblasts. These fetal liver derived progenitor cells 
also express cytokeratin 19 (CK19) and albumin. In culture, these cells also possess the 
capacity of proliferation with the supplementation of growth factors such as HGF and 
EGF, and are capable of differentiating to both hepatic lineage and cholangenic  lineage 
in culture [91]. 
These progenitor cells have also been isolated from fetal human liver. The Fausto 
laboratory isolated clonal progenitor cells from clusters of small cells arising from long 
term primary cultures established from fetal livers between the gestational stage of 74 
and 108 days [93]. These cells exhibited many markers reported in rodent hepatoblasts, 
including CK19, EPCAM, C-kit. However, maintained on feeder layers of irradiated NIH 
3T3 cells, they appear to be pre-hepatoblasts as they express neither albumin nor -fetal 
protein. They also lacked the transcripts of a number of liver transcription factors 
(HNF1, HNF3 and HNF4) and are capable of differentiating to not only hepatic 
lineage but also mesenchymal lineage. Thus, they claimed that the characteristics of these 
cells made them possibly closer to the more primitive mesendoderm stage of 
development. 
Using EPCAM and ICAM as markers, hepatic progenitors or hepatic stem cells were 
isolated from both human fetal and postnatal (neonatal, pediatric and adult) liver [94,95]. 
In the absence of a supporting feeder layer, EPCAM
+
NCAM
+
AFP
-
ICAM1
-
 cells became 
predominant. These cells were termed human hepatic stem cells (hHpSC). When cultured 
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on STO feeders (a mouse embryonic fibroblast line) cells, hHpSC will differentiate into 
EPCAM
+
NCAM
-
AFP
+
ICAM1
+
 hepatoblasts [94]. The proliferative capacity of these 
hepatoblast cells were demonstrated when the authors showed the maintained phenotype 
for over 150 doublings in culture.  
2.5.3 Adult liver stem cells 
Hepatocytes in an adult liver are capable of being highly regenerative when the liver 
experiences acute organ failure. Upon acute liver injury or partial hepatectomy, they 
replicate to generate the lost cell mass. Through serial transplantation of cells into the 
liver of metabolically deficient transgenic mice, hepatocytes isolated from adult mouse 
liver have been shown to proliferate up to 70 doublings and continue to contribute to the 
liver mass [96]. However, hepatocyte replication is not the only mechanism by which the 
liver can regenerate. In situations of chronic insult or severe liver injury, the regenerative 
capability of adult hepatocytes is overwhelmed and the resident hepatic stem cells will 
become the key contributor to the repair of the damaged hepatic tissue in a process 
known as ductal reaction [85,95].  These proliferative cells are often referred to as oval 
cells due to their shape in rodent livers.  
Thus, both hepatocytes and stem/progenitor cells in adult liver are capable of 
proliferation and reconstitution of lost liver mass. Such capability can potentially be 
harnessed for in vitro culture and clinical applications.  However, as briefly mentioned 
before, hepatocytes in culture lose their high proliferative capacity. In contrast, many 
have focused our ability to isolate and culture liver stem cells or progenitor cells in hopes 
of utilizing these specialized cell types towards clinical applications.  
Study of liver stem/progenitor cells often employs partial hepatectomy or treatment with 
drugs like acetylaminofluoren in rodents to enrich the cell population in the liver [97]. By 
BrdU labeling of proliferative cells in regenerating livers of rodents after induced 
acetaminophen injury, the region that stem cells reside and their niches were identified 
[98]. Four differently labeled  stem cell populations were identified, namely periductal 
mononuclear cells and peribiliary hepatocytes along with cells in the canal of Hering and 
intralobular bile ducts [98]. These findings suggest that there may be more than one cell 
type that gives rise to the regenerative process. Instead, multiple cell populations may 
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possess this ability and can respond to their specific niche cues differently allowing for 
their participation in the liver repair process. 
The availability of genomic data and the enhanced capability to identify genes expressed 
differentially under various differentiation states has helped identify markers suitable for 
cell isolation. The progenitor/stem cell markers identified in rodents has been used to 
enable for selective isolation of their counter parts in human liver. For example, EPCAM 
has been a key marker for enriching both fetal and adult liver stem/progenitor cells in 
rodents and human [94,99]. However, through the detection of high level expression of 
aldehyde dehydrogenase using a fluorescent substrate,  adult liver stem cells  from both 
mice and human liver were isolated without using any chemical stimuli to enrich their 
population [100]. This methodology could possibly provide a readily robust method of 
isolating a relatively homogenous population of hepatic progenitor cells. 
  A recent review by Turner et al. provides a more in-depth look at the current 
understanding of the localization of liver stem cells in the liver lobule and their 
characteristics [95]. They comprehensively describe the progression of liver stem cells 
during the development of the liver. It is postulated that the hepatic stem cells reside in 
the periportal region of the liver, specifically the canal of Hering. As these cells 
proliferate, “older” cells migrate along the cell plate toward the central vein and grow 
more committed and mature; first becoming bipotential, then becoming proliferative 
hepatocytes, and mature hepatocytes. As they move toward the central vein, they also 
become larger in size. Further details regarding the origin and repair mechanisms are 
described elsewhere [85,95,97]. 
Figure 2-5 summarizes the current stem cell/progenitor cells populations which have 
been isolated from stem cell hepatic differentiations, fetal liver, and adult liver. 
Multipotent cells from human fetal liver reported by the Fausto lab [93] are more 
primitive than the bipotential hepatic stem cells characterized by the Reid lab owing to 
the former’s capability to differentiate to mesenchymal cells.  
The hepatic stem cells have been isolated from both fetal liver and adult liver; whereas 
the mesendodermal cells have only been reported from human fetal liver. Both precede 
the hepatoblast; although both share many markers of hepatoblasts including EPCAM, E-
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cadherin, CK8, CK18, and CK19, both are also AFP and albumin negative. A distinction 
between hepatic stem cells and hepatoblast cells is their NCAM/ICAM-1 expression; 
++/- and -/++ for hepatic stem cell and hepatoblast respectively.  
Hepatic stem cells isolated from human adult liver are about 7-10 µm in diameter 
[95,100]; somewhat smaller than hepatoblasts in both adult and fetal liver (10-12 µm). 
They exhibit a high nucleus to cytoplasm ratio. Hepatoblasts are abundant in fetal liver 
(~80%), but decreases after birth to less than 0.01% in adult liver. In contrast, hepatic 
stem cells remain relatively stable comprising of about 0.5 to 1.5% of the liver cell mass 
throughout [101].  
Hepatic growth factors HGF, EGF are often included in the medium for hepatoblasts. In 
addition to growth factors, surface properties also affect the outcome of cell fate. 
Schmelzer et al. reported that both hepatic stem cells and hepatoblasts grew out from 
EPCAM sorted cell population when plated on plastic surface, but only hepatic stem cell 
colonies emerge when plated on STO feeder layer [94]. Turner et al report that angioblast 
feeder layers or collagen III  aid in proliferation of hepatic stem cells while stromal 
Figure 2-5: Isolation of Progenitor Cells in the Hepatic Lineage  [6] 
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feeder cells or collagen IV aid in hepatoblasts proliferation [95] .   
 
 Differentiation to hepatic lineage from stem cells 2.6
Due to the liver’s high regenerative capacity, there has been a long history of research on 
liver stem/progenitor cells and on their in vitro expansion. Those attempts aim to expand 
cells already committed to a developmental path. In contrast, another set of efforts seek to 
direct uncommitted embryonic stem cells, to the hepatic lineage. Embryonic stem cells 
have unlimited self-renewal and differentiation capacity thereby resulting in a potentially 
unlimited supply of hepatocytes. The recent emergence of iPSCs only amplified efforts 
towards generating functional hepatocytes from pluripotent stem cells.   
2.6.1 Differentiation of hepatic progenitor cells isolated from liver 
Hepatoblasts and liver stem cells isolated from fetal and adult livers have been shown to 
differentiate to hepatocyte-like cells in culture. A combination of growth factors, HGF, 
EGF, Oncostatin and Dexamethasone administered over one week was used to induce 
hepatic differentiation for mouse hepatoblasts [100].  Hepatic progenitor cells isolated 
from humans can be expanded and differentiated to hepatocyte-like cells with many liver 
functions including urea synthesis, albumin secretion and CYP activity. Decellularized 
liver biomatrix was used as an ECM for human differentiations, thereby reducing the 
need of commonly used growth factors HGF and EGF [100,102].  
2.6.2 Hepatic Differentiation of ES and iPS cells using soluble growth factors 
The development of liver in vivo entails the specification to definitive endoderm (about 
E8.5 in mouse), followed by commitment to hepatoblast and formation of liver bud, and 
finally fully differentiated hepatocytes and the emergence of bile ducts. The progression 
of the development is guided by a number of inductive signals dynamically described 
briefly above. The early differentiation to mesoendoderm and subsequent distinction of 
mesenchyme and endoderm is driven primarily by Nodal, BMPs and Activin signaling 
[103-105]. Further signaling from the FGF and BMP family, specifically BMP4, FGF2, 
FGF4 induce differentiation to hepatoblasts. After liver bud formation and expansion, the 
inductive signals of HGF and Oncostatin stimulate the hepatoblasts to differentiate 
towards hepatocytes.  
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Most hepatocyte differentiation protocols start with Activin and Wnt3a for a 3-5 day 
period to induce definitive endoderm commitment [103,106-108]. It has been shown in 
mice that Wnt3 signaling can maintain Nodal expression and Activin signaling can 
replace the Nodal/Crypto signal needed for endodermal formation [109,110]. FGF and 
BMP play a significant inductive role in promoting endodermal progenitor maintenance 
and expansion and will subsequently be used in the second stage of directed 
differentiation [68,71,111,112]. Further treatment with a mixture of FGFs facilitates the 
commitment to hepatic fate or the equivalent of the hepatoblast state in liver development 
based on the in vitro findings of Sekhon et al [113].  The last stage often entails the use of 
oncostatin or follistatin and HGF mixed along dexamethasone. It was previously reported 
that oncostatin-treated stem cells would lead to an increased activity level of STAT3 
[114]. The use of follistatin or oncostatin is used to favor hepatic differentiation over 
cholangiocytes, whereas HGF is used universally to mimic the hepatic environment 
[115]. HGF, on the other hand, was shown to contribute to liver development in a 
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STAT3-independent manner [114].Depending on the protocol, dexamethasone is often 
used as a mature hepatic inducer [116].  
 
 
Most efforts in guiding the differentiation of PSCs to hepatic lineage utilize multiple 
soluble growth factors to mimic the temporal dynamics of cues in hepatogenesis in vivo. 
However, it should be noted that the development of the liver and any other tissue in vivo 
is a continuous process, whereas our efforts to replicate these processes tends to be in 
discrete stages. Various protocols for guiding the differentiation of stem cells to hepatic 
lineage are segmented into separate differentiation stages. Thus, each protocol may 
implement different numbers of stages, with varying duration and medium composition. 
However, most protocols share common motifs across the duration of their differentiation 
which is depicted in Figure 2-6 that illustrates several representative protocols for 
differentiation to hepatic lineage in vitro.  
Figure 2-6: Comparison of Various Differentiation Protocols  [6] 
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2.6.3 Transdifferentiation to liver lineage from other tissue cells or stem cells 
In addition to the PSCs, a number of extrahepatic stem cells isolated from adult tissues, 
including adult mesenchymal stem cells (MSC) derived from human bone marrow 
[117,118] and adipose tissues [119,120], were shown to have the capacity to differentiate 
to hepatic lineage.  A protocol calls for treating MSCs with demethylating agent 5’-
azacytidine and then culturing them in hepatocyte maintenance medium containing HGF 
and EGF [118].  After 3 weeks the differentiated cell exhibited hepatic markers including 
albumin, CYP1A1, CYP3A4. Engraftment was shown upon transplantation into immune-
compromised mice which underwent partial hepatectomy. A similar protocol for adipose 
tissue-derived MSC underwent hepatic differentiation without the demethylation step 
[120], however, comparison of the effect of demethylation has not been available. The 
differentiation status of hepatocyte-like cells derived from MSC has not been 
characterized as well as the hepatocyte-like cells derived from PSCs. Nevertheless the 
results indicate that the future source of hepatocyte can still potentially be expanded to 
other adult stem cells in addition to the conventional PSCs. 
 
2.6.4 Directing to liver cell fate through gene transfection  
A number of laboratories have demonstrated the differentiation of iPSCs to hepatocyte-
like cells using the protocols developed for ES cells [121-123]. It appears that the 
protocols developed for embryonic stem cells are mostly applicable to iPSCs. This opens 
the possibility of personalized hepatocyte-like cells for drug screening and even for 
therapy.  However, deriving iPSC is a lengthy process.  Recently the feasibility of 
directly inducing fibroblastic cells to hepatic lineage through gene transfection mediated 
reprogramming was demonstrated in mice models. A combination of HNF4α with 
FOXA1, FOXA2 or FOXA3 was used to transfect and reprogram adult mouse fibroblasts 
to hepatocytes-like cells which are called iHEP cells [124]. The efficiency was about 1 in 
1000 of initially transfected embryonic fibroblasts. Interestingly the resulting iHep cells 
possess a very high proliferative potential, whereas such proliferative potential has not 
been reported for hepatocyte-like cells derived from from pluripotent cells. In another 
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study the over- expression of Gata4, Hnf1α and Foxa3 along with p19Arf inactivation 
enabled mouse fibroblasts to become iHep cells [125]. In this case inactivation of p19
 Arf
 
suppresses senescence of fibroblasts to enhance the success of reprogramming. The 
reprogrammed iHep cells expressed key hepatic genes and other liver functions and are 
successful engrafted in animal models. The obvious question then is why do the resulting 
iHep cells have a higher proliferative potential compared to the hepatocyte-like cells 
derived from pluripotent cells. The differences and similarities between the different 
types of hepatocyte-like cells derived from stem cells and primary hepatic stem cells have 
yet to be studied extensively. However, the approach will likely see many in vitro 
applications if it can be shown to work in reprogramming human cells. 
 
2.6.5 Expansion and differentiation of in vitro derived progenitor cells 
 
All reported directed differentiation of ES or iPS cells typically span a 20-25 day period 
and give rise to a mixture of differentiated cells that include a high percentage of 
hepatocyte-like cells at different degrees of maturity as assessed by the various liver 
specific markers. In the transition of pluripotent state to definitive endoderm stage, 
typically a significant degree of cell death is seen. Some cell expansion is typically seen 
in the endoderm stage and in the bipotential hepatic progenitor state. At the end of 
directed differentiation the differentiated cells typically are nearly confluent on the 
culture surface [126].  
In embryo development, cell expansion accompanies endoderm development, hepatic 
lineage commitment as well as in the hepatoblast stage. Directed hepatic differentiation 
of pluripotent stem cells passes through the corresponding differentiation stages of in 
vitro equivalents of the endoderm and hepatoblast stages. In these stages they are also 
likely to be capable of proliferation although their proliferative potential has not been 
quantified.   Zhao et al. isolated hepatic progenitor cells from hepatic differentiation of 
ES cells, using FACS sorting of N-cadherin positive cells [127]. These colony forming 
cells were cultured on mouse embryonic stromal feeders using serum free DMEM based 
medium which promoted their expansion. These cells, like their counter parts isolated 
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from fetal and adult livers, were bipotential and could be passaged several times in 
culture. 
Recently endoderm progenitor cells were isolated based on their expression of CXCR4 
and CD117 from cultures of directed human ES or iPS cells undergoing directed 
differentiation to the hepatic lineage [111]. These cells are apparently in an earlier 
differentiation stage than the hepatoblast stage and are capable of differentiating to both 
pancreatic and liver lineage. They possess a very large proliferative potential and can be 
maintained in medium containing BMP4, FGF, VEGF and EGF.  These endoderm 
progenitor cells are at an earlier developmental state than the hepatic stem cells and 
hepatoblasts; but are not as early as the cell line reported earlier by Fausto’s group that is 
capable of differentiating to mesenchyme in addition to endoderm. 
 Properties of the in vitro differentiated hepatocyte-like cells 2.7
 
The hepatocyte like cells derived from directed differentiation of pluripotent stem cells 
all have distinct epithelial morphology, express liver specific genes including albumin, 
alpha-antitrypsin, and a number of cytochrome P450 enzymes.  A direct comparison of 
different protocols is not easy because different combinations of assays were used in each 
report and the functionality is often evaluated at different levels, transcripts or protein or 
functional activities. Typically the maturity of the differentiated cells is evaluated by 
transcript and/or protein levels of marker genes, and assessed by representative 
characteristic markers of different aspects of liver functions, including drug metabolism, 
bile secretion, gluconeogenesis, urea synthesis, and protein synthetic functions (serum 
albumin, alpha antitrypsin). As the genomic tools become widely employed and data on 
transcriptome, miRNA and epigenetic state of cells at different differentiation states 
become available, we should gain a better understanding of cell differentiation under 
different protocols.  The hepatocyte-like cells obtained from directed differentiation of 
pluripotent cells are not mature hepatocytes. While they express higher level of 
transcripts of liver specific gene, the levels generally fall short of that of primary 
hepatocytes, especially for cytochrome P450 enzymes. As hepatocytes mature, many 
enzymes in metabolic pathways switch from the dominant infant isoform to an adult 
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isoform. Gluconeogenesis is one key metabolic pathway that is observed primarily in the 
liver. Using microarray analysis, we can quantitatively observe that the transcript-level of 
a fetal-specific isozyme, ADH1A, was significantly higher than its adult isozymes, 
ADH1C (data not published). Detailed transcriptome analysis then suggests that our 
current methodology of deriving hepatocytes from stem cells is more representative of 
the fetal state than the adult tissue.    
The capability of in-vitro cultured hepatocyte-like cells to progressing to mature 
hepatocytes have been demonstrated in animal models as illustrated in several studies 
[122,128]. However, the cues necessary to achieve that in vitro have yet to be unveiled. 
To increase the percentage of cells differentiated to hepatic lineage and enhance their 
maturity, transient forced gene expression of hepatic transcription factors was used. 
Lentiviral tranfection of FOXA2, HNF4α and C-EBPα in adult liver derived progenitor 
cells increased hepatic maturity and functional capabilities of albumin secretion and 
glycogen storage [129]. Similarly, by infecting differentiating  ES cells with SOX17 at 
Stage 1, HEX at Stage 2 and HNF4 at stage 3 of hepatic differentiation  and further 
incubation for 11 days, hepatic cells expressing higher transcript levels of all major genes 
examined was observed [130]. In a follow up study, adenoviral vector with Foxa2 was 
used to infect differentiating pluripotent stem cells at the definitive endoderm conversion, 
hepatic specification and hepatic expansion stages, followed by a combination of 
adenoviral vector-FOXA2 and HNF1 infection to further increase maturation [131]. The 
cytochrome P450 activities were markedly increased, albeit still lower than those in 
primary hepatocytes and the level desired for toxicity testing. Nevertheless, the work 
represents encouraging progress for in vitro generation of mature hepatocytes by directed 
differentiation. 
 Cell Culture Processes 2.8
2.8.1  Therapeutic proteins VS. Stem Cells  
 
The optimal cell culture process used for manufacturing stem cells needs to be designed 
with the end use in mind. As previously discussed, the fundamental property of stem cells 
to  be able to differentiate into various specialized cell types and lineages enables their 
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use in treating diseases as well as drug discovery and toxicity testing. The latter 
applications have gained even more attention with the discovery of iPSCs, as 
differentiated cells representing a diverse genetic background can now be generated from 
a large pool of patients. To this end, initiatives are launched to assemble banks of iPS-
derived cells for drug discovery, as exemplified by the pre-competitive initiative for iPS-
cells banking launched by a group of pharmaceutical companies called Stembancc 
(http://www.stembancc.org/) or by the University of Kyoto (http://www.cira.kyoto-
u.ac.jp/e/). For stem cell applications in drug discovery or toxicity testing, the quantity of 
cells that are required may not be large. Microfluidic devices with automated cell or 
medium manipulation capability are well suited to allow for process miniaturization and 
large scale parallel and combinatorial testing [132,133]. Nevertheless, the generation of 
stem cells as off-the-shelf reagents in larger quantities may require a different approach. 
In contrast to drug discovery and toxicity testing applications, stem cell based therapy at 
the clinical trial stage and beyond requires robust bioprocess technology in order to 
generate products of consistent quality at sufficient quantities. Cell culture processes have 
already been used for the production of therapeutic proteins for more than thirty years; 
this segment of the biotechnology industry currently represents tons of proteins with a 
commercial value of more than US $50 billion per annum worldwide [134]. The 
processes, technological know-how, and learning gained through these years of practice 
can now serve as a guide to develop an optimal process technology for stem cell 
applications. To benefit from those experiences and translate them to the stem cell field, 
it is important to first identify the similarities and the differences that exist between 
traditional cell culture processes for therapeutic protein production and emerging stem 
cell processes.  
The production cell lines for therapeutic protein production were first derived from 
transfecting the host cells with a vector containing the selective marker and the 
transgenes [135].  The transfected cells invariably undergo single cell cloning and 
screened and tested for productivity and product quality before they are further expanded 
to prepare master cell banks (MCBs) [135]. Prior to cell banking, further tests on 
microbial contamination, cell line stability are performed to ensure product quality and 
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consistency. It is not unusual that by the time a master cell bank is prepared those cells 
have undergone nearly forty population doubling [135]. Frozen vials from MCB are then 
used for further expansion to generate working cell banks (WCBs) from which cells for 
the manufacturing runs are obtained [135]. It is typical that the maximum passage 
number when reaching the final production scale is defined for a manufacturing process 
[135]. But over the lifetime of a product a total of 60-80 population doublings since 
single cell cloning would have occurred [135].  The cell banking protocols for stem cells 
are likely to be fairly variable depending on the type of stem cells used. While iPSCs are 
virtually all single cell cloned at their isolation stage, MSCs and others are used as 
unpurified population. Nevertheless with the exception of some autologous processes cell 
banking will be practiced and extensive quality control, including the control of number 
of population doublings or passages, will be imposed as practiced in current stem cell 
banking [136]. 
A typical manufacturing process for therapeutic protein production is initiated using cells 
obtained by thawing a frozen vial from a WCB. Subsequent cell expansion is performed 
in a series of bioreactors with increasing scale, before reaching production. For most 
recombinant proteins, the final production culture is operated under fed-batch mode with 
a scale ranging from 1,000 liters to 12,000 liters [30]. Fed-batch productions are initiated 
by inoculating with a seed culture derived from the WCB filled to 60-70% of the 
bioreactor capacity; nutrients typically fed in steps to bring the culture volume to a full 
capacity and avoid too high concentrations of nutrients at the beginning of the process. 
The production process may last for 12-15 days, reaching a final cell concentration of 
about 10
10
 cells/L and up to 10g/L of protein product [137]. Due to the nutrient feeding 
and base addition to neutralize lactate produced by proliferating cells, the final osmolality 
value may reach 400 mOsm or higher, far beyond 280-300 mOSm that is optimal for cell 
growth [137]. The protein product is recovered through a series of unit operations, which 
include cell removal, followed by a number of chromatography and membrane filtration 
steps. Residual cellular DNA is removed through an anion exchange adsorption process 
and possible retroviral contamination is eliminated through viral inactivation steps such 
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as low pH incubation. The final product is obtained after buffer exchange and sterile 
filtration [137,138].  
In the cell expansion bioreactors for therapeutic protein production, the cell concentration 
may reach 2-4 x 10
9
 cells/L; while in the final production reactor, a higher concentration 
of 10
10
 cells/L is commonly observed [139], [138]. A bioreactor of 1,000 L thus may 
contain 10
13
 cells.   
The number of cells required per dose of live cell therapeutics is relatively small in 
comparison. In Phase I of Geron’s clinical trial for spinal cord injury, 2 million 
oligodendrocyte progenitor cells were transplanted at the site of injury (http://cell-
therapies.geron.com/grnopc1). Cell transplantation for liver disease treatment will likely 
require at least 10
9
 cells or about one tenth of liver mass [140]. A similar number of beta 
cell equivalents is estimated to be required per patient for therapy of type I diabetes 
[141,142]. The Phase I clinical trials of acute myocardial infarction using Prochymal, 
bone marrow-derived human mesenchymal stem cells, by Osiris Therapeutics, Inc., used 
a dose of 300 million cells per patient. Moreover, in Phase 2 of clinical trials using 
Prochymal for the treatment of acute graft versus host disease (GvHD), 2-8 million cells 
were administered per kg of patient body weight (the equivalent of about 1-5 x 10
8
 cells 
per patient) (http://www.clinicaltrials.gov/ct2/show/NCT00482092). Similarly, in Phase 3 
clinical trials of Prochymal for treatment-resistant moderate-to-severe Crohn's Disease, 
600 million (low dose) to 1200 million (high dose) cells were intravenously delivered in 
four infusions (http://www.osiris.com/clinical_prochymal_piii_NDAGVHD.php). The 
number of cells required for therapeutic applications thus varies from about 10
8 
to 10
9
. 
Compared to the production process for therapeutic proteins, the operating scale is likely 
to be smaller even if thousands of doses are produced in each run.  However, the 
complexity of the process is likely to surpass that for protein production. 
Traditional flask culture, or its variations such as parallel flat plates, can routinely 
generate 10
10
 cells per production batch [139]. However, for economics of scale and thus 
to reduce the final cost of goods, a large number of doses should be produced in each 
batch. This will likely result in bringing the number of cell produced per batch to almost 
10
12
 cells, a level beyond the reach laboratory apparatuses. Larger scale production using 
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a bioreactor will also bring down the cost associated with assessing product quality, 
which is a major cost item in the manufacturing of the biologics product [139]. Beyond a 
3-dimensional environment that most closely mimics the natural cell niches, other 
advantages of using bioreactors include improved control over process parameters such 
as pH, dissolved oxygen or nutrient levels, and. Scalability. Even for smaller scale 
applications, as observed in industrial microbiology, cultivation in a well-constructed 
bioreactor enhances process robustness and product quality consistency [139].  
Commercial stem cell processes will increasingly bear a close resemblance to processes 
that have been developed for the production of recombinant protein, with the exception 
that batches will remain smaller in scale that those typically conducted to manufacture 
recombinant enzymes [143]. This is especially true at the cell expansion stage. On the 
other hand, the final steps of the production processes differ between industrial 
microbiology processes and cell therapeutic manufacturing processes, since in the former 
the aim is to achieve a final product titer while in the latter aim is to generate a live cell 
therapeutic at its optimal physiological state. Notably, the optimal physiological state of 
the live cells thus produced is defined by their ultimate application and does not 
necessarily relate to maximal cellular fitness. Beyond the field of stem cell therapeutics, 
an example of that concept can be found in the production of attenuated live vaccines. 
Those two very distinct process objectives thus impose a very different design space for 
defining process parameters. While it is a common practice for a recombinant protein 
process to reach a high osmolality due to the addition of base for neutralizing the pH and 
nutrient supplements; such culture conditions are likely to cause extensive cell damage 
and low viability and as a result are best avoided for stem cell manufacturing processes.  
It is relevant here to invoke a historical perspective on the evolution of cell culture 
processes during the past quarter century and relate these lessons learned to stem cell 
bioprocessing. At the dawn of cell culture production of therapeutic proteins, it was a 
common practice to provide cells with optimal chemical and physical conditions for 
growth. It was not until the years 2000 and particularly the advent of post-genomic 
technologies and systems biology techniques that the focus was shifted to finding the 
conditions that give rise to the highest productivities but not necessarily providing cells 
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with the most optimal conditions for cell growth [144].  Although we envision the 
employment of stem cells in bioreactors with culture conditions optimal for growth or 
differentiation, it is not unimaginable that a decade from now stem cell culture processes 
may look entirely different. For example, rather than operating at optimal  
 
conditions for cell growth or differentiation, the processing may be tailored to suit the 
purpose of producing cells with not only high quality and consistency but also superior 
efficacy for the specific treatment considered. 
 
 
Figure 2-7: Workflow of typical a cell culture process for recombinant protein 
production [5] 
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2.8.2 Autologous and allogeneic applications from a bioprocessing 
perspective 
To generate clinical grade stem cells products, the manufacturing process to produce 
stem cells will need to meet clinical requirements of cell quantity and quality. A major 
factor that will affect process decisions, and particularly obviously that of scale, is 
whether the cells will be used for autologous (using patient’s own cells) or allogeneic 
(using donor’s cells) applications.    
 Allogeneic cel l  process 2.8.2.1
A major advantage of employing allogeneic cells is that of establishing cell banks to 
derive industrially robust cell manufacturing systems for producing off-the-shelf cell 
preparations. Adult cells isolated from tissues, cell clones established from hESC or cells 
derived by reprogramming somatic cells using the iPSC protocol, all exhibit a wide range 
of intrinsic properties. For allogeneic applications, the “best” cells can be isolated for a 
particular application and characterized for their differentiation potential, risk of genetic 
abnormality or instability, and absence of adventitious contaminants as well as viability. 
 
 
 
Figure 2-8: Scenario of a stem cell process[5] 
  50 
Qualified cells can in turn be used to establish cell banks for production use over the 
entire product life cycle. This is an approach that has been implemented by companies 
developing MSC products, including among other Mesoblast, Athersys, or Pluristem 
[145]. The consistency in cell source during different runs, ensured by the use of MCBs 
and WCBs, also facilitates the development of a robust process to produce cells of 
consistent quality such that all patients are adequately treated. Moreover, allogeneic 
applications enable large-scale operations for the manufacturing of a large number of 
doses for each batch; this results in economy of scale with the additional flexibility that 
the same manufacturing suite can be used for producing different stem cells products by 
operating in production campaigns, as it the common practice in industrial microbiology 
plants. 
 Autologous cel l  processes 2.8.2.2
Autologous treatment using the patient’s own cells avoids risks associated with immune 
rejection as a result of graft vs. host reactions; notably, these treatments are also 
developed for MSCs despite these cells being recognized as immune privileged. With the 
prospect of generating iPSCs from the patient’s somatic cells, patient specific therapy 
seems increasingly plausible thus bringing the concept of personalized medicine to its 
most individual level [146]. The first step of an autologous stem cell production 
processes is that of cell isolation from either the patients’ own tissues or by the 
reprogramming of the patient’s somatic cells to generate iPS cells. What is more, cell 
manufacturing may extend beyond ex vivo expansion to include for example engraftment 
of the resulting cells in a tissue-engineering construct and sometimes further cultivation 
for additional expansion or differentiation. The quality and quantity of isolated cells and 
their response to culture conditions may vary from patient to patient. Developing and 
implementing a robust process that minimizes the variability of process outputs and the 
clinical outcome thus represents a major challenge. Processes employing autologous 
adult stem cells and iPSCs likely will involve extensive cell manipulations and may ipso 
facto be subject to a higher risk of microbial contamination. It is therefore critical to 
define the ranges of variability of each key production parameter, to establish strict 
change control procedures, and implement a model for predicting process output. Here 
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again, the best practices of industrial microbiology can be adapted with only minor 
changes to stem cell manufacturing. 
In pharmaceutical manufacturing, the production processes of different products are 
typically completely segregated from one another by either space or time to eliminate 
risks of cross contamination. Products simultaneously manufactured in the same plant are 
completely separated in space with its own supplies and staff [137]. For autologous stem 
cell processing, cells from each patient must be processed separately by time schedule, or 
by space. Such a production scheme may seem accomplishable in clinical trials or in the 
experimental stages, but will certainly pose additional operational constraints in the long 
term as the new technology reaches a larger population base. Processes for autologous 
applications will by nature be conducted at a scale that is much smaller than those used 
for allogeneic cells. Consequently, rather than economies of scale, the economics of 
autologous manufacturing stem cell facilities will be driven by economies of learning and 
economies of scope as a large patient base is reached and thus a large number of parallel 
lines of cultivation trains is deployed, with each train designated for only one patient at a 
time. Notably, this latter mode of manufacturing is more akin to a service business model 
such as that of a specialized clinic or hospital, than the traditional large-scale production 
of mass-market off-the-shelf products that large pharmaceutical firms have followed to 
date. One can envision that manufacturing cost considerations may drive autologous stem 
cell processes to become fully automated with robotic operations and artificial 
intelligence based personalized process optimization just like the erythropoietin process 
of roller bottle production was automated by robotics nearly three decades ago [147]. It is 
not too early to begin contemplating efficient designs for the large scale manufacturing of 
stem cells or their products. 
2.8.3 Open system vs. bioreactors 
 
Therapeutic applications based on hESCs or iPS cells require not only an ex vivo cell 
expansion step but also differentiation to the desired cell lineages. As discussed in the 
preceding paragraphs, the ex vivo expansion stages will most likely bear resemblance to 
the typical cell cultivation for recombinant protein production. Recombinant protein 
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production processes involve thawing frozen vials of cells and expanding them in a serial 
manner from a seed culture and progressively increasing the scale to thousands of liters 
[137]. At the end of the fermentation process, cells are separated from the spent growth 
medium and are discarded while the spent medium is further processed to isolate 
recombinant products. The use of flasks in a production process, with the exception of 
viral vaccine production, is limited to the steps immediately following initial thawing 
from a cell bank. In any of the remaining scale up cultivation steps, cells are in the 
completely enclosed environment of bioreactors. The opening of a flask destroys this 
barrier and generates de facto the risk of introducing contaminants or even adventitious 
agents. Therefore, even if some operations are performed in laboratory vessels, it is 
worthwhile to explore the possibility of a bioreactor system, or at least to establish a 
secure barrier between cells and their surroundings, and ensure that culture integrity can 
be maintained even during transfer of cultures between different reactors.  
 Stem cell niche and optimal culture conditions  2.9
To develop optimal culture conditions, it is useful to understand the niche or the native 
microenvironment in which the cells reside. Stem cells have extensive interactions with 
their underlying matrix as well neighboring cells [148]. Those complex interactions 
provide cues for their renewal, maintenance, differentiation or apoptosis [148].  
Understanding the nature of these stem cell niches will facilitate the development of 
processes from cell renewal and expansion. Some of the well studied stem cell niches 
include hematopoietic, skin, intestinal and muscle stem cells [149]. However, these 
niches are all rather complex. A plethora of intricate regulatory mechanisms, including 
cell-cell interactions and various spatial and temporal cues coach the cells to remain in a 
quiescent state, to transform into an activated state, or to differentiate. Even stem cells in 
a niche may be at different states as is governed by changes in specific set of regulatory 
cues. In fact most stem cells in vivo are likely to be at a resting state instead of 
proliferating; they begin to proliferate or differentiate only upon stimuli of the 
appropriate cues. Whereas stem cells in culture are continuously self-renewing except 
when under directed differentiation. While striving to understand stem cell niches, it also 
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important to keep in mind the dynamic nature of those niches in modulating stem cell 
state.  
Hematopoietic stem cells (HSC) residing in the bone marrow or blood can isolated from 
clinical samples to provide invaluable treatments of hematological and immune disorders 
as reviewed and tabulated by Burt et al [150] These cells have the potential to generate all 
the different types of cells of the hematopoietic and the immune system [151]. In the past 
two decades, significant advances have been accomplished for their isolation and 
subsequent transplantation [150]. Notably, to this end the knowledge gained regarding 
their specific niches in which they naturally reside is being used to guide and implement 
novel stem cell-based treatment strategies [151]. HSCs are associated with two different 
cell types within the bone marrow: osteoblastic cells and vascular cells [149]. These 
supporting cells interact with the HSCs either through soluble factors or through direct 
cell-cell interactions; remarkably, some of these mechanisms can be replicated in the 
laboratory of manufacturing suite to promote HSC expansion in vitro as reviewed in 
[152]. Particularly, this can be attempted through manipulating the Notch signaling 
pathway, since on the one hand HSCs express Notch receptors and on the other hand the 
supporting cell types in the bone marrow express Jagged 1, a Notch ligand [152]. 
Notably, soluble forms of Jagged 1 have been employed to expand HSCs isolated from 
bone marrow [152]. Additionally, osteoblasts secrete proteins such as angiopoetin and 
thrombopeotin that interact with their receptors present on the surface of HSCs to 
maintain them at a quiescent state; the vascular cells provide signals for HSC activation 
to generate mature differentiated cells to repair daily wear and tear [149].  
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From these various observations, it is clear-cut that the stem cell microenvironment plays 
an essential role in determining the appropriate culture conditions for stem cell culture 
and expansion. The niche presents a specialized platform for cross-talk between the stem 
cells and their microenvironment, involving compounded effects of cell-cell signaling, 
soluble factors and cell-ECM interactions as shown in Figure 2-9.  
 
Notably, advances in high-throughput technologies enable large scale screening of novel 
supporting factors, or small molecules with similar effects, and have shown great 
potential in deciphering these combinatorial interactions, whether they include growth 
factors, a variety of ECM molecules or mixtures of soluble signals. For example, such 
screens were employed to dissect the influence of ECM proteins on hepatocyte 
specification from ESCs. Thirty-two different combinations of ECM proteins were 
evaluated using a promoter-reporter system for fetal liver gene and a fold change of 140 
was observed between the least and most optimal conditions [153]. With the use of such 
high-throughput platforms, novel regulatory features can be uncovered and applied 
towards optimization of a well-defined environment for the maintenance of stem cells, 
even outside their native niches. 
In contrast to adult stem cells, which have their equivalents in vivo, embryonic stem cells 
are derived from the blastocysts, a transitory state that occurs only during embryonic 
Figure 2-9: Components of a Stem Cell Niche [2] 
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development [14], the “niche” concept may be very difficult to apply for these cells since 
the relatively stable ESCs observed in cultures do not exist in vivo. The first isolation and 
derivation of human embryonic stem cells was accomplished by culturing them on a 
supporting layer of mouse embryonic fibroblasts (MEF), which have been rendered non-
proliferative through irradiation treatment or exposure to chemicals [14]. The mechanism 
of action of these so-called feeder cells is to continue to support the undifferentiated state 
of ESCs by providing a microenvironment suited for self-renewal [154]. 
Remarkably, human ESCs were demonstrated to propagate under MEF-free conditions 
when cultured in the presence of mouse fibroblasts conditioned medium and on Matrigel, 
a complex mixture of extracellular proteins derived from mouse Engelbroth-Holm-
Swarm sarcoma cells [155].  This observation allowed for a systematic analysis of the 
factors present in the conditioned medium in an effort to determine the key components 
responsible for the remarkable maintenance of stemness of ESCs thus achieved. Of the 
several factors studied, basic fibroblast growth factor (bFGF) is one component that has 
been implicated to play a major role through modifications in the BMP signaling 
pathway: as a result large concentrations of bFGF have been employed to successfully 
establish reproducible feeder-free cultures [155-158].   
The inclusion of animal-derived components in the culture medium is ideally to be 
avoided, not only due to lot-to-lot variations, but also due to the risk of cross 
contamination with xenogenic components; and is of great concern for clinical 
applications.  The transmittance of infectious virus or mad cow disease has been 
associated with the use of animal serum or serum-based proteins and has fueled the move 
towards more defined culture systems [159,160]. A systematic analysis of the complex 
feeder based methods has already provided useful insights for the development of well-
defined, xeno-free ESC media such as mTESR and Essential-8-medium, which includes 
bFGF along with other important growth factors [156,158]. As it is evident in the use of 
MEF in ES culture, key components of the niche are often associated with auxiliary cells 
present in culture. The approach for medium development is thus to reproduce the niche 
environment with paracrine factors and all of the key ECMs provided by those auxiliary 
cells.  
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Even though these factors are invariably difficult to characterize and quantify, efforts are 
being made to elucidate the supportive components of the extracellular matrix secreted by 
the feeder cells in an attempt to move towards feeder-independent cultures. Matrigel, 
which as previously described is commonly used in ESC culture, is derived from mouse 
sarcoma cells; this creates de facto additional risks that are not compatible with the 
translation of these protocols to therapeutics manufacturing. Recent studies have focused 
on developing a defined biomatrix suitable for human ESC growth. For example, Ludwig 
et al [158] have demonstrated the use of a defined matrix composed of four different 
ECM proteins in conjunction with mTESR, thereby providing a defined system amenable 
for the scale up of ESC culture. Other examples of defined systems have been reported in 
recent years including Synthemax surface (Corning), Laminin-511 (Biolamina). 
Moreover, a defined surface incorporating a fusion protein composed of the extracellular 
domain of E-cadherin coupled with the IgG Fc domain has been demonstrated to 
maintain the self-renewal properties of ESCs and potentially replace Matrigel [161].  
Therefore, several studies are being conducted in an attempt to recapitulate all the 
different aspects of the niche; this involve either the direct analysis of adult stem cell 
niches or deductive analyses based on ESC derivation and feeder-based techniques. The 
use of advanced high-throughput screening methods enables to determine the complex 
and intricate signaling pathways between stem cells and their native microenvironments. 
In turn, these studies can contribute towards the development of a completely defined, 
animal source free system that can be scaled up with relative ease, thus enabling the 
successful translation of laboratory protocols to clinical applications.  
 
2.9.1 Media for stem cell culture processes 
The composition of the culture medium is amongst the most critical factors for 
determining the outcome of a particular process. What is more, this variable is represents 
the most important manufacturing cost burden when large production scales are used 
(Chapter 4). As discussed, insights into cell niches provide guidance for designing an 
industrially performing medium. In general, stem cell culture media can be broadly 
considered of consisting of three components that must be considered to design a new 
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expansion medium: the basal, medium consisting of small molecular weight biological 
molecules (glucose, amino acids, lipids, vitamins) and inorganic (bulk salts, trace 
elements) compounds, protein factors (e.g, insulin, transferrin), and complex additives 
(e.g., serum, conditioned medium) [139]. Additionally, chemical components, especially 
ECM components such as fibronectin or collagen are provided in different forms, such as 
thin coating under specific conditions or as gels to support cell adhesion and growth 
[147].  
The basal medium and defined protein components used for cell production process are 
generally the same as those devised for laboratory use. However, the inclusion of 
complex components, such as serum, serum substitutes, makes processes susceptible to 
parameter fluctuations that may result impact quality of the final product [158]. 
Therefore, switching to chemically defined medium and eliminating complex 
components represents an ideal solution that the industry will increasingly turn to [158]. 
Examples of serum free media developed for expanding ex vivo adult stem cells include 
StemPro MSC medium (Life technologies, Carlsbad, CA) for mesenchymal stem cells 
and the chemically defined X-VIVO medium (Lonza, Walkersville, MD) for 
hematopoietic cells. A number of chemically defined medium have also been developed 
for hESC culture including mTESR [158], HEScGro [162]. Small molecules, which 
confer specific biological activities, especially in inhibiting or activating signaling 
pathways involved in stem cell maintenance or differentiation, are increasingly being 
used during cultivation. For example, EHNA[erythro-9-(2-hydroxy-3-nonyl) adenine] is a 
small molecule used to support the maintenance of pluripotency markers in various hESC 
lines [163]. 
However, the difficulty in devising a robust defined medium for manufacturing should 
not to be underestimated. In general, a manufacturing process is even more susceptible to 
environmental fluctuations than laboratory-scale processes. Moreover, most chemically 
defined media are less resilient to counter environmental fluctuations than those 
supplemented with complex additives especially serum. Serum is thought to play a role of 
scavenger in buffering the effects of chemical assault that may arise from unforeseen 
factors, such as residual detergents or bleaching metal ions from corroded reactor parts.  
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Lessons learned from traditional cell culture processing can clearly be applied to stem 
cell bioprocessing at the expansion stage, bearing in mind that the final product will be 
the cells themselves and not biologics produced by them. Particularly, these cell products 
must be of high viability and quality. Traditional cell culture products undergo extensive 
downstream processing to attain a very high degree of purity after cell cultivation. These 
purification steps cannot be applied to the isolation of stem cell products. Therefore, it is 
critical at the medium design stage to minimize the quantity of any components that will 
absolutely need to be removed from the final cell product. Furthermore, extreme 
precautions must be taken to ensure that other contaminating molecules are not 
introduced during cultivation. 
 Reactor Considerations in Stem Cell Bioprocesses 2.10
In stem cell processes, robust systems with relatively large operating parameter windows 
and well defined change control procedures will be needed to meet the demand of clinical 
applications. In many cases, this will entail the employment of stirred tank systems 
ranging from tens to thousands of liters based on the needs of the process. A stirred tank 
bioreactor consists of a vessel fitted with impellers to provide a homogenous 
environment. Notably, it allows for the continuous monitoring and regulation of various 
chemical and physical parameters [5,138,139,164]. Cell sampling for monitoring the 
quality of the stem cells produced and their differentiation status can thus be readily 
performed.  
Stem cells require surface adhesion for growth. This is in contrast to cells used in 
 
Figure 2-10: Different Strategies for Large Scale Cell Expansion and Differentiation 
[2] 
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recombinant protein production most of which have been adapted to grow in suspension. 
To cultivate anchorage dependent stem cells in a stirred tank, suitable surfaces must be 
provided. This is achieved by using microcarriers. Alternately, some stem cells may grow 
as aggregates, essentially by clumping to one another [165]. The different strategies for 
hESC expansion and subsequent differentiation to hepatocytes are illustrated in Figure 
2-10. 
Embryonic stem cells can be cultured as aggregates called embryoid bodies (EB) 
allowing for their cultivation in stirred bioreactors [165]. These aggregates can be formed 
from a suspension of single cell using different strategies, including forced aggregation 
methods where cells are suspended in low attachment culture dishes or hanging drop 
methods where cells are suspended in a drop format from the lids of tissue culture dishes 
[166], [167]. EB are formed from human ESCs and undergo a 15-fold expansion in a 
stirred tank system compared to a 4-fold expansion in a static culture over a period of 21 
days [165]. These EBs maintain their potency and can be differentiated into 
hematopoietic progenitor cells [165]. In another study, homogenous EBs were formed, 
expanded in a stirred tank bioreactor and differentiated to cardiomyocytes [168]. 
Furthermore, recent reports of ESC single cell suspension survival with the Rho-kinase 
inhibitor [169] have led to the design of protocols yielding more homogeneous ESC 
cultures. This has been demonstrated in the formation of EBs that can be formed from 
single cell suspension of ESCs in the presence of this inhibitor with the resulting cells 
undergoing large scale expansion while retaining their properties when cultured in 
spinner flasks in the defined mTESR medium [170]. 
 However, the aggregates, if allowed to overgrow, can result in necrotic cell clumps 
owing to the deprivation of oxygen. Necrotic centers developed in the human glioma 
spheroids with diameters of 600-800 µm and oxygen tension continued to increase with 
size [171]. In addition, since many applications require the use of dispersed cells rather 
than aggregates of millimeter size, dissociating the cells from these EBs after 
differentiation poses a challenge as the procedure may involve enzymatic treatment, 
which could damage cell integrity and function. 
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An alternative route to the EB technology is the use of microcarriers. Microcarriers are 
beads of about 150-200 micron in diameter with a surface compatible for cell adhesion. 
Microcarriers can be either microporous or solid; they are made from a variety of 
materials such as dextran (Cytodex, GE Healthcare, Waukesha, WI), gelatin (Cultispher, 
Percell Biolytica AB, Astorp, Sweden) or polystyrene (Solohill, Sigma, St Louis, MO). In 
addition, their surfaces can be modified through coating with extracellular matrix proteins 
like collagen, peptides or different types of charged residues to facilitate cell attachment 
[172,173]. The main advantage that microcarriers offer is that they offer high cell culture 
surface to reactor volume ratios [139].  
Human ESCs can be cultured on matrigel-coated polystyrene beads and expanded by 30-
40 fold within 8 days [174]. Cells grown using this process typically differentiate to the 
definitive endoderm with 80% efficiency [174]. A similar system involving human ESCs 
cultured on microcarriers was shown to be useful to expand and differentiate ESCs into 
cardiomyocytes[175]. Rat multipotent stem cells seeded on Cytodex-1 microcarriers can 
be expanded over 80-fold in a spinner flask system and differentiated towards the hepatic 
lineage [176]. Several other similar studies have been reviewed [164]. 
In the scale up of stirred tank bioreactors for stem cell culture, important lessons can be 
learnt from the accomplishments of the past 3 decades in traditional cell culture 
processing. Robust protocols for oxygen and pH control, fluid transfer, mixing control, 
mechanical stability and aseptic operations are all in place [139]. This prior knowledge 
can provide a huge database of relevant information for the design of similar systems for 
suspension-based stem cell bioprocesses. 
 Concluding remarks 2.11
 
The availability of an expandable source of human hepatocytes will have profound 
implications in the treatment of liver failure and congenital liver diseases. Sources of 
hepatocytes include hepatic progenitors from fetal or adult liver, differentiation of 
pluripotent stem cells or mesenchymal stem cells and direct reprogramming to 
fibroblasts. Hepatocytes like cells obtained with current differentiation protocols are still 
far away from their primary counterparts in their functional maturity.  While these cells 
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may not be suitable for clinical transplantation currently, this may not limit their use in 
bio-artificial liver devices or as in vitro models for drug toxicity and diseases. This has 
been demonstrated in proof of concept studies in establishing liver disease models. 
Finally, prior expertise in cellular bioprocessing technology can be harnessed for the 
development of a bioprocess catering to the large scale production of stem cell derived 
hepatocytes. Thus, one can envision the translation of stem cell research to the clinic in 
the not too distant future.  
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3. MATERIALS AND METHODS 
  Human Embryonic Stem Cell Culture 3.1
 
The human embryonic stem cells (hESC) line H9 was cultured using  medium consisting 
of  80% Dulbecco’s modified Eagle medium (DMEM) (Gibco/BRL), 20% Knockout 
Serum Replacement (Gibco), 2mM glutamine, 0.1 mM nonessential amino acids, 0.1 mM 
-mercaptoethanol and basic fibroblast growth factor (bFGF, R&D) (10 ng/ml). These 
cells were cultured on irradiated mouse embryonic fibroblasts (MEFs) obtained from 
E13-E14 CF-1 mice (Charles River Laboratories, Wilmington, MA), at 37°C in 10% 
CO2. The cells were passaged on a regular basis every 2-3 days using 0.1% (w/v) 
Collagenase Type IV (Gibco) in DMEM. 
 Hepatocyte Differentiation 3.2
 
H9 cells were cultivated onto 12 well plates coated with 2% matrigel (BD biosciences) in 
mTESR medium until 50% confluency was reached. Differentiation was induced with 
addition of the differentiation medium.  This medium consisted of a 60/40 (v/v) ratio of 
low glucose Dulbecco’s Modified Eagle media (DMEM) (Gibco, USA) and MCDB-201 
(Sigma). This was supplemented with 0.026 g/ml ascorbic acid 3-phosphate (Sigma), 
linoleic acid bovine serum albumin (LA-BSA, Sigma), insulin-transferrin-selenium (ITS, 
Sigma) (2.5 g/ml insulin, 1.38 g/ml transferrin, 1.25 ng/ml sodium selenite), 0.4 g/ml 
dexamethasone (Sigma), 4.3 g/ml -mercaptoethanol (Hyclone), 100 IU/ml penicillin 
and 100 g/ml streptomycin (Gibco). Fetal bovine serum (2% (v/v) was added into the 
differentiation medium for the first six days and 0.5 % (v/v) for the remaining period. 
Growth stages and cytokines specific for each differentiation stage were supplemented 
accordingly. Activin A (100 ng/ml) and Wnt3a (50 ng/ml) were used to initiate definitive 
endoderm formation. FGF2 (10 ng/ml) and BMP4 (50 ng/ml) were used to initiate 
hepatic specification. FGF8b (25 ng/ml), FGF1 (50 ng/ml) and FGF4 (10 ng/ml) were 
added to induce formation of hepatic progenitor cells formation and finally HGF (20 
ng/ml) and Follistatin (100 ng/ml) were added for hepatocyte maturation.  
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 Endodermal Cell Expansion and Differentiation 3.3
 
For endodermal cell expansion, cells were harvested as small clusters at the end of six 
days of the first stage of differentiation using 0.1% (w/v) Collagenase Type IV (Gibco) in 
DMEM. These cells were passaged onto matrigel coated plates in Stage 2 medium 
containing bFGF (10 ng/ml) and BMP4 (50 ng/ml). The cells were passaged every three 
days up to a four passages. To initiate differentiation, medium was switched to Stage 3 
medium for 4 days and Stage 4 medium as described previously in Section 3.2. 
 Culture of Hepatic progenitor cells in Kubota’s medium 3.4
 
Kubota’s medium consisted of  500 ml RPMI 1640 (GIBCO # 11875-093), 0.5 g BSA 
(Sigma # A8806 fatty acid free),  270 mg Niacinamide (Sigma # N0636), 5 µg/ml Insulin 
(Sigma # I5500), 10 µg/ml Transferrin/Fe (Ado, bovine) (Sigma # T1283), 5 ml l-
Glutamine 200 mM (2 mM, GIBCO # 25030-081), 5.0 ml Antibiotics (GIBCO # 15240-
062, AAS), 10E-8 M Hydrocortisone (Sigma # H0888), 1.75 ml b-Mercaptoethanol (5E-
5 M, Sigma # M6250), 10E-10 M Selenium (Aldrich # 22,982-7), 10E-10 M Zinc sulfate 
heptahydrate (10E-10 M, Specpure # JMC156) , 10 µg/ml High density lipoprotein from 
human plasma (Sigma #L8039-solution, Sigma #L1567-lyophilized powder)and 38 µl of 
the free fatty acids mixture described below. The free fatty acids were reconstituted as 
1M  solutions  of  Palmitoleic acid (MW 254.4, Sigma # P9417) , Oleic acid (MW 282.5, 
Sigma # O1008), Linoleic acid (free acid, not sodium salt), Linolenic acid (MW 278.4, 
Sigma # L2376) and a 151 mM solution of stearic acid (MW 284.5, Sigma # S4751). 
These were then combined using 31.0 µl of 1.0 M palmitic acid, 2.8 µl of 1.0 M 
palmitoleic acid, 76.9 µl of 151 mM stearic acid, 13.4 µl of 1.0 M oleic acid, 35.6 µl of 
1.0 M linolenic acid, 5.6 µl of 1.0 M linolenic acid and 834.7 µl of ethanol. 
Day 14 cells were harvested as small clusters and plated in Kubota’s medium or Stage 4 
medium on different extracellular matrices, matrigel (BD, #354230) or collagen 1 ( BD, 
#354236) 
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 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 3.5
.  
Total RNA was obtained from cell lysates using RNAeasy microkit (Qiagen) and cDNA 
was synthesized using the Superscript III reverse transcriptase kit (Invitrogen) according 
to manufacturer's instructions. The cDNA samples were mixed with SYBR Green Mix 
PCR reaction buffer (Applied Biosystems) and primers (5 M working stocks). The qRT 
PCR reaction was carried out using the following program : 50C for 2 min, 95C for 10 
min, and 40 cycles at 95C for 15 sec and 60C for 1 min followed by a dissociation 
protocol to obtain a melting curve, on a Realplex mastercycler (Eppendorf). Transcript 
abundance levels were measured relative to a housekeeping gene GAPDH and calculated 
as Ct (Ct(gene of interest)-Ct(GAPDH)).  For comparison across samples, the transcript 
intensities were normalized to hESCs or any other reference sample and expressed as  
log2(Transcript  levels relative to hESCs) and calculated as Ct or  Ct (hESC)- 
Ct(day of sample).  
 Immunohistochemistry  3.6
 
The cells were fixed with 4% paraformaldehyde at room temperature for 20 min.  The 
cells were blocked with PBS containing 0.2% Triton-X-100 (PBST) with 3% donkey 
serum at room temperature for 1 hr and incubated with primary antibodies AFP (Dako, 
1:1000), SOX17 (R&D, 1:20), FOXA2 (Abcam, 1:1000) and DAPI (Life Technologies, 
1:500) overnight at 4 ˚C. The cells were then incubated with secondary antibodies anti-
mouse IgG1 A488 labeled (Molecular Probes, 1:500 dilution) and anti-rabbit IgG A488 
(Molecular Probes, 1:500 dilution) for 30 minutes at room temperature prior to 
visualization. The negative controls were cells incubated with only the secondary 
antibody and relevant isotype control and were processed simultaneously. 
 Flow cytometry 3.7
 
The differentiating cells were washed with PBS and treated with 0.1% (w/v) collagenase 
type IV (Invitrogen) for 10 minutes at 37C. The cells were scraped and harvested as 
small clumps. These cells were collected in a 15 ml tube and centrifuged. The cell pellet 
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was resuspended in a 0.05% (w/v) solution of trypsin supplemented at 2% (v/v) chicken 
serum at 37C for an additional 5-10 min. A single cell suspension was then obtained by 
passing the cell suspension through a 40 um nylon filter. These cells were fixed with 4% 
paraformaldehyde for 15 minutes and washed twice with PBS. The cells were treated 
with a blocking solution consisting of SAP buffer (PBS with 0.1% (w/v) saponin and 
0.05% (w/v) sodium azide) supplemented with 5% donkey serum for 1 hour. This was 
followed by incubation with primary antibodies used listed in Table 2. Isotype control 
antibody was used as negative control. The secondary antibody was anti-rabbit IgG A488 
or A546 (Molecular Probes, 1:500 dilution). Antibody dilutions were optimized using 
HepG2 and hESCs as positive and negative controls. For cell surface markers, the 
blocking and antibody incubation was performed using PBS with 5 % serum instead of 
SAP buffer. 
 Mass cytometry 3.8
 
Lyophilized antibodies for FOXA2, SOX17, GATA4, GATA6, AFP, ALB, DLK1, 
A1AT and HNF4α proteins were obtained from R&D systems. About 200 µg of 
antibodies were conjugated with a selected panel of heavy metal isotopes using the 
MaxPar® antibody labeling kit from Fluidigm according to the manufacturer’s 
instructions with slight modifications. The antibodies were eluted in 50 µl PBS instead of 
W buffer provided in the kit and this was found to improve antibody recovery. The 
conjugated antibodies were diluted to 0.5 mg/ml in antibody stabilizer solution (Candor 
Biosciences, 131050) and stored at 4 C until use.  Metal conjugated CXCR4 and CD44 
were directly obtained from DVS Sciences.  
Cells were dissociated into single cells by treatment with 0.1% collagenase in DMEM 
and trypsin as previously described [177].  About 500,000 cells per time point were fixed 
using 10% formalin for 20 minutes at room temperature. The cells were washed with 
PBS, centrifuged and each cell pellet were suspended in 5 μL Human TruStain FcX™ 
(BioLegend, 422302) and 95 μL PBS at room temperature for 10 minutes for blocking.  
The cells were first incubated in a cocktail of metal conjugated antibodies targeting 
surface markers in 100 µl of PBS for 30 minutes at room temperature. Cells were washed 
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twice with PBS and incubated with a second cocktail of antibodies targeting intracellular 
proteins suspended in 100 µl SAP buffer (PBS with 0.1% (w/v) saponin (Sigma, 
47036)  and 0.05% (w/v) sodium azide (Sigma, 438456) for 30 minutes at room 
temperature. After washing the cells twice with SAP buffer, cells were incubated with 
MaxPar® Intercalator-Ir 125 μM (DVS Sciences, 201192A) at a dilution of 1:1000 in 1 
ml of SAP buffer overnight at 4°C.  Cells were washed twice, suspended in 500 µl water 
and passed through cell strainer and were run on the CyTOF2 instrument (DVS 
Sciences). During titrations, an antibody cocktail was made at 8 µg/ml and serially 
diluted twofold to achieve a wide range of concentrations. The negative control used was 
hESCs. It was critical to run a negative control for every titration as well as experiment in 
case of changes in antibody activity. A list of working concentrations are listed in the 
Supplementary table. Data was analyzed using the Cytobank software and visualized in 
Spotfire (Tibco). 
 Functional Assays to Characterize HLCS  3.9
Albumin secretion was measured using an ELISA kit (Starters Kit Bethyl E101 and 
Bethyl E80-129) following the manufacturer’s instructions. The amount of albumin 
present in fresh medium was subtracted from albumin concentration in the samples to 
quantify the amount secreted by the cells over 24 hours. Cell numbers were estimated and 
albumin secretion is reported as pg/ cell/day.  
Urea was measured using QuantiChrom Urea Assay Kit (BioAssay Systems) according 
to manufacturer’s instructions. The concentration of urea was determined using a 
standard provided with the kit and reported on a per cell basis for the differentiated 
samples.  
Periodic-Acid-Schiff staining (Sigma-Aldrich) was performed according to the 
manufacturer’s protocol. The cells were immersed in Periodic acid solution for 5 minutes, 
in Schiff’s reagent for 15 minutes at room temperature and were washed with water prior 
to visualization.  
 Transcriptome Analysis  3.10
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Total RNA was extracted from human liver differentiation (H9) samples at various time 
points of endodermal cell expansion and differentiation using the RNeasy Mini kit 
(Qiagen). Samples were hybridized to the Illumina HT12 bead array v3 (Illumina Inc).   
Data was processed using the lumi package in R [178]. Transcriptome data from 34,000 
probes representing about 20,000 genes was obtained. Manually curated gene sets from 
(http://www.broadinstitute.org/gsea/index.jsp) containing genes belonging to different 
developmental stages such as pluripotent, endodermal and hepatic progenitor genes were 
used to visualize trends in the data. To gain a global perspective on the gene behavior, 
hierarchical clustering and principal component analysis (PCA) were performed in R.  
Pearson correlation analysis among the different time points of the original and modified 
protocols was performed to identify genes exhibiting opposite trends. Spotfire (Tibco), 
Database for Annotation, Visualization and Integrated Discovery (DAVID) and Ingenuity 
Pathway Analysis (IPA) (Qiagen) were software used for data visualization and 
functional analysis. Gene Set Analysis (GSEA), a technique used to interrogate gene sets 
that were statistically different between the EN and EN2 cell states was also implemented 
using the software from the Broad Institute (http://www.broadinstitute.org/gsea/index.jsp) 
[179,180] 
 
Table 3-1: List of Human primers for qRT-PCR 
Gene Forward sequence  Reverse sequence  
AAT  GTCAAGGACACCGAGGAAGA TATTTCATCAGCAGCACCCA 
AFP  AAATGCGTTTCTCGTTGCTT GCCACAGGCCAATAGTTTGT 
ALB TGGCACAATGAAGTGGGTAA CTGAGCAAAGGCAATCAACA 
CXCR4 AACTTCAGTTTGTTGGCTGC GAAACAGGGTTCCTTCATGG 
CYP3A4 AAGTCGCCTCGAAGATACACA AAGGAGAGAACACTGCTCGTG   
CYP3A7 TGCTTTGTCCTTCCGTAAGGG CAGCATAGGCTGTTGACAGTC 
CYP7A1 CTGAGGCTTTCCAGTGCCT AGGTAGTCTTTGTCTTCCCGT 
EOMES AACAACACCCAGATGATAGTC TCATAGTTGTCTCTGAAGCCT 
FOXA2 ATTGCTGGTCGTTTGTTGTG TACGTGTTCATGCCGTTCAT 
G6PC GTGTCCGTGATCGCAGACC GACGAGGTTGAGCCAGTCTC 
GAPDH  GAGTCAACGGATTTGGTCGT GACAAGCTTCCCGTTCTCAG 
GSC TCTCAACCAGCTGCACTGTC CCAGACCTCCACTTTCTCCTC 
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KRT18 TGATGACACCAATATCACACGAC TACCTCCACGGTCAACCCA 
MGST TTTGGAACACCATTCCAGAC TTTCAAGGTCATTCAGGTGG 
OCT4 CTTCGCAAGCCCTCATTTC CCTTGGAAGCTTAGCCAGGT 
PEPCK1 AAGAAGTGCTTTGCTCTCAG CCTTAAATGACCTTGTGCGT 
SOX17 CGCACGGAATTTGAACAGTA GGATCAGGGACCTGTCACAC 
TTR  ATCCAAGTGTCCTCTGATGGT GCCAAGTGCCTTCCAGTAAGA 
 
Table 3-2: Antibodies for flow cytometry and immunohistochemistry 
Name Company Catalog no. Dilution Type 
DLK1 Livtech DI-6 1:20 Primary 
AFP Dako A0008 1:1000 Primary 
ALB Dako A0001 1:1000 Primary 
FOXA2 Abcam  ab40874 1:1000 Primary 
SOX17 Abcam   ab84990 1:20 Primary 
Goat IgG 
Jackson 
Immunoresearch 
005-000-003 
Same as 
primary 
Isotype 
Rabbit IgG 
Jackson 
Immunoresearch 
011-000-003 Same as 
primary 
Isotype 
Donkey anti-goat Alexa 555 
(red) 
Invitrogen A21432 1:500 Secondary 
Goat anti-rabbit Alexa 555 
(red) 
Invitrogen A21429 1:500 Secondary 
Goat anti-rabbit Alexa 488 
(green) 
Invitrogen A11008 1:500 Secondary 
anti-mouse IgG1 A488 Molecular Probes A-21121 1:500 Secondary 
Hoechst (nuclear staining, blue) Sigma 33258 1:500 Secondary 
 
Table 3-3: Antibodies for mass cytometry 
Antigen Vendor 
Catalog 
number 
Metal 
Conjugated Concentration 
SOX17 R&D AF1924 Sm154 4 µg/ml 
FOXA2 R&D AF2400 Gd156 4 µg/ml 
AFP R&D AF1369 Nd143 4 µg/ml 
DLK1 R&D MAB1144 Tm169 4 µg/ml 
ALB R&D MAB1455 Er166 4 µg/ml 
A1AT R&D AF1268 Tb159 4 µg/ml 
GATA6 R&D AF1700 Eu151 4 µg/ml 
Gata4 R&D AF2606 Dy162 4 µg/ml 
CXCR4 DVS 3175001B Lu175 2 µl 
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CD44 DVS 3150018B Nd150 2 µl 
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4. ENDODERM CELL EXPANSION TO FACILITATE HIGHER 
YIELDS OF   STEM CELL DERIVED HEPATOCYTES 
 Introduction 4.1
 
The derivation of hepatocytes from embryonic and induced pluripotent stem cells, 
have the potential of replacing primary hepatocytes in cellular therapies for treatment of 
liver failure. Pluripotent stem cells, due to their self-renewal abilities, can provide a 
continuous source of hepatocytes upon differentiation, thereby circumventing issues of 
donor shortages, which are prevalent in applications relying on cells from primary 
sources. Stem cell derived hepatocytes also have applications in bio-artificial liver 
devices, disease modeling and drug toxicity screening.[6,11,181].  
Understanding the molecular signals guiding liver development has aided in the 
development of in vitro strategies to differentiate stem cells towards the hepatic lineage 
by several research groups [122,123,177,182,183]. The resulting hepatocyte-like cells 
(HLCs) at the end of differentiation begin to express desired hepatocyte transcripts and 
functions and have been extensively characterized in previous reports [78,182]. With the 
promising advances in differentiating stem cells to hepatocytes, one major challenge to 
overcome prior to clinical translation is the current low cell yields [5]. Any therapeutic 
application will require 10
9
-10
10 
cells per treatment. Production of large quantities of cells 
to meet clinical demands currently entails expanding large quantities of pluripotent stem 
cells followed by differentiating them. The conventional method of expanding and 
differentiating stem cells remain labor intensive and prone to batch variation. The process 
from thawing to cell expansion and differentiation is also time consuming. Expansion of 
an intermediate cell state during stem cell differentiation will circumvent this issue by 
reducing the reliability on large quantities of the initial starting pool of stem cells. 
Furthermore, it is well known that cells undergo extensive proliferation throughout the 
liver development process. With the appropriate signaling cues mentioned before, it may 
be possible to replicate this phenomenon in in-vitro differentiations.  
To address these issues, some reports have been published on the proliferation of 
intermediate cells during stem cell differentiation. Hepatic progenitor cells were enriched 
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using the surface markers EPCAM or N-cadherin and expanded on stromal feeders 
[127,184,185]. Recently, a self-renewing endodermal cell line was reported where the 
cells were sorted based on expression of CXCR4 and CD117 and expanded on mouse 
embryonic feeders [111]. In the current study, we demonstrated the expansion of an early 
stage of endodermal intermediates without the need for cell sorting or relying on feeder 
cells to achieve higher yields of HLCs after subsequent differentiation of these 
endodermal intermediates.   
 Results 4.2
4.2.1 Expansion of endodermal cells 
 
In this study, we demonstrated that during the course of hepatic differentiation from 
human embryonic stem cells, an intermediate endodermal cell could be expanded and 
continued to differentiate to a HLC phenotype. The hESCs were differentiated to 
definitive endoderm in Stage 1 medium containing Activin (100ng/ml) and Wnt3a 
(50ng/ml) to reach cell densities of 2.5x10
5
 cells/cm
2
 in six days. The cells were detached 
by collagenase treatment and passaged, at 8 x10
4
 cells/cm
2
 onto Matrigel coated plates in 
Stage 2 medium containing the growth factors FGF2 (10ng/ml) and BMP4 (50ng/ml). 
The morphology of the cells immediately after plating and after three days in Stage 2 
conditions are shown in Figure 4-3. After 3 days of expansion, cells were passaged again 
under the cues of FGF2 and BMP4, which are known to provide proliferative cues during 
embryonic liver development [71]. The cell population expanded approximately 8 fold 
after two passages as shown in Figure 4-2 (n=4). The passaged populations will herein be 
referred to as EN1 and EN2, respective of their passage number. Continued passaging 
could result in cell expansion up to 15 fold, however the growth rate began to slow down 
and fibroblastic looking cells began to overtake the native population. In contrast, the 
cells only expand two times from the endodermal to the hepatic stages during a regular 
differentiation protocol as seen in Figure 4-4. 
4.2.2 Expression of hepatic genes and proteins in expanded endodermal cells 
The transcript levels of gene markers for hepatic differentiation were assayed by 
qRT-PCR results are reported as fold changes with respect to undifferentiated hESCs 
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(n=4). Octamer-binding transcription factor 4 (OCT4), a master regulator of the 
pluripotency network in hESCs [186], decreased about 1000 fold during endodermal 
expansion as expected (Figure 4-5). This may be the result of preferential attachment of 
epithelial fated cells over undifferentiated hESCs upon cell passaging. 
 The endodermal transcription factors, goosecoid homeobox (GSC), a key marker 
for differentiating definitive and visceral endoderm that drives extraembryonic cell fate 
[187], and CXCR4, a surface marker co-expressed with GSC [187], were both highly 
expressed in the EN population and decreased by 1000 fold and 10 fold, respectively in 
EN1 and EN2 (Figure 4-5). The expression profile suggests the transitioning of the 
endodermal-committed cells towards a hepatoblast lineage. This is further confirmed by a 
1000 fold increase of alpha-fetoprotein (AFP) and albumin (ALB) over the same period 
[188]. 
Transcript levels were also compared with cells from two different differentiation 
stages using the original protocol; 1) day 10 (HPC) where cells were exposed to BMP4 
and FGF2 signaling for four days, 2) day 14 (HPC1), after 4 days of further treatment 
with Stage 3 growth factors. Fold changes of transcript levels for EN, EN1, EN2, HPC 
and HPC1 cells were reported with respect to hESCs ( 
Figure 4-6). The gene expression of samples from each protocol is represented as 
two continuous curves, with respect to the corresponding day of differentiation. The 
expression of OCT4, and endoderm markers GSC, CXCR4 decrease while hepatic AFP 
and ALB increase to higher extent in EN1 and EN2 cells when compared to both HPC 
and HPC1 cells. This indicates that the EN2 cells appear more differentiated than the 
corresponding cells (HPC1) from the conventional protocol. Notably, this increase in 
hepatic characteristics is simultaneously occurring with an 8-fold increase in cell number 
indicating that a selective proliferation of the desired cell type is occurring instead of 
proliferation of contaminating cell types. The transition from the endodermal stage to 
hepatic stage is also seen by immunostaining (Figure 4-7). Forkhead Box A2 (FOXA2) 
and SRY (Sex Determining Region Y)-Box 17 (SOX17), key transcription factors in the 
establishment of definitive endoderm are prominent in the EN stage but not the hepatic 
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marker, AFP. In contrast, a decrease in the expression of FOXA2 and SOX17 and 
increase in AFP expression is seen in EN1 and EN2.   
We next examined whether this endoderm-hepatic transition was restricted to a 
subpopulation or if it occurs in the entire population. Mass cytometry was employed to 
examine co-expression of a panel of endodermal and hepatic markers. This method 
allows for multiple markers of cell fate transition to be assayed at single cell resolution 
[189].  Time of flight analysis was performed on cells labeled with heavy metal 
conjugated antibodies. The co-expression of CXCR4, FOXA2, SOX17, ALB, DLK1, 
AFP, ALB, AIAT and CD44 proteins was evaluated in differentiating cells. Only four 
markers are shown in each graph, thus multiple figures are used to present the 
progression of different markers in the different stages (Figure 4-8, Figure 4-9). In Figure 
2c, SOX17, CXCR4 and ALB are represented on the three axes while CD44 is 
represented as the fourth dimension, with red indicating high and green indicating low 
protein expression. CD44, which plays an important role in HGF signaling through its 
receptor c-MET expressed in hepatocytes [190]. The data shown represents about 
150,000 cells of the endodermal cells in different stages of expansion. In Figure 2D, 
DLK1, CXCR4 and ALB are plotted on the three axes with CD44 represented through 
color. Similar to the gene expression results, cells display reduction of SOX17, CXCR4 
proteins and gain in DLK1, ALB, AFP, CD44 proteins with endodermal expansion. Also, 
this clarifies that majority of the cells co-differentiate from an endodermal to a hepatic 
fate i.e. all the cells simultaneously acquire hepatic and reduce endodermal expression. 
This reaffirms that the gain of hepatic phenotype occurs uniformly and is not a random 
event occurring with endodermal cell expansion.  
4.2.3 Differentiation potential and functional activity of expanded 
endodermal cells 
The differentiation capacity of the expanded cells (EN1, EN2) to the hepatic 
lineage was examined by switching the expansion medium to stage 3 medium and 
continuing to stage 4 medium. Transcript levels for Phosphoenolpyruvate Carboxykinase 
(PEPCK), a mature hepatic marker that participates in gluconeogenesis [191] was 
measured along with alpha-1 antitrypsin (AAT), an important hepatic glycoprotein 
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functioning as a serine protease inhibitor [192], AFP, a blood plasma protein produced by 
the liver during fetal development and ALB, a blood plasma protein produced by the 
adult liver. The resulting HLCs from expanded endodermal cells (EN2-HLCs) expressed 
the hepatic transcripts for PEPCK, and AAT at levels similar to HLCs derived using the 
original protocol (Figure 4-10). However, the expression for the AFP and ALB 
transcripts was higher for EN2-HLCs compared to HLCs, which could be a result of 
differentiating a more homogenous population of expanded endodermal cells. 
Cytochrome P450 enzymes play a key role in drug detoxification in the liver and 
are often used as markers of hepatocyte maturity. Drug exposure often induces CYP450 
enzymes levels resulting in accelerated transformation of the drug to allow for rapid 
clearance [193]. To evaluate if the induction could be recapitulated in-vitro, 
CYP2C8/2C9/2A6 transcript levels in HLCs were monitored after exposure to rifampicin 
[194]. The levels were reported as log2 expression relative to uninduced cells as shown in 
Figure 4-11. CYP2C8 and CYP2A6 transcripts were induced similarly in HLCs and 
EN2-HLCs, upon rifampicin stimulation while CYP2C9 was induced to a lower extent in 
EN2-HLCs. 
The rate of albumin secretion and urea synthesis of the EN2-HLC cells were 
compared to HLCs generated from the original protocol (Figure 3c). EN2-HLCs secreted 
albumin at a higher rate (4.2 pg/cell/day) than HLCs (1.6 pg/cell/day). Both are still 
within the same range as our previous reports [177]. Urea production was comparable in 
both HLCs and EN2-HLCs at approximately 15 pg/cell/day. Glycogen synthesis (red) 
was also seen using PAS staining in both HLC and EN2-HLC cells (Figure 4-13). The 
results demonstrate that HLCs and EN2-HLCs have similar functional and phenotypic 
characteristics. 
4.2.4 Comparative Transcriptome analysis of cells from original and 
modified protocols 
 Analysis of cell lineage subsets to confirm hepatic trends with endodermal 4.2.4.1
expansion 
Transcriptome analysus was performed on the cells at different stages of 
expansion and differentiation. First of all, characteristic gene markers for pluripotent, 
endodermal, hepatoblast and hepatic cells were used to evaluate the hepatic transition of 
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the expanded endodermal cells and their differentiation, in reference to the original 
protocol. The comparison is presented as a plot with two time curves corresponding to 
the gene expression dynamics in each of the protocols. The first curve represents the gene 
dynamics of EN, EN1, EN2 and EN-HLC while the other curve represents EN, HPC, 
HPC1 and HLCs. The x-axis represents the corresponding day during differentiation. 
(Figure 4-14). Pluripotent genes NANOG, SOX2, ZIC3, SALL4, and LIN28, which all 
participate in regulating the self-renewal and pluripotency of hESCs [195] decrease in 
expression to a greater extent with endodermal expansion as we had observed previously. 
The endodermal genes EOMES, CXCR4, GSC, and FOXA2 also decreased as the 
endodermal cells are further passaged. This was accompanied by a greater increase in 
hepatic progenitor genes such as AFP, DLK, TTR, and KRT8 in addition to the increase 
in mature hepatic genes including PEPCK or PCK2, transferrin (TF), apolipoproteinA 
(APOA1) as observed earlier. 
 Analysis of genes participating in key hepatic functions to confirm similarity 4.2.4.2
in HLCs from both protocols  
Genes pertaining to important liver functions such as glycolysis/gluconeogenesis, 
urea cycle, fatty acid metabolism, and detoxification were evaluated for HLCs and EN2-
HLCs and were found to be similar. The transcript intensities for HLCs (blue) and EN-
HLCs (red) are shown in a bar chart in Figure 4-16. Notably, PEPCK (PCK2), FBP1, 
ALDOB, ENO1/2/3, PGAM1 are important liver metabolic isozymes that participate in 
glycolysis or catalyze interconversion of glucose to glycogen. Urea cycle and amino acid 
metabolism genes including arginase (ARG), carbamoyl phosphate synthetase I (CPS), 
ornithine aminotransferase (OAT), Aminoacylase 1 (ACY1), Guanidinoacetate N-
Methyltransferase (GAMT) were also evaluated. Liver specific cholesterol 
acyltransferase ACAT2 [196], straight-chain acyl-CoA oxidase (ACOX), carnitine 
palmitoyltransferase 1a (CPT1a), CYP4A11 participate in fatty acid metabolism [197] 
while CYP1A1/1B1/2B6/2C8/3A4/3A7 are involved in xenobiotic biotransformation 
[193]. The transcript levels are very similar for all the comparisons, affirming the 
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endodermal cells that underwent 8 fold expansion could be successfully differentiated to 
HLCs similar to the original protocol. 
 Global analysis 4.2.4.3
To evaluate the transcriptome on a global basis, invariant genes were removed 
and hierarchical clustering was performed. This showed that the expanded endodermal 
cells (EN1 and EN2) cluster separately from the EN cells and more closely with cells 
from later stages of differentiation.  The HLCs and EN2-HLCs however cluster together.  
From, principal component analysis (PCA) commonly used to reduce the 
dimensionality of the data, two principal components (PCs) were found to represent 90% 
of the variance. Therefore, these two PCs were used to visualize the trends in the data 
while retaining its inherent variability. The samples can be represented by their 
corresponding PCs and plotted in the two-dimensional PC space, where PC1 and PC2 are 
represented on the y and x-axis respectively. As seen in Figure 4-15, the expanded 
endodermal cells follow a similar differentiation trajectory towards hepatocyte-like cells 
as unexpanded endodermal cells. Furthermore, while the EN1 and EN2 cells are more 
differentiated than the EN cells, the resulting HLCs are very similar. 
Pearson correlation, a measure of linear correlation was computed for 
differentiation time points of both protocols to identify any genes with contrasting trends. 
A value of 1 and -1 imply a strongly positive and negative correlation, respectively. The 
distribution of the Pearson coefficient is shown in Figure 4-17. The genes of interest are 
those that have a strong negative correlation of -0.8 to -1. As expected, only 12 genes 
(Table 4-1) follow this trend while most genes are positively correlated indicating they 
follow the same trends in both protocols.  
Finally, genes that were differentially expressed by fivefold between the endpoint 
HLCs and EN-HLCs are shortlisted in Table 4-3. About 40 genes out of the 20,000 were 
identified and used to perform functional analysis in DAVID. The only functional cluster 
that had an enrichment score greater than 2 was response to wounding which included 
genes SERPINC1, SERPIND1 and MSTI. The other genes belonged to various gene 
ontology categories such response to extracellular stimulus, ketone metabolic process, 
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response to stress and regulation of endocytosis. Key hepatic genes were not 
differentially expressed confirming the similarity of HLCs from both protocols. 
 Discussion 4.3
 
The first major differentiation event to occur in-vivo involves the formation of the 
endodermal germ layer. During gastrulation, signaling through Nodal, a member of the 
TGFβ family, establishes the distinction between endoderm and mesoderm [63,198]. The 
endoderm is further patterned into the foregut, midgut and hindgut regions [4]. The liver 
along with the lung, pancreas, and stomach are derived from the foregut section around 
embryonic day (E) 9 of gestation [4,109]. The Nodal protein activates several specific 
transcription factors including FOXA2 and SOX17 that help regulate cell fate 
commitment to different endoderm cell lineages [63]. Signaling cues from the adjacent 
mesoderm layer are responsible for inducing liver development to enable hepatic 
specification through the fibroblast growth factor (FGF) and bone morphogenetic protein 
(BMP) signaling pathways. Hepatic progenitor cells will arise and proliferate 
significantly to form the liver bud. Continued signaling via growth factors such as 
hepatocyte growth factor (HGF), FGF, and BMP from the surrounding mesenchyme 
region will aid in promoting the liver bud development. Soon, bipotential hepatic 
progenitor cells will arise to form either hepatocytes or cholangiocytes which will line the 
lumen of the intrahepatic bile ducts. Oncostatin-M (OSM) secreted by the hematopoietic 
cells along with HGF will be necessary for inducing further maturation towards 
hepatocytes. These signals will aid in increasing the activity of liver enriched 
transcription factors, such as C/EBPα and HNF4α which will be necessary in binding to 
promoters of key genes in liver maturation [4,6,7,109].  
Differentiation protocols typically mimic the key signaling cues occurring during 
embryonic development. However, cellular proliferation, which is integral especially 
during in vivo development, is typically not integrated during in vitro differentiations. In 
this study, we demonstrated that our hepatic differentiation protocol could be modified in 
order to generate larger quantities of HLCs. This was implemented during the 
intermediate endodermal stage by simply allowing more surface area for ENs cells to 
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propagate showing up to at least 8-fold increase in number.  The expansion process 
utilized signaling cues from the FGF and BMP signaling pathway to mimic the 
cardiogenic mesoderm and septum mesenchyme signaling. These factors play a key role 
in the transition of the foregut endoderm to the liver bud which is largely dependent on 
cell migration, proliferation and differentiation [109].  
The subsequent passages in the expansion medium were accompanied with a 
simultaneous 1000 fold increase in expression of hepatic markers and 1000 fold decrease 
in endodermal and pluripotent markers. The EN2 cells underwent the highest loss in 
pluripotent and endodermal expression while gaining the most hepatic expression when 
compared to HPC1 cells, which have been exposed to fibroblast growth factors present in 
Stage 3 medium. During liver development, extensive crosstalk amongst signaling 
pathways occurs and therefore cells may embark on varied trajectories to attain the same 
differentiated state [6]. Therefore, the endodermal expansion coupled with FGF2 and 
BMP4 signaling may extend the effect of other FGF signaling mechanisms used in 
achieving HPC1 cells. The continued differentiation that occurs during expansion can 
help reduce the contamination of undifferentiated stem cells in the subsequent progeny. 
However, the capability for proliferation is not unlimited as these cells transition into a 
fibroblastic phenotype and initiate apoptosis, upon continued culture beyond three 
passages. This growth restriction is expected as cells are not being propagated as 
progenitor cells, but are allowed to mimic liver development and differentiate through 
exposure to different signaling cues. 
The question of whether this endoderm to hepatic transition was occurring in a 
subpopulation of cells or if they were a bulk population event was answered using mass 
cytometry. Mass cytometry was developed as multiparametric single cell analysis tool for 
applications in cancer, hematopoietic and immune cell biology [189,199,200]. This is the 
first time, to our knowledge, that this technique has been applied to stem cell directed 
hepatic differentiations. This technique relies on inductively coupled plasma mass 
spectrometry to accurately identify the concentration of the heavy metal tags on a single 
cell and circumvents spectral overlap issues common to flow cytometry [189].  Mass 
cytometry allowed for multiplexing endodermal and hepatic markers to visualize the cell 
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fate transition on a per cell basis. This allowed probing into whether genes are activated 
individually or in a consorted manner and confirmed that hepatic genes are 
simultaneously activated along with endodermal gene repression for a successful 
differentiation outcome. Furthermore, this trend was a population-based event and not 
restricted to a specific sub population (Fig. 2C and D).  
 Functional activity was then assessed to compare HLCs and EN2-HLCs to 
conclude that propagation of the intermediate endodermal population did not compromise 
the quality of hepatic differentiation. HLCs generated from both protocols exhibited 
similar hepatic transcripts as well as secretory capabilities for albumin and urea. The 
HLCs generated after incorporating endodermal expansion exhibit similar properties to 
HLCs and HLCs cultured in the original protocol for 26 days especially as it relates to 
hepatocyte gene expression and albumin secretion, also reported previously [177].  This 
indicates that prolonged culture period does not affect cell quality. The end stage HLCs 
were also similar in expression of characteristic hepatic genes involved in key functions 
such as urea cycle, glycolysis/gluconeogenesis and xenobiotic biotransformation.  
Transcriptome analysis provided further insights in to the behavior of the cells 
from both protocols. Unsupervised statistical techniques, of hierarchical clustering and 
PCA, revealed that though the paths along which the differentiation progressed were 
different, the end goal achieved was the same. Correlation and differential expression 
analysis demonstrated that none of the key hepatic genes were found to be differentially 
expressed between both HLCs. Gene set enrichment analysis was used to determine if 
any key pathways or signaling mechanisms was responsible for the difference in 
phenotype [179]. Wnt signaling and TGFβ signaling through Nodal which are key in the 
patterning of the foregut endoderm were upregulated in the EN cells. P53, PPAR 
signaling, and other characteristic hepatic functions such as complement and coagulation 
and drug metabolism were upregulated in the EN2 cells Table 4-2. Interestingly, in spite 
of the advanced differentiated status of the EN2 cells, the EN2-HLC cells are similar to 
the original HLCs. In most stem cell differentiations, the progeny is not as mature as their 
primary counterparts, indicating that a roadblock may need to overcome to achieve 
further maturation. This study reiterates this phenomenon, wherein the initial cues 
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promote differentiation but only to an extent permissive to create hepatoblasts. A 
comprehensive comparative analysis between in-vitro and in-vivo liver development may 
shed light on further navigating this blockade. 
Overall, this modified protocol allows for generation of at least 8 fold higher 
quantities of HLCs without relying on a higher starting ESC population. The generation 
of higher quantities of hepatocyte like cells is critical for thorough in-vitro 
characterization and the translation of research protocols to clinical therapies. Typically, 
end stage HLCs face growth limitations owing to their differentiated state. Some 
laboratories have reported expansion of progenitor cells at different stages of 
differentiation [111,127]. However, these methods entail cell sorting based on surface 
markers [127] , the use of feeders [111] or transfection with SV40  large T antigen [201]  
to achieve higher cell yields. In Cheng et al., CXCR4+/CD117+ cells were sorted from a 
bulk population to obtain endodermal progenitor cells that were kept in culture in a 
complex media on a combination of Matrigel and feeder cells. These may cause 
unwarranted changes due to xenogeneic factors in affecting cell quality that may hinder 
clinical translation. The approach of endodermal cell expansion using typical 
differentiation culture conditions achieves higher cell yields with comparable cell quality 
to the original protocol.  
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 Figures 4.4
 
Figure 4-1: Protocol for Expansion of Hepatic Endodermal Cells. A) Cells were 
differentiated toward the  endodermal cells and subsequently expanded up to 8 folds 
in 6 days using a combination of bFGF and BMP4. The expanded hepatic 
endodermal cells were then further differentiated towards hepatocyte using the 
existing differentiation protocol. 
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Figure 4-2: Expansion of cells showed a 8-fold increase during the course of 6 days  
(n=4) 
 
 
Figure 4-3: Morphology of cells A) immediately after plating and B) after three days 
in Stage 2 conditions is shown 
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Figure 4-4: The increase in cell number during regular differentiation protocol is 
shown 
 
Figure 4-5: Phenotype of endodermal cells undergoing expansion. A)  Endodermal 
cells showed a slight increase in hepatic markers during the expansion process while 
losing expression of pluripotent and endoderm markers (n=4) 
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Figure 4-6: Comparison of gene expression in the original and endoderm expansion 
protocol are shown with respect to the corresponding day of differentiation 
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Figure 4-7: Immunostaining reveal similar behavior of endodermal cells undergoing 
differentiation. Cells expressed endodermal markers (FOXA2 and SOX17) during 
endoderm stages but begin to lose expression as it underwent through expansion. 
Instead, cells begin to gain expression in AFP while maintaining FOXA2 illustrating 
a more hepatic endodermal phenotype  
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Figure 4-8: Mass Cytometry data for hESCs,EN,EN1,EN2 cells is shown where the x, y 
and z axes represent ALB, SOX17 and CXCR4 and the color represents CD44 
expression. Green indicates low and red indicates high expression.  hESCs are shown as 
the negative control. The endodermal genes decrease in most cells with increase in 
hepatic gene expression in EN1 and EN2 cells when compared  to the EN cells. 
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Figure 4-9: Mass Cytometry data for hESCs,EN,EN1,EN2 cells is shown where the x, y 
and z axes represent ALB, DLK1  and CXCR4 and the color represents CD44 expression. 
Green indicates low and red indicates high expression.  hESCs are shown as the negative 
control. The endodermal genes decrease in most cells with increase in hepatic gene 
expression in EN1 and EN2 cells when compared to the EN cells. 
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Figure 4-10: Differentiation properties comparing hepatocyte -like cells obtained 
from the traditional method of differentiation and the method of differentiation 
using a intermediate stage of expansion at the endoderm stage. A) HLCs, EN1-HLC, 
and EN2-HLC show similar levels of hepatic markers at the transcript level where 
we saw an even high expression in EN2-HLC compared to the other two samples  
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Figure 4-11: HLCs and EN2-HLCs were subjected to rifampicin and revealed 
similar drug metabolism abilities  
 
Figure 4-12: Functional behavior of albumin secretion and urea secretion also 
showed that HLCs and EN2-HLCs have similar function 
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Figure 4-13: Functional analysis was carried out to compare HLCs and EN2-HLCs 
illustrating both differentiated cells were able to perform glycogen storage 
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Figure 4-14: Transcriptome analysis comparing differentiated cells from traditional 
protocol and the newly established expansion protocol. A) Pluripotent genes B) 
Endoderm genes C) Hepatoblast genes D) Hepatic genes . The color bar represent 
the transcript intensities . The black and blue curves represents the modified and 
original protocols. 
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Figure 4-15: Transcriptome analysis of different samples reveal similarities of 
hepatocyte-like cells between the existing protocol and the expansion protocol 
through A) hierarchical clustering B) Principal Component Analysis. The first two 
PC’s of all the samples are plotted in the B. The samples from the original protocol 
and modified protocol are marked in red and blue  
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Figure 4-16: Expression levels of different functions were compared between 
hepatocyte-like cells and hepatocyte -like cells from endodermal expansion.. 
Expression levels of A) Glycolysis B) Urea cycle C) Fatty acid metabolism D) 
CYP450 enzyme genes showed similar level between HLCs and EN2-HLCs. The 
HLCs and EN-HLCs are shown in blue and red respectively. 
 
Figure 4-17:  Pearson Co-efficient was computed among different time points in 
both protocols to identify genes with similar or contrasting dynamics. A distribution 
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of coefficients is shown. 1 indicates a strong positive correlation and -1 indicates a 
strong negative correlation. 
 
 
 
 
 
Table 4-1: Genes that are negatively correlated from the pearson correlation analysis 
reveal that these genes do not participate in important biological functions 
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Table 4-2: Geneset Enrichment Analysis results show the biologically relevant 
pathways upregulated in the different cell types  
 
 
Table 4-3: Genes differentially expressed by five fold or higher in HLCs and EN-
HLCs 
Symbol H9_D20 D6P2_Diff_d20 
Log2(Fold 
Change) 
ACTA1 11.1067 8.38899 2.71773 
ACTG2 9.60846 12.7988 3.19034 
ADAMTS1 8.65104 11.0802 2.4292 
AHSG 13.5762 10.1642 3.41201 
ANKRD38 10.2214 7.77595 2.44548 
ANXA13 7.42085 9.81904 2.39819 
APOA4 13.72 8.8395 4.88047 
APOC2 10.0518 7.48163 2.57013 
APOC3 13.3303 8.90385 4.42642 
BHMT 9.20836 6.79231 2.41605 
COL14A1 7.05913 9.41768 2.35855 
CRYAA 9.95287 7.1319 2.82097 
CST1 11.6516 7.88067 3.77094 
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EGFL6 8.48672 11.2259 2.73919 
FMO1 10.3366 8.00172 2.33493 
FOS 8.01669 10.4092 2.39256 
GABRP 11.1903 6.9078 4.28249 
GCGR 9.59124 6.77351 2.81773 
HOPX 8.4149 11.4235 3.00865 
HYAL1 10.3388 7.34903 2.98974 
IGSF1 11.0816 8.33392 2.74765 
IL1RL1 7.38202 10.4958 3.11374 
MGP 8.50984 11.9262 3.41632 
MST1 11.9363 9.51991 2.41634 
NNMT 7.89405 10.3769 2.48287 
SERPINA7 12.1384 8.9683 3.17013 
SERPINC1 10.4065 7.61234 2.79411 
SERPIND1 10.0648 7.3601 2.70465 
SLC13A5 11.4297 8.9906 2.43914 
SLC7A10 9.53267 7.17641 2.35626 
TF 13.9989 11.0814 2.91749 
TFF3 7.6737 10.4582 2.78447 
TFPI2 7.31491 9.7234 2.4085 
TSPAN8 7.0043 10.067 3.06273 
TXNIP 7.24371 9.57456 2.33085 
UGT2B28 10.8571 8.52376 2.3333 
VTCN1 9.71793 7.04247 2.67546 
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5. ENRICHING HEPATIC LINEAGE FATED CELLS FROM STEM 
CELL DIFFERENTIATIONS 
 Introduction 5.1
 
Liver failure is a major cause of mortality for which the only cure is self-regeneration or 
organ transplantation. The transplant option is severely limited by the shortage of organ 
donors.  Many liver disorders especially those that are related to metabolic deficiencies 
are caused by cellular malfunction in hepatocytes. Cellular transplantation in such 
scenarios could be a beneficial and less invasive alternative to whole organ 
transplantation [202]. Hepatocytes have been shown to successfully repopulate the liver 
in animal models with liver failure. Hepatocytes, derived from donors or cryopreserved 
cell banks, are typically infused through the portal vein and have been used to restore 
liver function or bridge patients to liver transplantation [11]. Hepatocyte transplantation 
however is also limited by the availability of donors and decline in cell viability and 
function with prolonged culture. Since, hepatocytes are terminally differentiated cells; 
their repopulation potential is limited when compared to a fetal hepatic progenitor or 
stem cell. Therefore, isolation of such cells from the fetal liver with high proliferative 
potential has been pursued as an alternative to hepatocytes for liver cell based therapy 
[203]. 
During embryonic liver development, hepatoblasts, a common progenitor cell for 
hepatocytes and cholangiocytes, undergo extensive proliferation during the formation of 
the liver bud. These cells are less likely to undergo de-differentiation in culture as 
primary hepatocytes and therefore are more suitable for transplantation [85]. Cells have 
mostly been isolated from embryonic day (E) 13-14 rodent fetal livers based on surface 
marker expression. Delta-like protein 1 (DLK1), typically expressed during early liver 
development, has been a popular surface marker to enrich rodent hepatoblasts [88-90] 
along with E-cadherin [91] , epithelial cell adhesion molecule (EPCAM) [92] and 
intercellular cell adhesion molecule (ICAM-1)[204]. These cells showed proliferative 
capabilities when cultured in appropriate culture conditions. A serum free medium 
developed by Kubota et al, was specifically tailored for the ex vivo propagation of 
  104 
hepatic progenitor cells isolated from fetal liver [94,204,146]. However, the reliability on 
fetal liver sources has restricted these studies mostly to animal models. 
Stem cells are an alternative source of generating hepatocyte like cells through 
differentiation strategies based on embryonic liver development. The differentiation 
protocol and the growth factors used have been described in the previous chapter. The 
differentiated hepatocyte like cells (HLCs) express key hepatic transcripts and functions. 
However, the key challenges with this protocol are the presence of heterogeneous cell 
populations after differentiation as well as limited functional maturity when compared to 
primary hepatocytes. We hypothesized that a similar strategy of enriching hepatic 
progenitor cells (HPCs), when applied to the in vitro differentiation process, could yield a 
homogenous population of cells, which can be used as a platform for future cell based 
therapies. These HPCs, if comparable to their in vivo counterparts could possess 
proliferative potential. Furthermore, the elimination of “unwanted” cells in culture would 
enable the pursuit of efficient differentiation strategies of these HPCs to high quality 
hepatocytes.  
 Results 5.2
5.2.1 HLCs are a heterogeneous population of cells 
The human embryonic stem cell line (H9) was differentiated using a protocol previously 
published [182], and  described in detail in the Material and Methods Section 3.2. Briefly, 
hESCs were passaged onto Matrigel coated plates. Differentiation was initiated by 
switching medium to a differentiation basal medium supplemented with stage specific 
growth factors or cytokines for specification of definitive endoderm (EN), hepatic 
progenitor cells (HPC) and hepatocyte like cells (HLCs). The hepatocyte like cells 
generated (HLCs) were found to express hepatic transcripts as shown by qRT-PCR in 
Figure 5-1A.  The results are reported as log2 intensity values with respect to expression 
in hESCs. Alpha-fetoprotein, Delta-like homolog 1, Albumin and Alpha-1 antitrypsin are 
common markers of fetal hepatocytes or hepatic progenitor cells. Cholesterol 7-alpha 
hydroxylase (CYP7A1), Glucose-6-phosphatase (G6PC) and arginase (ARG) are mature 
hepatocyte markers that participate in cholesterol metabolism, gluconeogenesis and urea 
cycle respectively. Expression of fetal transcripts AFP, ALB, DLK1 and A1AT were 
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significantly higher by 1000 fold than mature transcripts CYP7A1, G6PC and ARG in the 
HLCs. The pluripotent stem cell marker OCT4 decreases with differentiation as expected. 
Asialoglycoprotein receptor (ASGR1) is a mature hepatocyte marker that plays a role in 
processing glycoproteins with terminal galactose or N-acetylgalactoseamine residues. 
About 23% of the HLCs were mature hepatocytes as quantified by the number of ASGR1 
positive cells through flow cytometry as seen in Figure 5-1B. The secretory capabilities 
of HLCs are shown for albumin and urea in Figure 5-1C, D. However, similar functions 
in primary hepatocytes were at least an order of magnitude higher indicating that there is 
scope for further maturation. Transmission electron microscope imaging of HLCs 
showed hepatic features such as tight junctions and bile canaliculi as well as a high 
nucleus to cytoplasm ratio, which is indicative of a progenitor cell status. 
 The presence of an endothelial subpopulation was observed through co-staining for 
endothelial marker VE-cadherin along with fetal hepatic marker AFP, as early as D14 of 
differentiation, through flow cytometry (Figure 5-1E) This suggests that the differentiated 
progeny is a mixture of hepatic cells with varying maturity as well cells from other 
lineages. The presence of contaminating cell types during earlier stages of differentiation 
may have detrimental effects on the quality HLCs generated. Therefore, it is of interest to 
develop methods to enrich hepatic progenitor cells and then differentiate them to 
homogenous population of functional hepatocytes. 
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5.2.2  DLK1 as a surface marker for hepatic progenitor cells 
Hepatic progenitor cells express a number of characteristic genes, including alpha-
fetoprotein (AFP), Albumin, HNF-4α, CEBPα and CK-19 [1]. In addition to these 
intracellular markers, several surface markers characteristic of HPCs have been reported, 
such as CD29, CD34, CD133, c-kit, c-met, thy-1, N-cadherin, E-cadherin, EPCAM, 
NCAM, [127], CD44 [206], DLK1[88,89] and Liv2 [207]. Cell surface markers are 
desirable as they allow ease of cell enrichment without the genetic manipulation required 
for the development of hepatic promoter driven reporter cell lines. The gene expression 
dynamics of potential candidates in various stages of liver differentiation is shown in 
Figure 5-2. The expression values were obtained from time course microarray data 
collected using the protocol described in Section 3.10 and are reported as fold change 
with respect to expression in hESCs. DLK1 is transmembrane protein with six epidermal 
growth factor (EGF) repeats, N-cadherin is a calcium dependent cell adhesion protein. 
CD44, ICAM and NCAM are cell surface glycoproteins that play a role on cell adhesion. 
DLK1I was the only marker that increased significantly during hepatic differentiation. 
Therefore, DLK1 was a promising marker for enriching hepatic progentitor cells based 
on its gene expression dynamics. The increase in DLK1 expression during differentiation 
was also confirmed by qRT-PCR Figure 5-3A). The intensity increased by 100 fold and 
1000 fold in Day 14 HPCs and HLCs relative to hESC expression. The percentage cells 
expressing the DLK1 protein was found to be about 30% on day 14 or HPC1 cells by 
flow cytometry (Figure 5-3B). Finally, co-expression of DLK1 and AFP proteins was 
visualized through immunohistochemistry (Figure 5-3C). An isotype control was used the 
negative control for flow cytometry and immunohistochemistry experiments. 
Additionally, the protocol was optimized using hESCS and HEPG2 as a negative and 
positive control. Therefore, expression of DLK1, a hepatic progenitor marker, was indeed 
being upregulated during hepatic differentiation and enrichment of these DLK1+ cells 
would allow further investigation of their properties. 
5.2.3 Cell surface marker based enrichment of Hepatic progenitor cells 
Hepatic progenitor cells on day 14 of differentiation were harvested using a protocol 
described in Section 3.7. Magnetic activated cell sorting (Section 3.8) was used to enrich 
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the DLK1+ cell fraction from the HPC1 cells. Quantification of hepatic gene expression 
in DLK1+ cell fraction and the unlabeled (DLK-) cell mixture samples by qRT-PCR was 
used to confirm enrichment. Intensity values relative to expression in the unsorted day 14 
bulk population are reported. DLK1 and AFP expression were expressed eight fold 
higher in the DLK1+ cell fraction than the unlabeled population as expected (Figure 5-4) 
However, the efficiency of cell sorting was low as DLK1+ cell yields recovered was only 
about 10% of the total population. Furthermore, upon culturing the enriched cells in 
Stage 4 medium conditions, cells began to loose their epithelial and gain a fibroblastic 
phenotype rapidly (Figure 5-5). This suggested that this method of cell enrichment was 
sub-optimal for enriching the hepatic progenitor cells.  
5.2.4  Enrichment of HPCS using selective medium 
Hepatocytes mediate cell-cell communication via different types of cell junctions [208]. 
Since these cell-cell junctions are important for hepatocyte integrity and function, 
dissociation into single cells for cell sorting may not be optimal. An enrichment medium 
is one that is selective for cells of a desired phenotype. A selective medium-based 
strategy would be preferential in the enrichment of hepatic progenitor cells, as this would 
eliminate cellular stresses caused by single cell dissociation and culture. Kubota et al 
optimized a serum free medium for ex vivo expansion of hepatic progenitor cells isolated 
from fetal rodent and human livers [94,204]. These cells formed epithelial colonies when 
cultured on plastic, possessed proliferative capabilities and maintained expression of fetal 
hepatic markers AFP and EPCAM [94,95,205,209]. It was therefore hypothesized that 
Kubota’s medium could be selective for hepatic progenitors derived from stem cell 
differentiations. Hence, cell were harvested on day 14 and passaged as small clusters into 
different culture conditions. 
 Optimal extracellular matrix for hepatic progenitor cells 5.2.4.1
 Extracellular matrix (ECM) is a critical component of the hepatic cellular niche and is 
essential for cellular attachment, growth and differentiation [101]. Cells, whether in vivo 
or in vitro, typically bind to an extracellular matrix (ECM), which anchors them, allows 
them to multiply or migrate and, most importantly, provides signals that can affect their 
fate (Chen et al, 2007). Progenitor cells maintained viability and liver specific gene 
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expression when cultured on appropriate biomatrices [210]. The native fetal liver matrix 
is composed mostly of collagens (Type I, III, and IV) along with laminin and other 
proteins. Stem cell hepatic differentiations are routinely performed on Matrigel, a 
complex mixture rich in ECM protein derived from mouse sarcomas, that has been found 
to promote cellular adhesion and viability[211].  
 To evaluate optimal culture conditions, cells harvested from day14 of stem cell 
differentiations were cultured on collagen I, collagen III, collagen IV, laminin and 
matrigel, in the presence of either Kubota’s or Stage 4 medium. The cells were seeded at 
a density of 50,000 cells/cm
2
. Hepatic gene and protein expression in cells cultured under 
these various conditions was evaluated by qRT-PCR and immunohistochemistry after six 
days in culture (Figure 5-6). The gene expression values are reported relative to 
expression in the traditional Stage 4 microenvironment to observe any improvement over 
this condition. The gene expression of cells with the combination of Kubota’s with 
collagen I was the highest for hepatic markers (AFP, ALB, EPCAM and DLK1) 
compared to the other conditions. From immunohistochemistry, it is evident that majority 
of cells cultured in Kubota’s  medium on collagen I were expressing AFP, which is 
indicative of increased cell homogeneity. Cells cultured on other ECMs, with stage 4 
conditions clearly showed the presence of an AFP- cell type (Figure 5-7). Therefore, 
Kubota’s medium and collagen I were deemed suitable for culture of a homogenous 
population of hepatic progenitor cells. To evaluate the HPCs cultured in Kubota’s further, 
gene expression of additional hepatic markers CYP3A4 and CYP3A7 was measured. 
CYP3A7 and CYP3A4 are CYP450 enzymes that are predominantly expressed in the 
fetal and adult livers. In differentiating HLCs, the CYP3A7 transcript is expressed at 
approximately 30 fold higher levels than CYP3A4 consistent with their immature status. 
Both these transcripts increased by tenfold in cells cultured in Kubota’s medium 
compared to the Day 14 HPCs (n=4) (Figure 5-8). Furthermore, cells displayed an 
epithelial morphology upon culture in Kubota’s medium, with the absence of other 
fibroblastic subpopulations. This was confirmed again using immunostaining for AFP 
(hepatic marker) and DAPI (nuclei stain) for cells in Kubota’s medium and from Figure 
5-7, where only AFP positive colonies are seen in Kubota’s medium. The ce lls plated in 
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regular Stage 4 medium are also shown for comparison and consisted of several AFP 
negative cells (DAPI positive cells) alongside the AFP+ cells in the culture. The presence 
of a large non-hepatic sub-population suggests that these cells may have a growth 
advantage over HPCs in the Stage 4 conditions. To confirm this, D14 cells were 
harvested and stained with dye, Vybrant Dil labeling solution (Life Technologies) which 
is incorporated into the cell membrane. The labeled cells were replated into either 
Kubota’s or Stage 4 medium conditions and visualized after two days. From Figure 5-10, 
the epithelial colonies in Kubota’s largely retain the dye while the presence of unlabeled 
cells in Stage 4 conditions suggests that some cells may have undergone faster 
proliferation thereby diluting the dye in cell membranes. This along with the previous 
results indicate that some components of the Stage 4 medium may confer a proliferative 
advantage of undesired cells, which is absent in Kubota’s medium conditions, thereby 
conferring the selectivity for hepatic cells. 
Finally, the number of AFP and Albumin positive cells was found to be higher in 
Kubota’s at 30 and 15% respectively relative to 15 and 5% respectively, for D14 cells 
and cells cultured in Stage 4 medium as seen in Figure 5-11. These results indicate that 
the Kubota’s medium is useful as a selective medium for enriching hepatic cells. 
 Effect of growth factors on enhancement of hepatic phenotype 5.2.4.2
The combination of Kubota’s medium and collagen I was found to be selective for 
hepatic cells. To optimize the culture conditions, the effects of growth factors was 
investigated. Hepatocyte growth factor (HGF) is a growth factor that allows hepatoblast 
survival through interactions with its receptor c-met, which is present on the surface of 
these cells. C-met activation enhances hepatoblast survival by inhibiting signals 
responsible for hepatoblast apoptosis [212]. Epidermal growth factor (EGF) is another 
factor implicated in cell proliferation and survival. Chen et al and Sasaki et al have 
demonstrated the use of a serum free media based on DMEM/F-12 including growth 
factors HGF and EGF in the culture of hepatoblasts isolated from rat and human liver 
[206,213]. Hepatoblasts isolated from E12.5 mouse embryonic livers were shown to 
proliferate in media supplemented with HGF and EGF [91]. The day 14 HLCs were 
found to express the HGF receptor c-MET and the EGF receptor EGFR transcript levels 
  110 
about twofold higher when compared to hESCs based on microarray data. Therefore, the 
effect of supplementing growth factors, EGF and HGF to Kubota’s medium on hepatic 
cells was investigated. The conditions tested were Day 14 HPCs on Collagen I treated 
plates with a) Kubota’s medium without any growth factors b) Kubota’s with EGF (20 
ng/ml) and c) Kubota’s with HGF(50ng/ml) and EGF(20ng/ml). Hepatic gene expression 
after six days in culture was compared with respect to the bulk D14 HPC population 
(n=2) as shown in Figure 5-12. Hepatic gene expression was lower for all the markers 
when cells were cultured only in the presence of EGF, and was approximately twofold 
higher when they were cultured in the presence of HGF and EGF when compared with 
cells cultured in Kubota’s medium only. Therefore, a significant increase in hepatic 
phenotype was not observed upon growth factor supplementation to Kubota’s medium.  
While the combination of Kubota’s medium and collagen I is selective for hepatic cells, it 
fails to confer the proliferative ability observed in the counterparts obtained from fetal 
liver, even in the presence of hepatic growth factors. This is in contrast to results for 
hepatic progenitor cells isolated from the fetal liver. This may be a consequence of 
differences in cell surface topology for hepatic progenitor cells obtained from in vitro and 
in vivo conditions.  
5.2.5 Differentiation of hepatic progenitor cells to hepatocytes 
The hypothesis for selectively enriching the hepatic population on Day 14 was that they 
could differentiate to a homogenous population of functional hepatocytes subsequently. 
The Kubota’s medium enriched cells fated towards the hepatic lineage. To differentiate 
the HPCs to HLCs, the medium was changed from Kubota’s to Stage 4 differentiation 
medium consisting of maturation growth factors HGF and Follistatin. Hepatic gene 
expression was evaluated after four days. The transition in expression of hepatic 
transcripts from D14 HPCs, to HPCs cultured in Kubota’s medium for six days and then 
being differentiated to HLCs in Stage 4 medium is shown in Figure 5-13. The gene 
expression of D20 HLCs derived from the original protocol is also shown for reference. 
The highest change in expression of hepatic transcripts was observed between Day 14 
HPCs and HPCs enriched after culture in Kubota’s medium. Significant changes were not 
seen after the switch to the differentiation medium. Albumin, CYP3A4 and CYP3A7 
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showed a moderate two-fourfold increase in expression levels after treatment with Stage 
4 medium when compared with the HPCs enriched in Kubota’s medium (n=4) (Figure 
5-13). The error bars reflect the inherent variability in stem cell differentiations.  Effects 
on differentiation potential from addition of growth factors during HPC culture in 
Kubota’s was also investigated and significant impact on hepatic transcripts was not 
observed as seen in Figure 5-14, n=2). Furthermore, transcript levels of HLCs derived 
from cells cultured in Kubota’s medium were comparable to those of HLCs derived from 
the original protocol, in spite of starting with a more homogenous HPC population. While 
the initial results of enrichment using Kubota’s is promising, further optimization of 
culture conditions for the proliferation and differentiation of HPCs will be necessary.  
 Discussion 5.3
  
Stem cells are a promising source of hepatocytes for clinical applications. Cellular 
therapies will entail transplantation of at least 10
9
 cells per patient. Progenitor cells 
arising during differentiations are sought after, with the hypothesis that they can be 
proliferated like their in vivo counterparts and differentiated to hepatocytes, to sustain 
clinical demands.  
Conventional bioprocessing knowledge can be applied to develop a robust process to 
generate stem cell derived products for clinical applications, as discussed in the literature 
survey. A key difference in a conventional bioprocess for recombinant protein production 
and stem cell culture lies in the product isolation stage. While the aim of cell separation 
operations in recombinant protein production, is to recover the desired products from the 
cell supernatant, the aim of a stem cell bioprocess, is to isolate desirable cell types while 
removing other undesired cell types and medium components. As previously emphasized, 
stem cell differentiation often results in a heterogeneous population, and the target cell 
population needs to be separated from the other cells. Notably, even a small level of 
contamination with undifferentiated or partially differentiated cells can be highly 
detrimental to therapeutic applications as these cells can potentially form teratomas in the 
host as reviewed in [214]. Thus, it is important that product isolation be as selective as 
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necessary in addition to being efficient. The isolation and enrichment of the product cell 
type is largely based upon cellular characteristics, such as surface marker expression. 
One strategy is based on selective isolating or killing unwanted cells through the use of 
monoclonal antibodies [215]. Using an antibody against a surface glycoprotein 
specifically expressed on hESCs, the undifferentiated cells at the end of differentiation 
can be targeted for killing thereby reducing the risk of teratoma formation. On the other 
hand, the surface markers Stro1 and Stro3 are used to isolated specific MSC populations 
[216,217]. 
 Another technique for isolating the desired cell types is by using selectable markers 
through genetic manipulation. Using a transgene that provides selective advantage, driven 
by a tissue specific promoter, a highly enriched population of target cells can be obtained. 
This approach is particularly useful for non-clinical applications. Mouse cardiomyocytes 
car thus be enriched from a differentiated population of mouse embryonic stem cells 
through the use of aminoglycoside phosphotransferase driven by α-cardiac myosin heavy 
chain promoter [218]. This technique has also been used for achieving the enrichment of 
other cell types such as neurons [219] or hepatocytes [220]. However, for this method to 
be suitable for clinical applications, a transient vector would need to be employed that 
would be reliably lost from the cell after a certain number of cell doublings is reached. 
Cell surface markers are frequently used in the isolation of desirable cells from 
heterogeneous population, especially at the laboratory scale. Fluorescence-activated cell 
sorting (FACS) is a popular and effective tool for separating cells on the basis of 
fluorescent-antibody labeling of surface markers [106,221]. Magnetic cell sorting 
(MACS) is complementary to FACS in utilizing cell surface markers for selection and 
enrichment [222]. Cells are subjected to less stress during MACS isolation when 
compared to FACS procedures [223]. This makes it better suited for clinical and 
industrial scale up. It is noteworthy that this approach has been tested in a multicenter 
clinical trial conducted by the Bone and Marrow Transplant Clinical Trials Networks in 
which the CliniMACS® system was used to achieve sufficient levels of T cell depletion 
and isolating large numbers of CD34
+
 cells [224].  
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As previously emphasized, the fact that these techniques rely on specific cell surface 
markers makes their wide spread use restricted by the limited existing knowledge about 
the relationship between cell surface markers and cellular phenotype and function. For 
embryonic and induced pluripotent stem cells, cellular markers have been identified 
through extensive research that enables assessment of cell quality [225]. These include 
surface markers such as SSEA-3/4 and TRA-1-60/81, as well as intracellular transcription 
factors such as Oct4 and Nanog, for which even the relationship between phenotype and 
function is well understood [225]. For liver, and other adult stem cell types, even though 
multiple markers have been identified for cell characterization, the relationship between 
their expression and cellular functions is not always understood [61]. This lack of 
knowledge about the functional significance of those markers poses some uncertainty on 
the nature of cells isolated based on those markers. 
In this study, an extensive literature survey and analysis of transcriptome data were used 
to shortlist potential markers to enrich hepatic cells. Magnetic activated cell sorting was 
employed using DLK1 as a surface marker was shown to have increased hepatic 
transcripts compared to the unlabeled (DLK1-) cell fraction. However low cell yields and 
the inability to maintain a sustained hepatic phenotype in standard differentiation 
conditions was observed. Since cellular tight junctions play an integral role in hepatic 
integrity and function, dissociation of the hepatic cells to single cells and subjecting them 
to cell sorting could have effected cell yields and viability. Additionally, the Stage 4 
microenvironment that was developed for differentiation may not have been optimal for 
prolonged cell culture of the enriched hepatic cells. Multiple fibroblastic cells were seen 
upon culture in the Stage 4 medium, suggesting that either an undesired cell 
subpopulation was proliferating faster than the hepatic cells or the hepatic cells 
themselves were undergoing epithelial mesenchymal transition.  To preserve cellular 
integrity and eliminate cell sorting related stresses, a gentler method was sought to enrich 
HPCs. This would also enable easier downstream processing for product purification, 
when translating this approach into a therapy. 
Kubota’s medium combined with a collagen I surface were found to selectively enrich 
hepatic cells from stem cell hepatic differentiations. Culture of day 14 HPCs in Kubota’s 
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medium was accompanied by initial cell death. This reduction in cell yields is 
compensated by a limited 1.5 to 2-fold proliferation of the hepatic cells over six days in 
culture. This was accompanied by an increase in hepatic transcripts and proteins thereby 
indicating a selective pressure favoring cells fated towards the hepatic lineage. 
Interestingly when the same cells were cultured in Stage 4 conditions, a subpopulation of 
non hepatic cells were found to proliferate similar to the DLK1+ cells cultured in the 
same conditions. The additional surface area as well as the Stage 4 microenvironment 
could confer a growth advantage for these proliferating cells. In contrast, such cells are 
not observed in the Kubota’s medium and Collagen 1. Apart from the difference in the 
extracellular matrix, differences in the medium components could be responsible for this. 
While the basal medium composition is largely the same for both media, Kubota’s 
medium is additionally supplemented with nicotinamide, hydrocortisone and free fatty 
acids (linoleic, linolenic, palmitic, stearic and oleic acid), which could play a role in 
selectivity. Furthermore, the origin of these non hepatic cells is unclear as they could also 
arise as a result of dedifferentiation or epithelial mesenchymal transition of hepatic cells. 
In some conditions, the presence of HGF was found to stimulate EMT of epithelial 
cells[226]. 
The hepatic cells that were enriched did not possess the highly proliferative properties of 
their in vivo counterparts cultured in the same culture conditions. In addition, when these 
cells were differentiated further, the HLCs generated were very similar to HLCs 
generated using the original protocol. The homogeneity of the starting cell population 
was not reflected in an increase in differentiated status of HLCs after differentiation.  
While the Kubota’s medium and Collagen I microenvironment provide an encouraging 
start, further optimization of culture conditions for maintaining proliferative capability 
and successful differentiation will be needed. 
  Figures 5.4
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Figure 5-1: Characterization of stem cell differentiated HLCs. (A) Gene expression 
of pluripotent OCT4, fetal hepatic ( AFP, DLK, A1AT, ALB) and mature hepatic 
(ARG,CYP7A1,G6PC, mGST1) are shown relative to their expression in hESCs (B) 
The number of cells expressing mature hepatic marker ASGPR by flow cytometry is 
shown by the red histogram and  the  isotype control is shown in blue (C) 
Comparison of ALB secretion in HLCs and primary hepatocytes (D) Comparison of 
urea secretion in HLCs and primary hepatocytes (E) A transmission electron 
 AFP 
VE-cadherin (Endothelial 
marker)   Day 14 
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microscopy (TEM) micrograph of cells showing hepatic features along with high 
nucleus to cytoplasm ratio (F) Co-staining for hepatic marker (AFP) and endothelial 
marker (VE-cadherin) on Day 14 of differentiation by flow cytometry is shown. 
 
Figure 5-2: Dynamic gene expression of cell surface marker candidates for  D6 
endoderm (EN), D10,D14 hepatic progenitors (HPC,HPC1) and D20 hepatocyte like 
cells (HLCs)  are shown. These values were obtained from  transcriptome array 
data and are represented as fold change with respect to expression in hESCS. 
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Figure 5-3: DLK1 expression during differentiation. A) Expression of DLK1 
through various time points of differentiation was quantified by qRT-PCR. The 
values are reported as log2 intensity values relative to hESCs. B) About 30% of cells 
were found to express DLK1 on day 14 of differentiation. C) Immunostaining for 
AFP(red) with DLK1(green) on Day 14 of differentiation showed co-expression of 
these markers in many cells. The nuclei were stained with DAPI (blue) 
  120 
 
Figure 5-4: Hepatic gene expression in DLK1+ and unlabeled fractions after cell 
sorting on Day 14 of differentiation using MACS is shown (N=2). The values are 
reported  as log2 values relative to the unsorted bulk Day 14 cell population. DLK+ 
cells express higher transcripts for the markers probed. 
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Figure 5-5: DLK1+ cells gain a fibroblastic phenotype within three days of culturing 
in Stage 4 medium. 
 
 
Figure 5-6: Hepatic gene expression in Day 14 cells that were harvested and 
cultured on Matrigel (M), Collagen I (CI), Collagen III (CIII), Collagen IV(CIV), 
Laminin (L) in either Kubota(K) or Stage 4(S4) medium for six days 
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Figure 5-7: Immunostaining for AFP (red), DAPI (nuclear stain, Blue) in different 
culture conditions after six days is shown. A) Kubota, Collagen I B)Kubota, 
Collagen III C)Kubota, Collagen IV D) Kubota, Matrigel E) Stage 4 medium, 
Collagen I F) Stage 4 medium, Collagen III G)Stage 4 medium, Collagen IV H)Stage 
4 medium, Matrigel 
 
Figure 5-8: Hepatic gene expression of Day14 HPC cells cultured in Kubota's 
medium on Collagen I for six days (N=2). Increase gene expression relative to 
unsorted Day 14 cells was observed for cells in Kubota’s medium 
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Figure 5-9: Morphology and immunostaining for AFP (Green) and nuclear DAPI 
(blue) is shown for cells cultured in Kubota's medium for six days. For comparison, 
cell cultured in Stage 4 medium conditions are displayed. The Kubota’s medium is 
more selective for cells of hepatic morphology 
A 
C D 
B 
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Figure 5-10: D14 HPCs were labeled with cell membrane Vybrant dye (Red) and 
cultured in different conditions for two days (A, B) Most cells cultured in Kubota’s 
retain the dye (C,D) A non-hepatic subpopulation seems to be proliferating thereby 
diluting the dye in the Stage 4 conditions  
 
Figure 5-11: A higher number of cells expressing AFP and ALB were seen by flow 
cytometry in Kubota conditions vs the Stage 4 conditions after six days in culture  
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Figure 5-12: Effect of HGF and EGF growth factor supplementation in Kubota’s 
medium on hepatic phenotype of  Day 14 HPCs after six days in culture N=2. The 
error bars reflect inherent variability in stem cell differentiations. 
 
Figure 5-13: The change in hepatic transcripts of Day 14 HPCs through the process 
of enrichment in Kubota’s medium and subsequent differentiation in Stage 4 
medium is shown (N=4). The intensities are reported as Delta Ct values relative to a 
housekeeping gene GAPDH. Higher values indicate higher gene expression. The 
values for the original HLCs are also displayed and can be differentiated by the 
break in the curve. 
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Figure 5-14: The change in hepatic transcripts of Day 14 HPCs through the process 
of enrichment in Kubota’s medium supplemented with HGF and EGF and 
subsequent differentiation in Stage 4 medium is shown.  The intensities are reported 
as Delta Ct values relative to a housekeeping gene  GAPDH. Higher values indicate 
higher gene expression. The values for the original HLCs are also displayed and can 
be differentiated by the break in the curve. 
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6. CROSS-SPECIES TRANSCRIPTOME META-ANALYSIS 
WORKFLOW 
 Microarray Sample Processing 6.1
Total RNA was extracted from human and mouse liver differentiation samples at a 
various time points of differentiation using the RNeasy Mini kit (Qiagen). Human (H9, 
HSF6) samples were hybridized to the Illumina HT12 bead array v3 (Illumina Inc.), 
HES3 samples were hybridized to Human Genome U133 v2 array (Affymetrix) and the 
mouse samples were hybridized to the WG-6 v2 (Illumina) array.  
 Sample Collection from Public Depositories 6.2
The datasets and the samples, from which the data were acquired, are listed in Table 1. 
These data, encompassing transcriptome microarray data of different platforms 
Affymetrix, Agilent and Illumina, were downloaded from the Gene Expression Ontology 
(GEO) database (http://www.ncbi.nlm.nih.gov/geo). The human cell data included 
transcriptome of different human embryonic cell lines differentiating to hepatic lineage 
using different protocols [123,227,228]. Human differentiation data encompassed time 
series data from two sources, data from HLCs generated using various protocols, 
including regular differentiation, endodermal cell expansion followed by differentiation 
and formation of three dimensional spheroids upon HLC differentiation. Additionally, 
transcriptome data for liver bud generated through co-culturing iPS-derived HLCs with 
mesenchymal and endothelial cells was obtained [229]. Recently, HLCs generated 
through direct reprogramming of fibroblasts to HLCs by hepatic transcription factor 
transduction has been reported as an alternate source to stem cell derived HLCs. This 
data was also included in the analysis [201]. 
The mouse liver development data covered developing liver tissues from prenatal (E9.5 
to E19.5) and postnatal embryonic development [78,229]. RNA-Seq data for mouse E8.5, 
E14.5 and adult liver (6 months female) was obtained from 
(http://www.alexaplatform.org/alexa_seq/Morgen/Summary.htm) [230]. In vitro 
differentiation data for mouse HLCs derived from iPSC differentiation and direct 
reprogramming of fibroblasts was also incorporated into the analysis [124,125].  Both the 
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human and mouse datasets consisted of primary hepatocyte and adult liver data that 
allowed for direct comparison. 
 Data Processing 6.3
6.3.1 Microarray Data Processing 
The raw data of Affymetrix, Illumina and Agilent array platforms were processed using 
the affy, lumi and limma packages in R respectively to convert to expression intensity 
values. Logarithmic transformed (log2) intensity from different platforms were corrected 
for depth of digital precision (16 bit) [231]. The expression level of each gene is 
condensed by the median expression value of multiple specific probes. Common 
ENSEMBL identifiers established the same genes from arrays of different platforms. The 
cross platform data was then combined into a master expression dataset based on 
matching these ENSEMBL identifiers. Each of the human and mouse datasets were linear 
normalized. The initial data processing until normalization was performed using the  
virtualArray package in R [231]. The average expression values from replicates were 
used in further analysis. The mouse and human datasets consisted of 16415 genes and 
17683 genes respectively, of which 14,333 were common based on orthologous 
ENSEMBL identifiers. Transcript intensity values for mouse RNA-Seq embryonic 
development data were directly obtained from [230] 
(http://www.alexaplatform.org/alexa_seq/Morgen/Summary.htm) 
 Removal of batch dependent effects in combining data of different 6.4
platforms 
To eliminate platform-dependent bias in combining all hESC differentiation data,  mouse 
differentiation and embryonic data respectively, empirical Bayes methods were used as 
means of location and scale adjustment [232]. The ComBat algorithm in the sva package 
in R was used due to its robustness in handling batches with fewer samples [232]. All the 
human in vitro differentiation was combined into a master set based on matching 
ENSEMBL identifiers prior to platform correction with ComBat. Datasets from different 
sources were treated as separate batches, therefore human data from seven sources were 
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treated as 7 different batches for correction. A similar platform correction was performed 
on the mouse embryonic as well the in vitro differentiation dataset respectively. 
The human in vitro and mouse in vivo datasets had to be combined prior to further 
analysis. Towards this goal, the platform corrected  human and mouse datasets were first 
combined, based on homologous genes using the biomaRt package in R [233]. Batch 
correction using empirical Bayes methods was performed again on the collective human 
and mouse dataset by treating data from each species as one batch [234].  The same 
procedure was followed for combining the mouse in vitro differentiation and in vivo 
datasets, except the in vivo and in vitro data were treated as separate batches. The 
combined human and mouse dataset consisted of 14,312 genes while the combined 
mouse dataset consisted of 16,627 genes. 
 Data Analysis 6.5
 Global analysis to elucidate trends in the data was performed using hierarchical 
clustering, principal component analysis and non-negative matrix factorization. Prior to 
subjecting the data to these techniques, genes with static expression profiles in that 
dataset were removed. Only those genes changing greater than fourfold among any 
sample pair were retained in the global analysis.  
6.5.1 Hierarchical Clustering 
Hierarchical clustering analysis was performed on the batch corrected datasets of human 
and mouse separately using the statistical software R and  its hclust function. Euclidean 
distance between the expression value of all gene (i) was used as the metric for the 
distance between different pairs of samples (a and b).  
     ||a-b||2 = √∑ (𝑎𝑖 − 𝑏𝑖)2𝑖  
In a second clustering Unweighted Pair Group Method with Arithmetic Mean (UPGMA) 
was used as the distance metric. 
  
1
|𝐴||𝐵|
∑ ∑ 𝑑(𝑎, 𝑏)𝑏∈𝐵
 
𝑎∈𝐴     where d is the metric chosen (i.e. Euclidean 
distance) 
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6.5.2 Principal Component Analysis  
Principal Component Analysis (PCA), a multivariate statistical technique 
commonly used to reduce the dimensionality of a dataset, was performed using the 
prcomp() function in R. Principal component calculation is based on a singular value 
decomposition (SVD) of the mean centered gene expression data [235]. The 
transcriptome data of all sample was organized in n gene x m sample matrix. Let xij be 
the expression value of gene i in sample j and A be the n x m mean centered expression 
matrix, where n is the number of genes and m is the number of samples. The elements of 
A are thus aij = xij - 𝑥 ?̅? 
By single value decomposition, 
   𝐴 = 𝑈𝐸𝑉𝑇   
Where U is the (n x m) eigenvector matrix of A
T
A, E is an (m x m) diagonal 
matrix and V is the (m x m) eigenvector matrix of AA
T
. Elements of U are referred to as 
eigen vectors and are ordered by their corresponding eigenvalues, which capture the 
variance of that element. Each eigenvector corresponds to a principal component (PC). 
The projection of the samples in the principal component space is given by  
          𝑈𝑇𝐴 = 𝐸𝑉𝑇  
 EV
T
 contains the coordinates or scores for the samples in the PC space, which were 
calculated using the prcomp() function in R.  If the first few PCs can capture most of the 
variance, one can visualize the coordinates of the samples defined by the first few PCs 
without losing much information. The n x m dimensions of A is therefore reduced to an 
m x v matrix, where v represents the number of PCs reflecting the largest variance in the 
dataset. In our analysis, the first two PCs captured about 90% of the variance in all 
datasets. Therefore, the multidimensional transcriptome data was reduced to m x 2 
matrix, where m represents the number of samples in the dataset. The x and y co-
ordinates of this matrix are represented by PC1 and PC2, the components which retain 
the most variance in the data. These co-ordinates were then used to visualize the ordering 
of the samples in the two dimensional PC space. 
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6.5.3 Non-negative matrix factorization 
Non-negative matrix factorization, another dimension reduction analysis method 
[236], was used to analyze the batch corrected human or mouse datasets using a NMF 
R/Bioconductor package [237].  
Briefly, A , an n x m transcriptome expression data  matrix of n genes of m 
samples was resolved as a product of two matrices containing only non-negative values 
W and H of size n x k  and k  x m respectively. k is the optimal factorization rank or the 
number of  clusters that A can be represented by. This is a critical parameter, its value is 
usually determined by plotting the cophenetic coefficient corresponding to different 
values of ranks, and selecting the rank at which the cophenetic coefficient begins to 
decrease [236]. The samples are then assigned to these clusters by performing several 
iterations. In the human and mouse NMF analysis, 100 iterations were used to confirm 
sample assignments.  
 The elements of matrix W are referred to as  metagenes while the matrix H 
corresponds to the metagene expression profiles. [237]. To evaluate metagenes that 
contribute most significantly to the biological variance in the phenotypes of interest, they 
were assigned scores based on a scoring schema outlined in [238]  between values 0 and 
1. Higher values correspond to larger contributions of the gene to that cluster. A threshold 
criteria was set and genes above this threshold were designated as significant metagenes 
[238].  
 Developmental time 6.6
A two dimensional plot was used to examine how samples at different time points are 
segregated, by plotting the value of principal components (PCs) 1 and 2 of each sample 
on a PC1 vs. PC2 plane.  The same procedure was used for individual datasets of in vitro 
stem cell differentiation, mouse embryo development and the combination of the two. For 
each scenario, a second order polynomial curve was fit to the data points of all samples. 
The arc length with respect to the earliest time point was computed as the developmental 
time (DT) of each sample using the equation shown below, where x corresponds to PC2 
values of samples for that dataset. Developmental time of the human and mouse in vitro 
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data (DT
h
, DT
m 
) was computed with respect to the earliest differentiation time point EN.  
The development times for the mouse embryonic data (DT
dev
) as well as the combined in 
vitro and in vivo data (DT
hm
) for human and (DT
mm
)
 
for mouse
 
differentiations
 
was 
computed with respect to E9.5 as reference. Each sample irrespective of its origin is 
assigned an arc length to allow for direct comparison of gene dynamics especially 
between in vitro stem cell differentiation and mouse in vivo development.  
 
where x corresponds to PC2 , P(x) corresponds to the polynomial fit of the curve in the 
PC1/PC2 space and a ,b and c correspond to the coefficients of the polynomial function. 
 Differential expression of transcriptome of HLCs with E19.5 and 6.7
primary hepatocytes  
Differential expression analysis of human (13 samples) or mouse differentiated HLCs (4 
samples) with mature cells was performed using Significance Analysis of Microarrays 
using the ‘samr’ package in R. All HLCs were treated as one group and mature cells as 
another group for this analysis. The mature group consisted of E19.5 from mouse 
development and species-specific primary hepatocytes.  A criteria of false discovery rate 
(q-value <0.05) and fold change of four or higher in gene expression between the two 
groups was used to identify differentially expressed genes.   
 Dynamic differential gene expression analysis based on 6.8
developmental time 
Limited time series data was available for human and mouse in vitro differentiations for 
dynamic trend analysis.  These time series human and mouse differentiation data were 
aligned with mouse development based on the similarity in developmental times (DT
hm
, 
DT
mm
) respectively. For both species, the culmination of differentiation coincided with 
E15.5 of mouse development. Hence, gene dynamics of differentiation data from D5 to 
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D20 was compared with E9.5-E15.5 of embryonic development.  Using these DT
hm
 
values as reference, the data was separated into a human in vitro differentiation dataset 
incorporating time series data from both sources and a mouse development dataset. To 
identify orthologous genes whose time dynamic profile is different between human stem 
cell differentiation and mouse embryo development, the expression profile (i.e. the 
intensity value of the transcript) of each gene was expressed as a second order 
polynomial function of the unified developmental time, for each of the differentiation and 
development datasets individually. The difference of the dynamic expression profile of a 
pair of orthologous genes was computed in three ways: Pearson’s coefficient, Spearman’s 
coefficient and Euclidean distance as shown below. Curves generated using the 
polynomial functions obtained for human differentiation and mouse development datasets 
were sampled at fifty equal intervals between the minimum and maximum value of DT
hm
 
to compute the different correlation coefficients. 
Pearson’s correlation where Xij represent expression intensities  for gene i and 
species j  
𝒓 =  
∑(𝒙𝒊𝒎− 𝒙𝒊𝒎̅̅ ̅̅ ̅)(𝒙𝒊𝒉−𝒙𝒊𝒉̅̅ ̅̅̅)
√∑(𝒙𝒊𝒎−𝒙𝒊𝒎̅̅ ̅̅ )̅
𝟐 ∑(𝒙𝒊𝒉 −𝒙𝒊𝒉̅̅ ̅̅̅)
𝟐
         𝑥𝑖ℎ is the gene in human  and 𝑥𝑖𝑚 is the corresponding 
gene in mouse  
Spearman’s correlation where Yij represent the ranks of gene expression intensities  
for gene i in species j 
  𝒓 =  
∑(𝒚𝒊𝒎− 𝒚𝒊𝒎̅̅ ̅̅ )̅(𝒚𝒊𝒉−𝒚𝒊𝒉̅̅ ̅̅̅)
√∑(𝒚𝒊𝒎−𝒚𝒊𝒎̅̅ ̅̅ ̅)
𝟐∑(𝒚𝒊𝒉−𝒚𝒊𝒉̅̅ ̅̅̅)
𝟐
           
Euclidean Distance where Xij represent expression intensities for gene i and species 
j 
𝒅 = |(𝒙𝒊𝒎 − 𝒙𝒊𝒉  | = √∑ |𝒙𝒊𝒎 − 𝒙𝒊𝒉 |
𝟐
𝒏
𝒊=𝟏
 
 
Genes for which the Pearson’s or Spearman’s coefficient is < -0.9 were identified as 
candidates whose  expression dynamics between human in vitro differentiation and 
  134 
mouse embryo development follow opposite trends; while genes for which  the Euclidean 
distance is > μ+2σ (where μ and σ  are average value and standard deviation of Euclidean 
distance), were identified as candidates of dynamically  differentially expressed genes. 
Genes with expression values changing fourfold in both human and mouse data were 
further shortlisted as these represent highly expressed dynamically different genes. A 
Matlab program, Time view, was then used to plot the expression profiles of each gene 
for visual inspection to confirm the differential expression profile [239]. 
 Functional Analysis 6.9
Relevant KEGG pathways for were downloaded to provide functional context to 
differentially expressed genes. Additionally, gene lists from published data encoding for 
1391 transcription factors [240], 400 cellular transporters [241], 3700 genes on the cell 
surfaceome [242] were incorporated to group the data into functional groups. 
Additionally, data visualization and functional analysis were performed using Spotfire 
(Tibco), Database for Annotation, Visualization and Integrated Discovery (DAVID) and 
Ingenuity Pathway Analysis (IPA) (Qiagen). Functionally enriched clusters from DAVID 
with enrichment scores greater than 2 were considered significant. DAVID was also used 
to predict representative pathways as well as transcription factors (TFs) regulating the 
differential expressed genes via TF binding site prediction from the UCSC Genome 
Browser (http://genome.ucsc.edu/ENCODE/).  
 MiRNA Analysis 6.10
Microarray assay was performed for D6, D14 and D20 (HLCs) using a service provider 
(LC Sciences).  The miRNA intensities were normalized using a LOWESS filter 
(Locally-weighted Regression) by the provider [243]. The data consisted of 2615 probes 
targeting all the human miRNAs present in the latest miRNA depository miRBase 21. 
Since miRNAs are global regulators, differential expression analysis was performed by 
imposing a high cutoff for tenfold change during differentiation and requiring that 
miRNA intensity in at least one sample was greater than 1000.  
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6.10.1 mRNA-miRNA Target Analysis 
mRNA-miRNA interaction information was downloaded from various databases 
mirTARBase[244], miRDB(v5) for the genes with differential dynamics between human 
and mouse. Of these, the interaction information of miRNAs from miRDB v5 was based 
on the most recent miRNA annotation release. miRDB is based on support vector 
machine (SVMs) approach using high-throughput experimental data to train the target 
prediction model and using that to predict genes downregulated by miRNAs[245]. Scores 
for each interaction was calculated from the target prediction algorithm and ranged from 
50-100; values above 80 were recommended for high confidence interactions. Hence 
miRNA-mRNA interactions with miRDB target prediction scores greater than 80 were 
used in the analysis. mirTARBase and IPA databases consisted of a collection of 
experimentally verified miRNA-target interaction information. The target genes for 
highly differentially expressed miRNAs were therefore compiled from all the above 
sources. 
The interaction of a miRNA with its target mRNA is valid if both are expressed with 
opposite dynamics, i.e one increases while the other decreases. miRNA microarray data 
was combined with the transcript intensities of differentially expressed genes from the 
previous analysis to investigate miRNA-mRNA interactions. A fourfold change in 
miRNA or mRNA intensities in the opposite direction was considered a valid interaction. 
6.10.2 Cross species miRNA comparative Analysis 
RNA-Seq data for mouse liver developmental stages E8.5 and E14.5 consisting of both 
transcript and miRNA information was obtained from Hoodless et al [230]. This study 
was based on older version of miRBase 18, hence only 200 mouse miRNAs were 
available for comparison. This was consolidated with the human differentiation 
transcriptome and miRNA data using the conserved miRNA nomenclature across species 
for comparative analysis. Each species was first individually surveyed for valid miRNA-
target interactions using the procedure described above. Those miRNAs exhibiting 
contrasting miRNA-mRNA regulation in either species were shortlisted as potential 
targets for intervention. 
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7. UNVEILING THE ROAD BLOCKS OF STEM CELL 
DIFFERENTIATION THROUGH CROSS SPECIES 
TRANSCRIPTOME DATA META-ANALYSIS   
 Introduction 7.1
The prospect of deriving functional cells from pluripotent stem cells has raised hope 
for cell therapy to treat various ailments [181]. Using different combinations of growth 
factors in stages to mimic the chemical environment leading endoderm commitment, liver 
specification and maturation, stem cells can be directed to differentiate to the hepatic 
lineage [182,227].  Those differentiated cells resemble hepatocytes in many ways, they 
secrete albumin, have some cytochrome P450 activities, and are capable of synthesizing 
urea. However, those cells derived from directed differentiations of embryonic stem cells 
(ESCs) and other stem cells are still marked by functional immaturity, many mature liver 
markers are either not expressed or are expressed only at very low levels. They are often 
referred to as hepatocyte-like-cells (HLC) because they still lack many mature liver 
functions [246].  
Many approaches have been explored to enhance maturation of HLC, including the 
formation of tissue-like 3D structure [177] and co-culture of HLC and endothelial cells 
[229], small molecule screening [247] and transfection with transcription factors 
[131,248,249]. When HLC were transplanted into animals under selective conditions, 
engraftment was observed [122,229]. Using a cell aggregate formed by co-culturing HLC 
and endothelial cells for transplant, some mature liver markers were seen in some 
transplanted cells [229].  However, these HLCs are still immature in most of their 
functional capabilities when compared to their primary counterparts and adult liver. 
Comparison of transcriptome data of differentiation to embryonic development can 
elucidate the genetic roadblocks preventing stem cells from reaching the functional 
maturity of their tissue counterparts. While transcriptome data for in vitro stem cell 
differentiation is easy to obtain, human in vivo developmental transcriptome data is hard 
to come by. Such in vivo data may be obtained from other species. A cross-species 
comparison of human stem cell in vitro differentiation data with rodent in vivo liver 
development data may reveal the deviation of the in vitro process from that in vivo, with 
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the hypothesis that the embryonic development in rodents and in human bears a high 
degree of conservation in gene expression dynamics.  
Human gestation occurs over 280 days compared to 20 days in mouse. A typical directed 
stem cell differentiation process for both human and mouse ESCs lasts for about 20 days 
[250,251]. Although these processes differ in time scales, they share similar progression 
through different stages (Figure 7-1). If the dynamics of gene expression of the in vitro 
and in vivo processes of the two species bear a high degree of similarity, it should be 
possible to identify cells of corresponding stages through cross-species meta-analysis. 
Such a comparison may provide us crucial insights on possible gene targets for 
intervention that can enhance the maturity in stem cell differentiations.  
Systematic variations and random errors in the assay of samples of different sources often 
bear the characteristics of the course.  Frequently samples of different sources, or of the 
same source but attained at different time are assayed with different measurement 
platforms and also bear the characteristics of the platform. These sample source and assay 
platform derived system variations from multiple batches of data need to be removed 
before those data can be combined and analyzed. The ComBat algorithm [232] is  an 
empirical Bayes method that performs a location and scale adjustment by pooling 
information across each  gene in every batch and using this information to center the data 
to an overall grand mean. This technique can be applied to multiple batches and is robust 
for small sample sizes [232]. ComBat consistently outperformed the common batch 
correction techniques, including distance-weighted discrimination (DWD) [252] which 
uses a support vector machine based approach, mean-centering (PAMR) which relies on 
gene based analysis of variance [253], and surrogate variable analysis (SVA) which uses 
a combination of single value decomposition and linear model analysis  [254-257].  
In this study, we employed the Combat algorithm to integrate transcriptome data from 
human stem cell differentiation and mouse embryonic liver development obtained using 
different assay platforms. The batch correction allowed data of mouse embryonic liver 
and HLC derived from human ESCs to be clustered according to their degree of 
maturation. We identified the genes whose expression profiles in stem cell hepatic 
differentiation deviate from of embryonic liver development and may contribute to 
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blocking further maturation of HLC in stem cell differentiation. Such meta-analysis of 
highly heterogeneous transcriptome data from mouse and human, in vivo and in vitro, 
provides clues of genetic intervention, either suppression or overexpression to advance 
directed differentiation of stem cell to hepatic and possible other lineages.  
 Results 7.2
7.2.1 Compilation of Human in vitro hepatic differentiation Data 
The transcriptome data of the differentiation of human stem cells to the hepatic lineage 
were assembled from many published studies and consisted of 101 samples. Included in 
the datasets are embryonic and induced pluripotent stem cell differentiation using similar 
but somewhat different protocols [123,166,227,228]. Two of the studies included data 
from various time points during the stage-wise differentiation; others presented the 
transcriptome data of final differentiated cells (HLCs). One study performed a 
comparative study between HLCs and HLCs generated from endodermal cell expansion 
and subsequent differentiation (Hu et al, in preparation). Another study utilized formation 
of three-dimensional spheroids to enhance maturity [177]. Transcriptome data for all 
HLCs and HLC derived spheroids was also obtained. All have shown that the resulting 
cells exhibited key hepatic functions. Another study employed co-culture of endothelial 
cells, mesenchymal cells and iPSC derived HLCs, which were termed as an organoid or 
liver bud [229]. These are shown in Table 7-1. However, all studies generated 
hepatocyte-like cells (HLC), which, although expressing hepatic lineage markers, still 
lack mature liver functions such as key energy metabolic genes (glucokinase, aldolase B) 
and cytochrome P450 genes. Also included was the transcriptome of differentiated cells 
derived from hepatic lineage reprogramming of fibroblasts, primary human hepatocytes 
(pooled mRNA after 1 day of culture), fetal liver (18 weeks of gestation) and adult liver.  
The data from different sources were derived using various platforms with different probe 
design and gene coverage.  A total of 17,683 genes were commonly present in all arrays 
were combined into human hepatic differentiation dataset used in this study.  
7.2.2 Batch correction of human in vitro data 
The transcriptome data from various sources cannot be directly compared. To remove the 
systematic bias of different sources and platforms batch correction was performed as 
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described in the Materials and Method section. The effect of batch correction is vivid by 
examining the clustering of samples in the entire dataset. Without batch correction, data 
obtained from the same studies clustered together as seen from Figure 7-2. After batch 
correction, data of samples obtained from similar stages of differentiation from different 
sources, clustered together (Figure 7-3). All the differentiation protocols employed 
growth factors to guide stem cells first to differentiate to endoderm stage, then to hepatic 
progenitors, and finally to hepatocytes. Most protocols treat cells for about 20 days using 
similar but not identical differentiation protocols. It can be seen that the time course data 
from two different sources clustered based on their differentiation day indicating a similar 
progression through differentiation. Data from Duncan et al for day 5 (D5_D) and day 10 
(D10_D) clustered with our data for day 6 (D6_H) and day 10 (D10_H) in spite of being 
from different sources. Furthermore, most data of differentiated HLCs from all studies 
cluster in a separate group, with the exception of a few HLC samples clustering near 
primary hepatocytes. However, the HLC data from all sources consistently clustered 
separately from tissue samples of fetal and adult liver. 
Additionally, NMF analysis was performed on the data to further validate the results. The 
optimal number of clusters for the data was chosen based on its cophenetic coefficient as 
described in the Materials and Methods (Figure 7-4). NMF analysis categorized human 
data into three groups as seen in Figure 7-5, which depicts the average of results from 
100 iterations. Additionally, hierarchical clustering on these three categories is shown, 
further grouping samples based on similarity. The smallest group consists of data from 
liver and primary hepatocytes, the other two groups consists of transcriptome from early 
(D6, D10) and late differentiation (D14, D20) stages respectively. Only two samples, the 
HLCs from [123] and HLC spheroids based on [177] were separately grouped into tissue 
group instead being grouped together with the other HLC samples. However, from the 
clustering, it is evident that though these HLCs are assigned to the tissue group, they are 
separated during hierarchical clustering, indicating a slight but not complete advanced 
differentiation status. Notably, the grouping of early and late differentiation samples and 
the separations from tissue samples are similar to the results of hierarchical clustering 
shown in Figure 7-3.  
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To further examine the NMF classification scheme we surveyed the 969 metagenes used 
in the classification as listed in Table 10-1 and used DAVID to probe their functional 
significance. The number of human metagenes is high due to the number of samples and 
their inherent variability. The metagenes used to classify the early differentiating cell 
states were involved mainly in developmental processes, those dictating the late 
differentiation states were mainly involved in cell differentiation, adhesion, extracellular 
matrix reorganization, epithelial specification and drug response. The metagenes 
classifying the tissue group were involved in mature liver functions such as CYP450 drug 
detoxification, electron carrier activity, carbohydrate metabolism among many others.  
Therefore, two independent unsupervised classification methods classified the batch 
corrected transcriptome data into similar groups. Data from different sources were 
categorized based on their functional relevance. This gives credence to the data 
processing method we adopted to conduct the meta-analysis. 
7.2.3 Alignment of human in vitro data along a differentiation scale 
The batch corrected transcriptome data of human hepatic differentiation was subjected to 
PCA. Two principal components, PC1 and PC2, captured 90% of data variance, 
suggesting that the two components are sufficient to display the variability of 
transcriptome data of those samples. PC1 and PC2 of each sample were then plotted on a 
PC1 v. PC2 graph. Interestingly all samples, starting from endodermal cells to HLCs 
were aligned along an arc while primary hepatocytes and adult liver laid further out to the 
high PC2 region (Figure 7-6). The two data sets that included differentiation data of 
different stages both align from left to right in order their time duration of differentiation. 
The samples of iHEP and the liver bud aligned with earlier stages of D10 and 14. 
Interestingly all HLC samples, regardless of the source, all align within a narrow region 
in the principal component space, suggesting that they all had similar degree of hepatic 
maturity. The results also suggest that the distance along the arc from the initiation of 
differentiation can possibly be used as a metric of human embryonic stem cell 
differentiation toward hepatic lineage.  
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7.2.4 Alignment of the transcriptome dynamics of rodent fetal liver 
development   
Mouse embryonic development transcriptome data (E9.5 to post-natal) were compiled 
from two sources [78,229]. CD45
-
Ter119
-
 liver cells were isolated from C57/BL6/Tg 
mice embryos at different stages of development in the first study while whole embryonic 
livers were dissected from C57/B6 mice embryos in the second study. RNA samples for 
expression analysis were prepared by pooling several embryos at the same stage of 
development in both these studies. The first study consisted of samples E9.5, E10.5, 
E11.5, E13.5, E15.5, E17.5, E19.5 while the second study consisted of samples E11.5, 
E12.5, E13.5, E14.5, E15.5, E16.5, E17.5 and E18.5 along with some postnatal samples.  
The data processing pipeline described for human dataset was used to process the dataset 
of genome-wide transcript profiles during the development of mouse embryonic liver. 
The batch corrected data of 47 samples from 2 studies using two strains of mice, and with 
16,415 genes common in all samples, were then subjected to hierarchical clustering, 
NMF and PCA. Similar to the observation made with the human dataset, batch correction 
removed the effect of different platforms and sources; the transcriptome data, which were 
clustered largely by their sources and platforms without batch correction, were clustered 
according to their developmental stages (Figure 7-7). Furthermore, the samples now 
clustered based on the level of their maturity into early (E9.5-E14.5) and late (E15.5-
E19.5) stage (Figure 7-8) upon hierarchical clustering. NMF also classified the batch 
corrected dataset into two groups, early and late development, which was identical to 
hierarchical clustering results (Figure 7-10). The optimal value of two clusters was 
determined based on the cophenetic coefficient shown in Figure 7-9.  Only E14.5 and 
E19.5 were reversed in their order with E13.5 and E19.5, which could be a result of 
heterogeneous sample preparation protocols in both studies. 
This technique also identified 129 metagenes that contribute significantly to the 
difference between the two states [21] and thus contain key liver development 
information.  Indeed these metagenes belonged to important liver functional classes 
including development, carbohydrate metabolism, cholesterol homeostasis, response to 
drugs and urea cycle. This classification agrees with prior understanding of liver 
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development that the E14.5 stage represents a transition from primarily hematopoiesis to 
hepatocyte maturation [39, 40]. These metagenes are tabulated in Table 10-2. Of these 
129 mouse metagenes, 96 were common with those from the human analysis, mainly 
overlapping with metagenes classifying mature cells or tissue and not HLCs. This hints 
that the HLCs correspond to an early state of liver development. 
 The first two principal components of each sample from PCA are plotted. In this case, 
samples, in order of their developmental stage line up with increasing PC2 (Figure 7-11). 
PC1 and PC2 essentially can constitute a developmental vector describing the stage of 
hepatic development. Identical results were seen with clustering, NMF and PCA analysis. 
7.2.5 Integration with mouse RNA-Seq data 
RNA-Seq data for mouse embryonic stages of endoderm (E8.5) and hepatic progenitor 
cells (E14.5) along with adult liver (6 months female) from [230], was integrated with the 
mouse development microarray data to add additional insights to the analysis. The data 
was integrated based on ENSEMBL identifiers and the platform correction using ComBat 
was applied. PCA was used to verify the overall data trends and the developmental stages 
and adult liver from both microarray and RNA-Seq datasets fall on the same 
developmental trajectory thereby validating the approach (Figure 7-12). While transcript 
intensities of individual samples may not be directly comparable for RNA-Seq and 
microarray studies, dynamics trends can easily investigated. Hence, this resulted in a 
comprehensive rodent embryonic liver development dataset to gain insights into 
mechanism of hepatic fate acquisition. 
7.2.6 Compilation of mouse in vitro differentiation data 
Transcriptome data at different time points of differentiation (D6, D14, D20 and D28) of 
mouse iPS cells differentiating to HLC based on [250] were obtained. Data from 
reprogramming of fibroblasts to HLCs by transfection with hepatic transcription factors 
was obtained from [124,125], and integrated into the mouse in vitro differentiation 
dataset using the same methods used from the previous analyses. The order of the 
samples in the PC space is shown in Figure 7-13. Similar to the human differentiation 
data, the samples were ordered by their differentiation state (DT
m
) and away from the 
primary hepatocytes indicating a similar barrier to maturation across species. 
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7.2.7 Integration of mouse in vitro differentiation and in vivo development 
data 
The mouse in vitro differentiation data was combined with mouse embryonic 
development data based on common ENSEMBL identifiers. The developmental and 
differentiation data clustered as separate group upon integration and hence were 
subjected to another batch correction to allow for meaningful analysis. These combined 
data were then subjected to PCA. On a space of PC1 and PC2 the in vitro differentiation 
data and in vivo development data can be seen to line up along an arc as seen in Figure 
7-14. The mouse iPSC differentiation data spanned over the same range as the early 
stages of embryo development (E9.5 to E15.5), while the data points for further 
developed embryo continues to spread to the region with a higher value of PC2. The 
results suggest that stem cell derive HLC differentiated to an equivalent of ~E15 stage 
and still lack the maturity of fully developed prenatal E19 and postnatal liver.  
7.2.8 Alignment of mouse in vivo and human in vitro developmental paths  
Having shown that mouse iPSC in vitro differentiation data and in vivo embryo 
development data can be integrated and projected onto a PC1 vs PC2 plane, we next 
integrated the hESC in vitro differentiation data with mouse in vivo embryo development 
data. The batch corrected mouse embryo liver development (E9.5-19.5) transcriptome 
data was combined with the entire set of batch corrected human transcriptome data. A 
master dataset with 14,312 genes was generated by their homologous identifiers extracted 
using the BioMart database. Data from ESCs and fibroblasts were not included, as the 
mouse embryonic development data started at E9.5, which corresponds to the endodermal 
cell stage. The merged dataset of 35 samples (replicates averaged yielding nine mouse 
developmental and 26 human differentiation samples), were again subjected to batch 
correction using ComBat to eliminate bias of species.  
The batch correction on the cross species gene expression profiles transformed the data to 
eliminate species-specific features. This can be verified by plotting the expression levels 
of hepatic marker alpha-fetoprotein (AFP) and albumin (ALB) before and after batch 
correction for mouse development and one of the time series of human differentiation (). 
Before batch correction the human and mouse data showed increasing trends in gene 
expression of these hepatic markers. After batch correction, while the expression profiles 
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of the two species were shifted slightly higher in human and lower in mouse, the 
increasing data trend for each species is strictly preserved (Figure 7-15, Figure 7-16).  
PCA analysis was performed on the integrated dataset of human HLC differentiation and 
mouse embryo liver development. PC1 and PC2 of each sample of both species was 
projected into a two dimensional PC space. The data points of mouse and human aligned 
along the same arc, and lined up in order of their development or HLC differentiation 
stages respectively (Figure 7-17).  
From the alignment of human HLC and mouse embryo liver development data, the 
plausible corresponding stages in human HLC differentiation and mouse liver 
development can be postulated.   HLC samples of the endodermal stage of differentiation, 
after stage I and around D6, are aligned with E9.5-E10.5 samples. The majority of fully 
differentiated HLCs (at the end of final stage of differentiation ~ D18-20 of 
differentiation) are aligned to the E13.5-E15.5 of development. The results strongly 
indicate that HLCs derived from stem cells were more similar to the fetal state of ~E14-
15 or hepatic progenitor state than more mature hepatocytes. This was the case for all 
HLCs surveyed regardless of the different differentiation protocols used.  
Interestingly HLC differentiation of both hESC and mouse iPSC appear to stop at the 
same corresponding state E15. This indicated that irrespective of species of origin, or the 
protocols used, all the HLCs encounter universal roadblocks preventing maturation. The 
integration of embryonic development with differentiation data across species allows for 
further investigation of these barriers.  
7.2.9 Comparison of HLCs with mature cells 
The transcriptome of all HLCs for human (hHLCs) and mouse (mHLCs) were separately 
compared to E19.5 and primary hepatocytes using SAM, where criteria of q<0.05, fold 
change>four was imposed to identify differentially expressed (DE) genes. For the human 
HLCs vs. mature cell states, 129 differentially expressed genes were found. Among 129 
genes human DE genes, many functional classes including CYP450 drug metabolism, 
carboxylic acid, amine and lipid metabolic processes and complement and coagulation 
cascades were identified as enriched by DAVID. The differential expression pattern, in 
term of hepatic genes and functional classes, is rather similar to those seen when 
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comparing mouse HLC and mature mouse hepatocytes. From the mouse comparison, 159 
genes were found to be significantly differentially expressed, of which  42 genes were 
common in both analyses. These are listed in Table 10-3. Prominent hepatic genes 
differentially expressed in both species include metabolic genes G6PC, FBP1 and 
cytochrome P450 enzymes CYP3A4 and CYP2C9 indicating the lack of the maturity in 
the metabolic profile of HLCs from both species. 
7.2.10 Expression profile comparison on a Unified Developmental Time scale 
The alignment of human in vitro HLC and mouse in vivo embryonic development 
data on a common platform presents the opportunity to compare the similarities and 
differences in their gene expression profile. We treated the trajectory or the arc formed by 
those data points as a common developmental path. Using the first point (E9.5) as a 
reference point, the distance of a sample from the reference point along the 
developmental path can be taken as a “unified developmental time scale”. Each sample, 
irrespective of its species or differentiation state, is assigned a developmental time (DT). 
The DT for samples in each analysis can be calculated to obtain a measure of their 
differentiated state. DT
h
, DT
dev
, DT
m
 correspond the values calculated from the human 
and mouse in vitro differentiations and mouse development respectively. DT
hm
 and DT
mm
 
represent the distance along the arc for the combined human and mouse in vitro with 
mouse development respectively. In all the analyses, a higher value of DT indicates a 
more differentiated status for that sample. 
The PC2 of a few human differentiation samples and mouse developmental samples 
are plotted against their developmental time (DT
hm
) is shown in Figure 7-18. This allows 
the transcript level of orthologous genes in human HLC differentiation and in mouse 
embryonic liver development to be plotted on the same unified developmental time scale 
and compared systematically.  
Among all the human HLC differentiation, transcriptome data only two sets provided 
coverage over different time points. Both dataset ended at a developmental time (DT) of 
approximately 0.4 (equivalent to E15.5). We combined the two human HLC datasets, 
from DT=0 to DT=0.4 into a string of data, and all mouse development data in the same 
DT range (E9.5-E15.5) into another string. While some hepatic genes (e.g. Albumin) 
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show similar trends between the human in vitro and mouse in vivo data, others showed 
inconsistent trends (e.g.TGFBI) as seen in Figure 7-19 and Figure 7-20). Dynamic 
differential expression analysis (Pearson correlation, Spearman’s coefficient and 
Euclidian distance) were performed to compare the two strings of data for each of the 
14332 orthologous genes. The Pearson measures the linear correlation while the 
Spearman’s coefficient is a measure of the monotonic relation between two variables. 
Threshold criteria were set and the difference in the time dynamics of expression between 
human HLC and mouse embryo was confirmed by inspection after the time series profile 
of the differentially expressed genes were plotted (Figure 7-23).  
7.2.11 Functional Analysis and comparative gene expression 
Genes whose expression were found to be dynamically differentially expressed between 
hHLC and mouse in vivo development, were 197 (Table 10-4), including 17 
Transcription factors, 7 transporters and 33 other cell surface markers. The major 
functional classes or pathways that these genes represent were analyzed using DAVID 
[43]. Functional clusters with enrichment score greater two included genes participating 
in the developmental process, organ development, cell adhesion and communication as 
shown in Figure 7-21. ECM-receptor interaction, focal adhesion and arginine and proline 
metabolism were among the pathways represented in the differentially expressed genes as 
seen in Figure 7-21. This suggests that the surrounding microenvironment may have to be 
further optimized for hepatocyte differentiation. 
Several important developmental transcription factors, including ALX1, CDX2, HAND1, 
PITX1, MSX2, SOX9, FOXA1 and SNAI2, are prominent among those. ALX1 in 
involved in forebrain development [258], CDX2 plays a role in lineage segregation of the 
inner cell mass and trophectoderm [259,260], intestinal fate and is involved in epithelial 
mesenchymal signaling [261], HAND1 regulates embryonic cardiac development [262], 
PITX1 and MSX2 participates in limb development [263,264], SOX9 regulates 
pancreatic development [265] and SNAI2 which regulates epithelial mesenchymal 
transition [266,267]. FOXA1 plays critical role in pancreatic and renal functional 
specification [268] while TSHZ1 in involved in pancreatic cell development and 
maturation [269]. All of those TFs were expressed at high levels in both HLCs studies, 
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but became low at DT~0.4 corresponding to E15.5 in in vivo development, suggesting 
that a down regulation of those TFs may be an in vivo developmental control that has not 
occurred in in vitro differentiation.  
Genes encoding cell surface proteins are of interest, as these represent the main gateway 
for cellular signaling and crosstalk to occur. Typically, these are specialized proteins that 
can relay information about the outside environment to the cells, thereby eliciting cellular 
adaptation or apoptosis. The expression of an EMT regulator SPARC, an extracellular 
matrix secreted factor, activates a downstream transcription factor SNAI2 and regulates 
CDH3 (P-Cadherin) expression which then induces epithelial mesenchymal transition 
[267]. The expression of all three genes is upregulated in human differentiation but is 
downregulated by E15.5 of development. Cells surface receptors Frizzled (FZD2) and 
TGFBR3, receptors for Wnt and TGFβ signaling respectively, are highly expressed in 
HLCs at DT~0.44, but low in the in vivo sample. This along with the increase in 
expression of other participants of Wnt and TGFβ signaling such as WNT5A, PITX1 
could indicate an untimely activation that might need to be suppressed to achieve further 
maturity. SLC2A2 (GLUT2), a liver specific glucose transporter, SLCO1B3, a bile 
transporter and SLC27A5, a fatty acid transporter all increased their expression levels 
during mouse development but not in HLC at DT~0.44, corresponding to D20 of 
differentiation. 
A quantitative observation of the contrasting dynamics for these genes for differentiation 
(Hu et al) and development was obtained through plots of gene intensities against the 
corresponding developmental distance using the TimeView software. For ease of 
visualization, again the genes were categorized into transcription factors, transporters, 
cell surface markers. The expression profiles of genes in these categories are shown in 
Figure 7-22. The efficacy of the correlation analysis is high as seen from the contrasting 
trends the gene expression profiles between human stem cell differentiation (black curve) 
and mouse liver development (blue curve).  The genes exhibiting stark contrast in their 
profiles and participating in important developmental or hepatic functions are likely the 
reason the in vitro hepatocytes are lacking in functional maturity and are suitable targets 
for genetic intervention. 
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7.2.12 Regulators of differentially expressed genes 
The genes with disparate profiles were identified and were found to participate in 
important biological process of organ development, metabolism and drug detoxification. 
It is impractical to genetically manipulate about 200 genes, therefore transcriptional 
regulators, both transcription factors (TFs) and miRNA regulators of these genes were 
sought after.  
 Transcription Factors 7.2.12.1
TFs interacting with the genes of interest were predicted based on the overrepresentation 
of corresponding TF binding sites in the promoter regions of the genes. These 
interactions were sourced from the UCSC genome browser and mapped to the gene list 
through DAVID. The top TFs that were found to have overrepresented binding sites in 
the genes of interest including GATA, FOXO1, CREBPH, GATA6 are shown in Table 
7-3: Transcription factors with overrepresented binding sites in the dynamically 
differentially expressed genes. These transcription factors along with the suppression of 
the developmental transcription factors can be used to modulate the gene expression of 
the potential targets. 
 MicroRNA Analysis  7.2.12.2
MicroRNAs are small non-coding RNAs about 22 bp in length, which play an important 
role in post transcriptional regulation[270]. These miRNAs can bind partially to the 3’ 
UTR region of the target gene causing its repression. This partial complementarity is 
responsible for the ability of a single miRNA to modulate the expression of several genes 
simultaneously. miRNAs are therefore global regulators and  have been implicated in the 
regulation of hepatic fate during liver development [271]. 
Human miRNA microarray data was obtained at EN (D6), HPC1 (D14) and HLC (D20) 
of differentiation to add another dimension to the meta- analysis. From the miRNA 
microarray data, 24 differentially expressed were found. These changed greater than 
tenfold throughout differentiation and at least one sample had miRNA intensity greater 
than 1000 and are displayed in Table 10-5.  The most abundant liver miRNA, miR-122 
increased by 10,000 fold through the course of differentiation [272].  Similarly, 
homologous miRNA’s miR-192/miR-215 increase by 175 and 93 fold by D20 compared 
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to D6 of differentiation and are known to negatively regulate cell cycle genes [273]. miR-
194 which was reported to be  marker of hepatic epithelial cells increases by 340 fold 
[274]. Conversely, embryonic cell specific miRNAs miR-302 and miR367 decrease by 
20 fold and 37 fold respectively through the differentiation process [275]. miR-302b is 
also expressed highly in mouse endoderm (E8.5) and participates in liver development by 
modulating TGF-β signaling [230]. 
From the miRNA-mRNA interaction data obtained from different databases, 20 of the 
differentially expressed miRNAs were potential regulators of 85 dynamically 
differentially expressed genes from the previous analyses. The table of these miRNAs 
and their gene targets is shown in Table 10-6. However, when assayed for valid miRNA-
mRNA interactions, only miR-367, miR-122 and miR-335 showed opposite expression 
trends with their gene targets COL1A2, NODAL, CHD10 and IFITM1. These 20 
differentially expressed miRNAs could therefore be potential targets for genetic 
intervention to regulate their target genes in a desirable manner. Overall, these 20 TFs 
and 20 miRNAs and are good candidates for developing a high throughput screening 
method to evaluate their effect on hepatic maturity.  
 Discussion 7.3
Stem cells derived hepatocytes have been sought after as a renewable source of cells for 
regenerative medicine and for in vitro toxicity studies. To date HLCs derived from stem 
cells still lack the functional maturity of hepatocytes. Several approaches have been 
attempted, including cultivation as 3D structure and co-culture with endothelial cells, and 
increased expression of some hepatic functions have been reported. Those hepatic 
differentiation studies employed an array of protocols and assessed the differentiation 
using different genetic and functional markers, making a direct comparison of their 
results difficult. With the increasing affordability of global gene expression analysis, 
public depositories have become populated with transcriptome data of embryonic 
development as well as stem cell differentiations from different species. We hypothesized 
that genome wide gene expression profile carries more relevant information on the state 
of differentiation or development than a few selected genetic or functional markers and 
set out to conduct a meta-analysis on those transcriptome data. A comprehensive 
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comparison of the maturity of HLCs derived from those studies and their relative position 
to in vivo fetal liver development can tell us much about the potential road block on in 
vitro differentiation.  
The transcriptome data available on fetal liver development were of mouse origin, while 
those for in vitro differentiation were mostly from human and a limited number from 
mouse. The data were heterogeneous in their sources, assay methods and platforms. It 
was imperative to remove platform and source dependent effects to allow for meaningful 
comparison. For removal of those batch effects we chose to employ the empirical Bayes 
based Combat algorithm that has been reported to be its robustness [254] and  has been 
shown to be efficacious when applied to gene expresion data obtained from different 
patients of two types of arthritis [256].  
Batch correction did remove systematic variations for both human and mouse data sets as 
illustrated by unsupervised clustering before and after batch correction (Figure xx and 
xx). PCA resulted in two interesting observatios: first, differentiating HLCs align along 
their progression in differentiation in a PC1 vs. PC2 plot; second, the final HLCs of 
different protocols and sources all line up in a region that is well differentiated but at a 
distance from the mature hepatocytes of adult liver. With the small amount of 
transcriptome data available for mouse stem cell derived HLCs, the data was combined 
with mouse fetal liver development. Again, similar two observations were made as in 
human HLC, except that, in this case the in vitro differentiation could be aligned to in 
vivo development. Stem cell derived HLCs appear to cease to differentiate further beyond 
the equivlanet of E15 in embryo development. The results also suggest that PCs from 
PCA can be used as a measurement of the developmental stage comparing in vitro and in 
vivo data. We examined the identity of the metagenes used in the alignment of both 
human and mouse samples. They are related to development and liver functions, giving 
further credence to the biological relevance of the alignment of samples. 
To identify gene expression differences between human HLC differentiation and mouse 
fetal liver development, we need to take one step further to combine human in vitro and 
mouse in vivo data. To accomplish that, we treated human dataset and mouse dataset as if 
each were one batch dataset, i.e. assuming that their transcriptomes were sufficiently 
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similar but bear systematic variations that can be removed by batch correction. The 
classification of samples into groups identifiable by their biological characteristics using 
unsupervised hierarchical clustering, non-negative matrix factorization and principal 
component analysis gives credence to the data processing scheme we employed in this 
meta-analysis. The alignment of samples along their PC2/PC1 space placed the 
differentiated human HLCs and E15 mouse embryonic liver at an equivalent stage.  The 
alignment thus give the in vitro and in vivo data from the two species a common “scale” 
of their development. 
The development of mammals bears many common morphological, biochemical and 
genetic hallmarks. Based on those marks, similar stages of development can be identified 
in spite of the vastly different time scale in different mammals. These are referred to as 
Thieler stages. For example, in human embryo development 22 day and 52 days are 
considered to be equivalent to mouse E9.5 and E14.5 respectively[276]. In an early study 
neural development events were codified and used to generate a regression model for 
predicting a translation table of times of corresponding stages across nine species ([277]). 
In another study feature measurements of leaves of different tomato species were 
subjected to principal component analysis to establish a developmental trajectory ([278]) 
Recently transcriptome data of nematode species were compared to morphological 
markers to establish embryo developmental milestones in different species of 
Caenorhabditis ([279]). A algorithm that takes RNA-seq data of a species’ developing 
embryo and subject them to principal component analysis for alignment in PC plane was 
reported to describe the developmental stage ([280]).  
In this work we extend those prior studies to tackle transcriptome of in vivo and in vitro 
samples from different species, and in multiple assay multiple platforms. Important in our 
data processing scheme is the batch correction that removes systematic variations 
inherent in the heterogeneous data. By aligning the human in vitro and mouse in vivo data 
in the same “unified time scale”, the expression of orthologous genes between cells of the 
same “time” can be systematically compared.  
Our metaanlaysis revealed that all HLCs, regardless of their differentiation protocol or 
species, were closer to early liver development (~E15.5) than to primary adult 
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hepatocytes. Among the differentially expressed genes between HLCs and mature cells 
(E19.5, PHH) are key CYP450 enzymes (CYP2C8, CYP2C9, CYP2E1, CYP2D6 and 
CYP3A4) and metabolic izozymes (ALDOB, SLC2A2 (GLUT2), G6PC and FBP1) that 
are the hallmarks of liver metabolism.  This analysis is in concordance with the study by 
Baxter et al, where they demonstrate that HLCs were more representative of fetal 
hepatocytes, especially in the expression of CYP3A4 and CYP2D6 through proteomic 
and functional analysis [281]. 
The dynamic profile of gene expression during HLC differentiation was compared to that 
of early embryo development along the unified developmental time. Gene whose time 
dynamics follow opposite trend were identified as a pivotal gene set of about 200 genes. 
These genes spanned across important functional clusters of development and 
metabolism. Many transcription factors regulating organ development, including 
HAND1, PITX1, PITX2, MSX1, CDX2, SNAI2 and TWIST1 were highly expressed in 
early stage but subsided in E15 but remained highly expressed in D20 of in vitro 
differentiations. Genes of cell surface receptors (TGFBR3, FRZB) of the TGFβ and WNT 
signaling pathways increased their expression during HLC differentiation as compared to 
in vivo liver development, suggesting that these signaling mechanisms, which play key 
roles in early liver development, may be discordantly regulated in HLC differentiations. 
Furthermore, TGFβ signaling in conjunction with upregulation of SNAI2 and TWIST1 
hint the occurrence of epithelial to mesenchymal transition (EMT) [266].  
An upregulation of CDX2, a regulator of intestinal cell fate, was reported during lineage 
programming of fibroblasts to hepatocytes [282]. A recent study by Godoy et al 
performed transcriptome comparison  of HLCs generated from three labs to different cell 
lineages using the gene regulatory network analysis using the CellNet platform [283,284] 
which is currently applicable only to Affymetrix expression platforms. They concluded 
that all HLCs display a mixed gene signature corresponding to different lineages. 
Notably, some genes reported by Godoy et al coincided with differentially expressed 
genes identified in our study. Godoy et al saw a similar increase in expression of 
intestinal transcription factor CDX2 along with EMT regulator SNAI2. While they 
compared HLCs with hESCs and primary hepatocytes, our study focused on investigating 
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gene dynamics of differentiation with early embryonic development to elucidate genes 
with contrasting trends. Hence, we discerned several unexpected TF’s regulating not only 
intestinal but heart, limb, pancreas development. Such upregulation of TFs responsible 
for other endodermal and mesoderm cell lineages suggests that the strict control of 
developmental mechanisms occurring through crosstalk among developing organs in the 
embryo, is lacking during stem cell differentiation [285,286] . This combined with the 
previous comparative analysis with mature cells, provides a comprehensive view of genes 
that warrant intervention to achieve enhanced maturation.   
Transcription factors and miRNAs regulators for the dynamically differentially expressed 
genes were identified. These global regulators and can initiate the path forward for 
developing uniform strategies for genetic manipulation, to tailor the cell fate specifically 
towards the hepatic lineage.  
 In conclusion, an unbiased cross species comparative analysis of miRNA and 
transcriptome of in vitro stem cell differentiations from heterogeneous sources with in 
vivo mouse embryonic liver development was performed. It was demonstrated that HLCs 
not only represent an immature hepatic cell fate, but a mixed cell gene signature more 
representative of early development, of which an exact in vivo equivalent may not exist. 
Finally, pivotal gene targets were identified that merit combinatorial genetic intervention 
to enhance maturation of stem cell derived hepatocytes.  
 
 Figures 7.4
 
  154 
 
Figure 7-1: The timelines for mouse and human embryonic liver development and 
in vitro stem cell differentiations 
 
 
Figure 7-2: Platform dependent batch effect were evident for human in vitro 
differentiation data. The different colors indicate different platforms  
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Figure 7-3: Human in vitro Data after batch correction. The labels indicate the 
group the differentiation samples were obtained from and color represents the 
differentiation state (Endoderm: Red, Hepatic Progenitor Cell: Blue, Hepatocyte 
like cells: Green and Mature Cells: Black) 
 
Figure 7-4: The cophenetic coefficient for the human differentiation dataset is 
plotted for different ranks. Since the coefficient begins to decrease at 3, the data was 
optimally clustered into three groups  
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Figure 7-5:  NMF on human in vitro data after batch correction separates the data 
into three groups of  differentiating  cells until D14, HLCs and mature cells and 
tissue. The consensus matrix shown was generated after 100 iterations. The value 1 
(Red) and 0 (Blue) represent the confidence of sample assignment to that cluster. 
About 950 metagenes were found to classify the data into three groups.  
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Figure 7-6: The first two principal components represent 90% of variance in data. 
The samples are arranged according to their differentiation status in the PC space, 
starting with the endodermal cell flowed by HLCs and mature cells to the far right. 
The colors represent different stages of differentiation and shapes represent 
different sources of data  
 
Figure 7-7: Platform dependent effects were seen in the mouse development data 
where both platforms are represented in red and blue  
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Figure 7-8: Platform correction for mouse embryonic development data separates 
early and late stages of development. The two platforms are represented in red and 
blue. 
 
Figure 7-9: The cophenetic coefficient begins to decrease at 2 for mouse 
development, therefore data was optimally clustered into two groups  
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Figure 7-10: NMF optimally clusters mouse data into two groups of early and stages 
of development. The consensus matrix was generated after 100 iterations. About 120 
metagenes were found to classify both the developmental states. 
 
Figure 7-11: After PCA analysis on the batch corrected data, samples aligned 
according to their developmental stage in the PC space starting with the earliest 
(E9.5) to latest prenatal stage (E19.5) 
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Figure 7-12: Transcriptome data for mouse embryonic development, both 
microarray and RNA-Seq were combined after correcting for platform effects. The 
samples align along the same developmental stages validating the technique  
 
Figure 7-13: Mouse in vitro differentiation data was compiled and upon batch 
correction, the HLCs clustered together in the PC space and consistently away from 
primary hepatocytes 
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Figure 7-14: Mouse in vitro differentiation data was combined with embryonic liver 
development. After subjecting the entire dataset to PCA analysis, the samples 
aligned according to their differentiation status along the PC curve. The open circles 
represent embryonic development while the closed ones represent in vitro 
differentiation All the HLCs lay between E13.5 and E15.5 on this curve while E19.5, 
primary hepatocytes (PHH) lay in the region with higher PC2 values.  
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Figure 7-15: The gene expression profile in mouse developmental samples before 
and after combining the human in vitro and mouse in vivo data by performing batch 
correction for species effects. The gene profiles are shifted but are preserved in their 
dynamic trend. 
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Figure 7-16: The gene expression profile in human differentiation samples before 
and after combining the human in vitro and mouse in vivo data by performing batch 
correction for species effects. The gene profiles are shifted but are preserved in their 
dynamic trend. 
 
 
Figure 7-17: Human in vitro differentiation was combined with mouse development. 
Endodermal cells, hepatic progenitor cells and HLCs are represented in red, blue 
D6_
H
D14_
H
D20_
H
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and green. The circles, squares and diamonds correspond to samples from Hu et al, 
Duncan et al and Adjaye et al. Most HLCs lie before E15.5 in the PC space. 
 
 
 
Figure 7-18: The PC2 values for mouse and human samples are plotted against 
their unified developmental time (DT). The DT increases with increase in maturity, 
and most HLCs fall within DT corresponding to E15.5 
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Figure 7-19: Human and mouse gene profiles can be evaluated on the same 
developmental scale. Albumin follows similar dynamics in development and 
differentiation 
 
 
Figure 7-20: Human and mouse gene profiles can be evaluated on the same 
developmental scale. TGFBI follows opposite dynamics in development and 
differentiation 
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Figure 7-21: Functionally enriched clusters and pathways in the dynamically 
differentially expressed genes 
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Transcription Factors 
TRANSPORTERS 
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Figure 7-22: Dynamically differentially expressed (A) transcription factors (B) 
transporters (C) Cell surface markers (D) Other genes between human 
differentiation (Black : D6_H,D10_H,D14_H,D20_H) and mouse development (Blue 
:E9.5,E11.5,E13.5,E15.5)  
 
 
 
 
  169 
 
 
 
 
 
 
 
  170 
 
Figure 7-23: Dynamically differentially expressed genes between human 
differentiation belonging to other functional groups (Black: D6_H, D10_H, D14_H, 
D20_H) and mouse development (Blue : E9.5, E11.5, E13.5, E15.5)  
Table 7-1: Summary of human transcriptome data 
Data Platform Samples Brief Description Abbreviations of 
important samples 
GSE14897 Affymetrix H9: D0,D20 
iPS: Fibroblasts,D20 
H9 Differentiation D20_D 
GSE25417 Affymetrix H9:D5,d10,d15,HNF4 
KD D20  
HNF4a KD in H9 
and differentiated 
D5_D, D10_D, D15_D 
GSE25744 Illumina H1: D0, HLC 
iPS: D0, HLC 
fibroblasts, fetal liver 
H1 and iPS cells 
differentiated using 
2 protocols 
D20_A1, D20_A2, 
D20_A3,  D20_A4, 
D20_A5,D20_A6 
Hu et al, 
to be 
deposited 
Illumina H9: D0,D6,D9, D10, 
D12, D14,D20 
H9 cells 
differentiation to 
HLCs 
D6_H, D9_H, D10_H, 
D12_H, D14_H,D20_H 
Hu et al, 
to be 
deposited 
Illumina HSF6: D0, D20,D32 
spheroids, Adult Liver 
HSF6 cells 
differentiated fro 20 
days and cultured as 
spheroids 
D20_H1, D32_H 
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Hu et al, 
to be 
deposited 
Affymetrix HES3: D0, D20 HES3 
differentiation to 
HLCs 
D20_H2 
GSE42643 Agilent Fibroblasts, HLCs, Human fibroblasts 
reprogrammed to 
HLC 
iHEP 
GSE46631 Agilent Liver bud from iPS Liver bud: 
HUVECs,MSCs 
and iPS derived 
HLCs 
LiverBud 
 
Table 7-2: Summary of mouse transcriptome data 
Data Platform Brief Description Samples 
GSE46631 Agilent Mouse liver 
development 
E9.5, E10.5, E11.5, E13.5, E15.5, E17.5, 
E19.5 
GSE13149 Affymetrix Mouse liver 
development 
E11.5, E12.5, E13.5, E14.5, E15.5, E16.5, 
E17.5 ,E18.5 
www.alexap
latform.org 
Illumin HiSeq Mouse liver 
development 
E8.5, E14.5 
GSE23635 Agilent MEFS reprogrammed 
to hepatocyes 
iHEP1 
GSE29725 Agilent MEFS reprogrammed 
to hepatocyes 
iHEP2 
GSE48486 Agilent MEFS reprogrammed 
to hepatic progenitor 
cells 
iHEP3 
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Table 7-3: Transcription factors with overrepresented binding sites in the 
dynamically differentially expressed genes 
 
Source Transcription Factor 
# Genes with 
overrepresented 
TFBS 
UCSC_TFBS GATA 55 
UCSC_TFBS CHX10 51 
UCSC_TFBS FOXO1 50 
UCSC_TFBS NFKAPPAB65 32 
UCSC_TFBS HFH1 52 
UCSC_TFBS MEIS1AHOXA9 43 
UCSC_TFBS RORA2 53 
UCSC_TFBS CREBP1 52 
UCSC_TFBS FREAC4 51 
UCSC_TFBS S8 50 
UCSC_TFBS E47 62 
UCSC_TFBS PBX1 59 
UCSC_TFBS GATA6 24 
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8. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Stem cells have the ability to propagate in a self-renewing manner, while possessing the 
potential to differentiate into more specialized cell types in response to molecular cues 
[14,15]. These special intrinsic characteristics have engendered much interest in using 
them not only for clinical applications such as regenerative therapy but also for 
facilitating research by providing better in vitro models of diseases for developing novel 
small molecules of biologics drugs, and drug toxicity testing. The latter applications have 
gained even more attention with the discovery of iPSCs, as differentiated cells 
representing a diverse genetic background can now be generated from a large pool of 
patients, bringing personalized medicine closer to reality. Stem cells for therapeutic 
applications particularly will entail a robust process that is free from transgene systems or 
xenogeneic products. Furthermore, the stem cell products will need to meet high quality 
standards and require thorough characterization to eliminate any undifferentiated or 
potential tumor forming cells before delivery to patients. Therefore, to harness the full 
potential of these advances, an enabling technology for consistently and safely producing 
large quantities of high quality cells is critical.  
To address key goals prior to clinical translation of stem cell research, a two-pronged 
approach was used in this study encompassing both process improvement and a system 
based analysis for target discovery. The key objectives were a) to increase product cell 
quantity (Chapter 4) and quality (Chapter 5) from stem cell hepatic differentiations  b) to 
discover the genes that are responsible for a universal gap in maturation of stem cell 
derived hepatocytes by performing a comparative transcriptome analysis with mouse 
embryonic liver development (Chapter 6,7) 
 Process Improvement 8.1
8.1.1 Increasing cell yields through endodermal cell expansion 
 
In Chapter 4, we demonstrated that our hepatic differentiation protocol can be further 
extended to generate larger quantities of HLCs without utilizing cell sorting or culture on 
xenogeneic feeder cells. This was implemented by expanding the intermediate 
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endodermal cell population by at least eight fold by providing a larger culture surface for 
growth. Stage 2 medium containing FGF2 and BMP4 was chosen to mimic the 
mesodermal signaling cues occurring in native liver development. These factors play a 
key role in the transition of the foregut endoderm to the liver bud which is largely 
dependent on cell migration, proliferation and differentiation [109]. The cell expansion is 
accompanied with a simultaneous 1000 fold increase in expression of hepatic markers 
and 1000 fold decrease in endodermal and pluripotent markers in EN2 cells indicates that 
this phenomenon is selective for cells fated towards the hepatic lineage.  The 
differentiated status of the expanded endodermal cells reduce the contamination of 
undifferentiated stem cells in the subsequent progeny. Mass cytometry was used to probe 
the nature of  the endodermal to hepatic transition and confirmed that this was  occurring 
in all the cells and not a specific subpopulation. This technique also revealed that the 
hepatic and endodermal genes are activated and repressed simultaneously for a successful 
differentiation outcome. Upon continuation of later stages of differentiation, HLCs 
generated from both protocols exhibited highly similar hepatic transcripts as well as 
secretory capabilities for albumin and urea. Glycogen synthesis was also seen in both cell 
types.  
Transcriptome analysis  further verified hepatic fate acquisition by endodermal 
expansion through comparison of expression of genes characteristic to pluripotent, 
endodermal and hepatic fates. The end stage HLCs were also similar in expression of 
characteristic hepatic genes involved in key functions such as urea cycle, 
glycolysis/gluconeogenesis and xenobiotic biotransformation.  Extensive crosstalk 
amongst signaling pathways is rampant during embryonic liver development leading cells 
to embark on different trajectories to attain a similar differentiated status [6]. This is 
visualized by plotting principal components of samples generated from PCA analysis. 
While the path to differentiation is different, i.e. the expanded cells are further along in 
their hepatic phenotype, the HLCs eventually attain the same differentiated state. This 
suggests that the cells may encounter an upstream barrier to maturation,which will need 
further evaluation. This approach of endodermal cell expansion using typical 
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differentiation culture conditions is a simple way to achieve achieving higher cell yields 
with comparable cell quality with the original protocol. 
8.1.2 Enriching hepatic cells from stem cell differentiations to improve 
product quality 
As discussed previously, product purity is critical prior to use of HLCs in clinical 
applications. The current protocol yields cells with varying hepatic maturity as well as 
from other lineages. We explored the potential of cell surface marker based sorting and 
selective medium based enrichment to enrich the desired fraction of cells from Day 14 of 
differentiation with the hypothesis that these cells may retain the proliferative capabilities 
of their in vivo counterparts.  
DLK1 was chosen as a suitable marker and magnetic activated cell sorting was used to 
enrich hepatic progenitor cells. While the DLK+ population exhibited higher hepatic 
transcripts, the sorting efficiency was low and cell morphology deteriorated upon 
resuming culture in Stage 4 conditions. An alternate, gentler method of selection was 
then pursued using Kubota’s medium, a serum free, defined medium which was 
developed for the ex vivo culture of hepatic progenitor cells isolated from rodent 
embryonic livers [204]. It was found that cells cultured in Kubota’s medium on Collagen 
1 were selective for hepatic cells from stem cell differentiations through quantitative PCR 
and immunohistochemistry. Interestingly, this condition did not support the proliferation 
of fibroblastic AFP- cells, arising during culture in other combinations of ECM and 
media. A higher percentage of cells expressing AFP and ALB was seen using flow 
cytometry. However, these cells did not display the extensive expansive potential of 
embryonic fetal liver cells. The supplementation of hepatic growth factors commonly 
used during expansion of in vivo fetal liver cells, did not have effects on the phenotype of 
the in vitro cells. Upon differentiation, the hepatic transcripts were comparable to the 
HLCs generated from the original protocol. 
Similar results were also observed in the previous study, where the HLCs from 
the expanded endodermal cells, which were expressing higher hepatic transcripts, did not 
show a significant change when compared to the original protocol. This suggests that all 
differentiating cells encounter a roadblock during the final stages preventing maturation, 
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which warrants further investigation. Clues from the embryonic liver development, 
particularly about the progenitor cells and their  native microenvironment or  ‘niche’ 
would be key in deciphering culture conditions for the ex vivo propagation and 
differentiation of stem cell derived hepatocytes for cell therapies and other clinical 
applications. 
8.1.3 Unveiling the Road Blocks of Stem Cell Differentiation through Cross 
Species Transcriptome Data Meta-analysis   
Comparison of transcriptome data of differentiation to embryonic development can 
elucidate the genetic roadblocks preventing stem cells from reaching the functional 
maturity of their tissue counterparts. While transcriptome data for in vitro stem cell 
differentiation is easy to obtain, human in vivo developmental transcriptome data is hard 
to come by. Such in vivo data may sometimes be available from other species. Hence, we 
attempted to combine human in vitro data with mouse in vivo data with the hypothesis 
that mouse embryonic development bears a high degree of conservation in gene 
expression dynamics. The meta-analysis may provide us crucial insights on possible 
genetic targets that can enhance the maturity in stem cell differentiations. 
Briefly, transcriptome data was obtained during the time course of our human hepatic 
differentiation protocol. This data was augmented with human in vitro hepatic 
differentiation data in the public depository. The data were heterogeneous in their 
sources, assay methods and platforms. Data were treated with an empirical bayes method 
based algorithm to remove platform dependent effects and allow for meaningful data 
comparison. These data of were subjected to hierarchical clustering, principal component 
analysis (PCA) and non-negative matrix factorization (NMF).  Interestingly, in all 
analyses, data of the same differentiation day from different sources, were grouped 
together, thereby validating the technique. This same workflow was repeated for mouse 
in vitro stem cell hepatic differentiations. The majority of HLC are similar irrespective of 
the cell source and protocol. The entire cohort of HLCs clustered separately from the 
primary hepatocytes and adult liver in both human and mouse differentiations, indicating 
an inherent roadblock to maturation. 
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We compiled transcriptome data from various depositories for mouse fetal liver 
development (from E8.5 to post-natal). We next integrated the transcriptome data of both 
human and mouse stem cell hepatic differentiations with mouse liver embryonic 
development data for a comparative analysis. A batch adjustment was performed to 
integrate the mouse in vivo and the different in vitro differentiation datasets and validated 
through the previously described methods. A differential expression analysis between all 
the HLCs and mature cells revealed that all the major cytochrome P450 enzymes and 
important metabolic genes were not upregulated in HLCs of both species. 
The trajectory of the progression of the developing embryo and differentiating cells 
were defined as unified “developmental time” with respect to a reference point (E9.5). 
The unified time scale allowed us to identify that the corresponding embryo development 
stage at which the in vitro stem cell differentiation is blocked is around E15.5. It further 
allowed the transcriptome dynamics at the critical time points of development to be 
analyzed systematically. The analysis uncovered a pivotal gene set of about 200 genes 
with contrasting profiles in hESC differentiation and mouse embryonic liver development 
and their regulators, that merit combinatorial genetic intervention to enhance maturation 
of stem cell derived hepatocytes.  
8.1.4 Future Outlook 
 
The availability of an expandable source of human hepatocytes has profound implications 
in the treatment of liver diseases. While these cells may not be suitable for clinical 
transplantation immediately, this may not limit their use in bio artificial liver devices or 
as in vitro models for drug toxicity and diseases. All these applications will require the 
reproducible generation of large quantities of high quality functional cells. 
With the advent of induced pluripotent stem cells, personalized or population-
specific drug screening platforms can be now be established to screen for potential 
candidates during early stages of drug discovery. This will require the stem cell derived 
hepatocytes to express the drug metabolizing and detoxification enzymes at levels on par 
with primary hepatocytes and respond appropriately upon exposure to the respective 
inducers and inhibitors. 
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For clinical transplantation where patient safety is paramount, high quality 
standards will need to be established in addition to requirements of functional maturity.  
This will entail thorough characterization to confirm cell purity through a combination of 
cell sorting based on several markers and single cell based techniques. Additionally, the 
cells will need to undergo routine testing to ensure that they have not acquired any 
genetic instability through the culture. 
The lack of functional maturity in HLCs when compared to their primary 
counterparts represents a bottleneck in most stem cell applications. The comprehensive 
transcriptome analysis presented in Chapter 7, shows that this phenomenon is a universal 
to the state of the art and provides a basis for genetic intervention to overcome this 
roadblock. The pivotal genes and their regulators could be manipulated genetically using 
strategies for knock down or overexpression to enhance functional maturity. 
Additionally, it was revealed that stem cell differentiation is blocked at a stage 
corresponding to embryonic day E13-15 in mouse development. Typically, stem cell 
derived HLCs are transplanted in adult livers of animal models with liver failure and face 
limited engraftment and restoration of liver function. An alternative strategy will involve 
transplantation of HLCs in embryonic livers around E13.5 even before the development 
of the immune system. These HLCs will most likely have a higher chance of engraftment 
and may even proliferate in the native microenviroment of the developing embryo. 
Furthermore, these HLCs if tagged with a fluorescent marker could be isolated from 
mouse livers after birth. A comparative transcriptome and proteomic analysis of both cell 
states would then reveal critical developmental cues, which can then be recapitulated in 
in vitro systems.  
Lastly, stem cell based clinical applications require the development of robust cell 
production processes. Foremost to developing a robust process is the optimization of 
culture medium suitable not only for laboratory practice but also for manufacturing and 
clinical applications. The development of stem cell process technology has the benefit of 
learning the tremendous expertise accumulated in the past few decades on the 
manufacturing of therapeutic proteins and viral vaccines. For most applications, the scale 
up will rely on closed bioreactor systems with stem cells grown on suspended cell 
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supports such as microcarriers. Untested in those applications is the effect of mechanical 
and fluid dynamic stresses on selfrenewal and differentiation. For safety reasons and 
enhanced process robustness, medium used for stem cell culture will increasingly become 
more chemically defined and animal component free. Innovations in those areas of stem 
cell bioprocessing will greatly facilitate the translation of discovery to clinical practice.  
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10. APPENDIX A: GENE LISTS FROM META ANALYSIS 
Table 10-1: Metagenes from NMF analysis of human differentiation data 
Ensembl_ID SYMBOL Metagene 
ENSG00000165495 PKNOX2 1 
ENSG00000157827 FMNL2 1 
ENSG00000160326 SLC2A6 1 
ENSG00000158270 COLEC12 1 
ENSG00000171208 NETO2 1 
ENSG00000134323 MYCN 1 
ENSG00000090530 LEPREL1 1 
ENSG00000147869 CER1 1 
ENSG00000169169 CPT1C 1 
ENSG00000196376 SLC35F1 1 
ENSG00000143768 LEFTY2 1 
ENSG00000243709 LEFTY1 1 
ENSG00000149201 CCDC81 1 
ENSG00000174469 CNTNAP2 1 
ENSG00000167157 PRRX2 1 
ENSG00000172348 RCAN2 1 
ENSG00000101144 BMP7 1 
ENSG00000137285 TUBB2B 1 
ENSG00000121966 CXCR4 1 
ENSG00000240694 PNMA2 1 
ENSG00000158246 FAM46B 1 
ENSG00000272398 CD24 1 
ENSG00000137821 LRRC49 1 
ENSG00000019144 PHLDB1 1 
ENSG00000178531 CTXN1 1 
ENSG00000105270 CLIP3 1 
ENSG00000138650 PCDH10 1 
ENSG00000109705 NKX3-2 1 
ENSG00000128045 RASL11B 1 
ENSG00000184261 KCNK12 1 
ENSG00000130294 KIF1A 1 
ENSG00000131914 LIN28A 1 
ENSG00000159167 STC1 1 
ENSG00000169992 NLGN2 1 
ENSG00000131711 MAP1B 1 
ENSG00000213190 MLLT11 1 
  202 
ENSG00000164659 KIAA1324L 1 
ENSG00000152377 SPOCK1 1 
ENSG00000082497 SERTAD4 1 
ENSG00000121570 DPPA4 1 
ENSG00000148143 ZNF462 1 
ENSG00000161249 DMKN 1 
ENSG00000125285 SOX21 1 
ENSG00000043355 ZIC2 1 
ENSG00000258947 TUBB3 1 
ENSG00000176887 SOX11 1 
ENSG00000187772 LIN28B 1 
ENSG00000143768 LEFTY2 1 
ENSG00000243709 LEFTY1 1 
ENSG00000156925 ZIC3 1 
ENSG00000105655 ISYNA1 1 
ENSG00000144810 COL8A1 1 
ENSG00000106278 PTPRZ1 1 
ENSG00000128683 GAD1 1 
ENSG00000104728 ARHGEF10 1 
ENSG00000168268 NT5DC2 1 
ENSG00000164434 FABP7 1 
ENSG00000133636 NTS 1 
ENSG00000181449 SOX2 1 
ENSG00000179431 FJX1 1 
ENSG00000204335 SP5 1 
ENSG00000177519 RPRM 1 
ENSG00000124766 SOX4 1 
ENSG00000106631 MYL7 1 
ENSG00000033170 FUT8 1 
ENSG00000136943 CTSV 1 
ENSG00000126878 AIF1L 1 
ENSG00000122861 PLAU 1 
ENSG00000139946 PELI2 1 
ENSG00000165588 OTX2 1 
ENSG00000104722 NEFM 1 
ENSG00000154188 ANGPT1 1 
ENSG00000184613 NELL2 1 
ENSG00000144834 TAGLN3 1 
ENSG00000183145 RIPPLY3 1 
ENSG00000088756 ARHGAP28 1 
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ENSG00000082397 EPB41L3 1 
ENSG00000198795 ZNF521 1 
ENSG00000138829 FBN2 1 
ENSG00000184304 PRKD1 1 
ENSG00000006118 TMEM132A 1 
ENSG00000095596 CYP26A1 1 
ENSG00000138180 CEP55 1 
ENSG00000166503   1 
ENSG00000067445 TRO 1 
ENSG00000151640 DPYSL4 1 
ENSG00000128567 PODXL 1 
ENSG00000114948 ADAM23 1 
ENSG00000144339 TMEFF2 1 
ENSG00000150551 LYPD1 1 
ENSG00000026025 VIM 1 
ENSG00000168280 KIF5C 1 
ENSG00000092445 TYRO3 1 
ENSG00000088882 CPXM1 1 
ENSG00000138795 LEF1 1 
ENSG00000116729 WLS 1 
ENSG00000041982 TNC 1 
ENSG00000153707 PTPRD 1 
ENSG00000198467 TPM2 1 
ENSG00000162551 ALPL 1 
ENSG00000075213 SEMA3A 1 
ENSG00000196526 AFAP1 1 
ENSG00000154277 UCHL1 1 
ENSG00000109255 NMU 1 
ENSG00000128596 CCDC136 1 
ENSG00000136231 IGF2BP3 1 
ENSG00000143320 CRABP2 1 
ENSG00000132688 NES 1 
ENSG00000134531 EMP1 1 
ENSG00000111716 LDHB 1 
ENSG00000050165 DKK3 1 
ENSG00000076716 GPC4 1 
ENSG00000165349 SLC7A3 1 
ENSG00000046653 GPM6B 1 
ENSG00000123560 PLP1 1 
ENSG00000104332 SFRP1 1 
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ENSG00000103449 SALL1 1 
ENSG00000141971 MVB12A 1 
ENSG00000143632 ACTA1 1 
ENSG00000166086 JAM3 1 
ENSG00000149591 TAGLN 1 
ENSG00000166426 CRABP1 1 
ENSG00000163508 EOMES 1 
ENSG00000204711 C9orf135 1 
ENSG00000170373 CST1 1 
ENSG00000184867 ARMCX2 1 
ENSG00000134775 FHOD3 1 
ENSG00000163629 PTPN13 1 
ENSG00000175928 LRRN1 1 
ENSG00000113758 DBN1 1 
ENSG00000167657 DAPK3 1 
ENSG00000114854 TNNC1 1 
ENSG00000136011 STAB2 2 
ENSG00000145321 GC 2 
ENSG00000151365 THRSP 2 
ENSG00000163959 SLC51A 2 
ENSG00000196620 UGT2B15 2 
ENSG00000156096 UGT2B4 2 
ENSG00000196620 UGT2B15 2 
ENSG00000156096 UGT2B4 2 
ENSG00000213424 KRT222 2 
ENSG00000264058 KRT222 2 
ENSG00000162267 ITIH3 2 
ENSG00000055957 ITIH1 2 
ENSG00000112337 SLC17A2 2 
ENSG00000164406 LEAP2 2 
ENSG00000266964 FXYD1 2 
ENSG00000250799 PRODH2 2 
ENSG00000159189 C1QC 2 
ENSG00000173369 C1QB 2 
ENSG00000160862 AZGP1 2 
ENSG00000171236 LRG1 2 
ENSG00000151655 ITIH2 2 
ENSG00000112299 VNN1 2 
ENSG00000118514 ALDH8A1 2 
ENSG00000131910 NR0B2 2 
  205 
ENSG00000198099 ADH4 2 
ENSG00000151224 MAT1A 2 
ENSG00000132693 CRP 2 
ENSG00000167711 SERPINF2 2 
ENSG00000168509 HFE2 2 
ENSG00000182326 C1S 2 
ENSG00000160870 CYP3A7 2 
ENSG00000160868 CYP3A4 2 
ENSG00000143819 EPHX1 2 
ENSG00000229314 ORM1 2 
ENSG00000121858 TNFSF10 2 
ENSG00000136881 BAAT 2 
ENSG00000117009 KMO 2 
ENSG00000127951 FGL2 2 
ENSG00000139547 RDH16 2 
ENSG00000069535 MAOB 2 
ENSG00000177575 CD163 2 
ENSG00000138075 ABCG5 2 
ENSG00000130208 APOC1 2 
ENSG00000170608 FOXA3 2 
ENSG00000161944 ASGR2 2 
ENSG00000171840 NINJ2 2 
ENSG00000273259 SERPINA3 2 
ENSG00000196136 SERPINA3 2 
ENSG00000188488 SERPINA5 2 
ENSG00000106538 RARRES2 2 
ENSG00000129151 BBOX1 2 
ENSG00000110887 DAO 2 
ENSG00000132840 BHMT2 2 
ENSG00000138115 CYP2C8 2 
ENSG00000138109 CYP2C9 2 
ENSG00000157873 TNFRSF14 2 
ENSG00000005471 ABCB4 2 
ENSG00000138308 PLA2G12B 2 
ENSG00000111249 CUX2 2 
ENSG00000169856 ONECUT1 2 
ENSG00000117707 PROX1 2 
ENSG00000135423 GLS2 2 
ENSG00000155659 VSIG4 2 
ENSG00000169174 PCSK9 2 
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ENSG00000154262 ABCA6 2 
ENSG00000099769 IGFALS 2 
ENSG00000175336 APOF 2 
ENSG00000012504 NR1H4 2 
ENSG00000169562 GJB1 2 
ENSG00000214274 ANG 2 
ENSG00000140107 SLC25A47 2 
ENSG00000144891 AGTR1 2 
ENSG00000105697 HAMP 2 
ENSG00000180432 CYP8B1 2 
ENSG00000180745 CLRN3 2 
ENSG00000144035 NAT8 2 
ENSG00000170458 CD14 2 
ENSG00000176919 C8G 2 
ENSG00000244734 HBB 2 
ENSG00000134716 CYP2J2 2 
ENSG00000148584 A1CF 2 
ENSG00000134716 CYP2J2 2 
ENSG00000134716 CYP2J2 2 
ENSG00000172955 ADH6 2 
ENSG00000165092 ALDH1A1 2 
ENSG00000196600 SLC22A25 2 
ENSG00000149742 SLC22A9 2 
ENSG00000171747 LGALS4 2 
ENSG00000160870 CYP3A7 2 
ENSG00000160868 CYP3A4 2 
ENSG00000133574 GIMAP4 2 
ENSG00000196620 UGT2B15 2 
ENSG00000156096 UGT2B4 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000144891 AGTR1 2 
ENSG00000145850 TIMD4 2 
ENSG00000160870 CYP3A7 2 
ENSG00000160868 CYP3A4 2 
ENSG00000143546 S100A8 2 
ENSG00000139547 RDH16 2 
ENSG00000139344 AMDHD1 2 
ENSG00000105697 HAMP 2 
ENSG00000080910 CFHR2 2 
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ENSG00000141293 SKAP1 2 
ENSG00000144035 NAT8 2 
ENSG00000129988 LBP 2 
ENSG00000196620 UGT2B15 2 
ENSG00000156096 UGT2B4 2 
ENSG00000117594 HSD11B1 2 
ENSG00000244067 GSTA2 2 
ENSG00000273259 SERPINA3 2 
ENSG00000196136 SERPINA3 2 
ENSG00000205403 CFI 2 
ENSG00000084734 GCKR 2 
ENSG00000198670 LPA 2 
ENSG00000187045 TMPRSS6 2 
ENSG00000154274 C4orf19 2 
ENSG00000108515 ENO3 2 
ENSG00000214274 ANG 2 
ENSG00000170099 SERPINA6 2 
ENSG00000229314 ORM1 2 
ENSG00000179761 PIPOX 2 
ENSG00000100197 CYP2D6 2 
ENSG00000140093 SERPINA10 2 
ENSG00000149124 GLYAT 2 
ENSG00000188582 PAQR9 2 
ENSG00000151726 ACSL1 2 
ENSG00000187048 CYP4A11 2 
ENSG00000162365 CYP4A22 2 
ENSG00000134716 CYP2J2 2 
ENSG00000163825 RTP3 2 
ENSG00000273259 SERPINA3 2 
ENSG00000196136 SERPINA3 2 
ENSG00000142484 TM4SF5 2 
ENSG00000137204 SLC22A7 2 
ENSG00000138115 CYP2C8 2 
ENSG00000138109 CYP2C9 2 
ENSG00000138115 CYP2C8 2 
ENSG00000138109 CYP2C9 2 
ENSG00000100197 CYP2D6 2 
ENSG00000160282 FTCD 2 
ENSG00000144035 NAT8 2 
ENSG00000164089 ETNPPL 2 
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ENSG00000133488 SEC14L4 2 
ENSG00000145692 BHMT 2 
ENSG00000139547 RDH16 2 
ENSG00000165140 FBP1 2 
ENSG00000143845 ETNK2 2 
ENSG00000196620 UGT2B15 2 
ENSG00000156096 UGT2B4 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000214274 ANG 2 
ENSG00000105707 HPN 2 
ENSG00000186115 CYP4F2 2 
ENSG00000171903 CYP4F11 2 
ENSG00000186204 CYP4F12 2 
ENSG00000118513 MYB 2 
ENSG00000118520 ARG1 2 
ENSG00000244734 HBB 2 
ENSG00000084110 HAL 2 
ENSG00000187758 ADH1A 2 
ENSG00000248144 ADH1C 2 
ENSG00000171759 PAH 2 
ENSG00000122862 SRGN 2 
ENSG00000139547 RDH16 2 
ENSG00000145692 BHMT 2 
ENSG00000132437 DDC 2 
ENSG00000160255 ITGB2 2 
ENSG00000146678 IGFBP1 2 
ENSG00000131482 G6PC 2 
ENSG00000084674 APOB 2 
ENSG00000273259 SERPINA3 2 
ENSG00000196136 SERPINA3 2 
ENSG00000110077 MS4A6A 2 
ENSG00000144035 NAT8 2 
ENSG00000141485 SLC13A5 2 
ENSG00000141505 ASGR1 2 
ENSG00000197249 SERPINA1 2 
ENSG00000273259 SERPINA3 2 
ENSG00000196136 SERPINA3 2 
ENSG00000100652 SLC10A1 2 
ENSG00000196139 AKR1C3 2 
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ENSG00000198610 AKR1C4 2 
ENSG00000198650 TAT 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000124568 SLC17A1 2 
ENSG00000131187 F12 2 
ENSG00000145826 LECT2 2 
ENSG00000172497 ACOT12 2 
ENSG00000258818 RNASE4 2 
ENSG00000055955 ITIH4 2 
ENSG00000080618 CPB2 2 
ENSG00000120915 EPHX2 2 
ENSG00000113600 C9 2 
ENSG00000039537 C6 2 
ENSG00000136305 CIDEB 2 
ENSG00000147647 DPYS 2 
ENSG00000132541 HRSP12 2 
ENSG00000100197 CYP2D6 2 
ENSG00000135447 PPP1R1A 2 
ENSG00000163347 CLDN1 2 
ENSG00000099937 SERPIND1 2 
ENSG00000113924 HGD 2 
ENSG00000113790 EHHADH 2 
ENSG00000145192 AHSG 2 
ENSG00000090512 FETUB 2 
ENSG00000113889 KNG1 2 
ENSG00000113905 HRG 2 
ENSG00000198300 PEG3 2 
ENSG00000130988 RGN 2 
ENSG00000178772 CPN2 2 
ENSG00000002933 TMEM176A 2 
ENSG00000175003 SLC22A1 2 
ENSG00000146233 CYP39A1 2 
ENSG00000125730 C3 2 
ENSG00000186115 CYP4F2 2 
ENSG00000171903 CYP4F11 2 
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ENSG00000186204 CYP4F12 2 
ENSG00000166278 C2 2 
ENSG00000115718 PROC 2 
ENSG00000204444 APOM 2 
ENSG00000166927 MS4A7 2 
ENSG00000110077 MS4A6A 2 
ENSG00000110077 MS4A6A 2 
ENSG00000165092 ALDH1A1 2 
ENSG00000196600 SLC22A25 2 
ENSG00000149742 SLC22A9 2 
ENSG00000165471 MBL2 2 
ENSG00000124713 GNMT 2 
ENSG00000152804 HHEX 2 
ENSG00000138207 RBP4 2 
ENSG00000108242 CYP2C18 2 
ENSG00000138115 CYP2C8 2 
ENSG00000138109 CYP2C9 2 
ENSG00000189221 MAOA 2 
ENSG00000148702 HABP2 2 
ENSG00000215644 GCGR 2 
ENSG00000241935 HOGA1 2 
ENSG00000023839 ABCC2 2 
ENSG00000120054 CPN1 2 
ENSG00000144837 PLA1A 2 
ENSG00000163687 DNASE1L3 2 
ENSG00000174990 CA5A 2 
ENSG00000170439 METTL7B 2 
ENSG00000025423 HSD17B6 2 
ENSG00000135218 CD36 2 
ENSG00000160255 ITGB2 2 
ENSG00000165828 PRAP1 2 
ENSG00000125246 CLYBL 2 
ENSG00000138115 CYP2C8 2 
ENSG00000138109 CYP2C9 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000021826 CPS1 2 
ENSG00000172482 AGXT 2 
ENSG00000072080 SPP2 2 
ENSG00000143278 F13B 2 
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ENSG00000019169 MARCO 2 
ENSG00000123838 C4BPA 2 
ENSG00000132703 APCS 2 
ENSG00000198734 F5 2 
ENSG00000196660 SLC30A10 2 
ENSG00000007933 FMO3 2 
ENSG00000117601 SERPINC1 2 
ENSG00000077420 APBB1IP 2 
ENSG00000148346 LCN2 2 
ENSG00000115919 KYNU 2 
ENSG00000106804 C5 2 
ENSG00000073734 ABCB11 2 
ENSG00000091583 APOH 2 
ENSG00000121691 CAT 2 
ENSG00000186115 CYP4F2 2 
ENSG00000171903 CYP4F11 2 
ENSG00000186204 CYP4F12 2 
ENSG00000171766 GATM 2 
ENSG00000101323 HAO1 2 
ENSG00000140284 SLC27A2 2 
ENSG00000047457 CP 2 
ENSG00000163581 SLC2A2 2 
ENSG00000114771 AADAC 2 
ENSG00000114200 BCHE 2 
ENSG00000169903 TM4SF4 2 
ENSG00000116882 HAO2 2 
ENSG00000134240 HMGCS2 2 
ENSG00000171560 FGA 2 
ENSG00000151790 TDO2 2 
ENSG00000131781 FMO5 2 
ENSG00000108924 HLF 2 
ENSG00000138823 MTTP 2 
ENSG00000116791 CRYZ 2 
ENSG00000136872 ALDOB 2 
ENSG00000106927 AMBP 2 
ENSG00000229314 ORM1 2 
ENSG00000132855 ANGPTL3 2 
ENSG00000134716 CYP2J2 2 
ENSG00000134709 HOOK1 2 
ENSG00000187048 CYP4A11 2 
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ENSG00000162365 CYP4A22 2 
ENSG00000187048 CYP4A11 2 
ENSG00000162365 CYP4A22 2 
ENSG00000159423 ALDH4A1 2 
ENSG00000187017 ESPN 2 
ENSG00000009724 MASP2 2 
ENSG00000109758 HGFAC 2 
ENSG00000138030 KHK 2 
ENSG00000109819 PPARGC1A 2 
ENSG00000134962 KLB 2 
ENSG00000196620 UGT2B15 2 
ENSG00000156096 UGT2B4 2 
ENSG00000163631 ALB 2 
ENSG00000079557 AFM 2 
ENSG00000158104 HPD 2 
ENSG00000160870 CYP3A7 2 
ENSG00000160868 CYP3A4 2 
ENSG00000021852 C8B 2 
ENSG00000106327 TFR2 2 
ENSG00000106258 CYP3A5 2 
ENSG00000105852 PON3 2 
ENSG00000106565 TMEM176B 2 
ENSG00000144035 NAT8 2 
ENSG00000144908 ALDH1L1 2 
ENSG00000111181 SLC6A12 2 
ENSG00000175899 A2M 2 
ENSG00000111796 KLRB1 2 
ENSG00000165682 CLEC1B 2 
ENSG00000139144 PIK3C2G 2 
ENSG00000134538 SLCO1B1 2 
ENSG00000111700 SLCO1B3 2 
ENSG00000157103 SLC6A1 2 
ENSG00000111796 KLRB1 2 
ENSG00000111796 KLRB1 2 
ENSG00000105398 SULT2A1 2 
ENSG00000083807 SLC27A5 2 
ENSG00000021488 SLC7A9 2 
ENSG00000011600 TYROBP 2 
ENSG00000137491 SLCO2B1 2 
ENSG00000062282 DGAT2 2 
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ENSG00000110169 HPX 2 
ENSG00000066813 ACSM2B 2 
ENSG00000101981 F9 2 
ENSG00000036473 OTC 2 
ENSG00000123561 SERPINA7 2 
ENSG00000126218 F10 2 
ENSG00000126231 PROZ 2 
ENSG00000009950 MLXIPL 2 
ENSG00000104760 FGL1 2 
ENSG00000109511 ANXA10 2 
ENSG00000164344 KLKB1 2 
ENSG00000088926 F11 2 
ENSG00000257017 HP 2 
ENSG00000261701 HPR 2 
ENSG00000187193 MT1X 2 
ENSG00000198417 MT1F 2 
ENSG00000205364 MT1M 2 
ENSG00000125144 MT1G 2 
ENSG00000086696 HSD17B2 2 
ENSG00000166816 LDHD 2 
ENSG00000135744 AGT 2 
ENSG00000110243 APOA5 2 
ENSG00000110245 APOC3 2 
ENSG00000103569 AQP9 2 
ENSG00000166035 LIPC 2 
ENSG00000158874 APOA2 2 
ENSG00000138115 CYP2C8 2 
ENSG00000138109 CYP2C9 2 
ENSG00000129596 CDO1 2 
ENSG00000100024 UPB1 2 
ENSG00000144035 NAT8 2 
ENSG00000196139 AKR1C3 2 
ENSG00000198610 AKR1C4 2 
ENSG00000171557 FGG 2 
ENSG00000211452 DIO1 2 
ENSG00000245848 CEBPA 2 
ENSG00000157131 C8A 2 
ENSG00000060566 CREB3L3 2 
ENSG00000139547 RDH16 2 
ENSG00000100197 CYP2D6 2 
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ENSG00000091513 TF 2 
ENSG00000100197 CYP2D6 2 
ENSG00000113492 AGXT2 2 
ENSG00000174567 GOLT1A 2 
ENSG00000100197 CYP2D6 2 
ENSG00000125398 SOX9 3 
ENSG00000121440 PDZRN3 3 
ENSG00000132854 KANK4 3 
ENSG00000129514 FOXA1 3 
ENSG00000120708 TGFBI 3 
ENSG00000165379 LRFN5 3 
ENSG00000122691 TWIST1 3 
ENSG00000111913 FAM65B 3 
ENSG00000139174 PRICKLE1 3 
ENSG00000172380 GNG12 3 
ENSG00000183876 ARSI 3 
ENSG00000139329 LUM 3 
ENSG00000163171 CDC42EP3 3 
ENSG00000180318 ALX1 3 
ENSG00000170955 PRKCDBP 3 
ENSG00000108244 KRT23 3 
ENSG00000125850 OVOL2 3 
ENSG00000141696 LEPREL4 3 
ENSG00000113196 HAND1 3 
ENSG00000106366 SERPINE1 3 
ENSG00000129757 CDKN1C 3 
ENSG00000125384 PTGER2 3 
ENSG00000109472 CPE 3 
ENSG00000203857 HSD3B1 3 
ENSG00000262655 SPON1 3 
ENSG00000164107 HAND2 3 
ENSG00000106031 HOXA13 3 
ENSG00000141744 PNMT 3 
ENSG00000211448 DIO2 3 
ENSG00000117152 RGS4 3 
ENSG00000198121 LPAR1 3 
ENSG00000146197 SCUBE3 3 
ENSG00000260027 HOXB7 3 
ENSG00000130812 ANGPTL6 3 
ENSG00000150687 PRSS23 3 
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ENSG00000104723 TUSC3 3 
ENSG00000144642 RBMS3 3 
ENSG00000143036 SLC44A3 3 
ENSG00000132698 RAB25 3 
ENSG00000010932 FMO1 3 
ENSG00000142227 EMP3 3 
ENSG00000164683 HEY1 3 
ENSG00000171729 TMEM51 3 
ENSG00000084636 COL16A1 3 
ENSG00000185559 DLK1 3 
ENSG00000144645 OSBPL10 3 
ENSG00000168743 NPNT 3 
ENSG00000127472 PLA2G5 3 
ENSG00000001626 CFTR 3 
ENSG00000100739 BDKRB1 3 
ENSG00000166900 STX3 3 
ENSG00000152137 HSPB8 3 
ENSG00000122176 FMOD 3 
ENSG00000163362 C1orf106 3 
ENSG00000168032 ENTPD3 3 
ENSG00000148942 SLC5A12 3 
ENSG00000126016 AMOT 3 
ENSG00000123700 KCNJ2 3 
ENSG00000183853 KIRREL 3 
ENSG00000174307 PHLDA3 3 
ENSG00000134369 NAV1 3 
ENSG00000110660 SLC35F2 3 
ENSG00000138615 CILP 3 
ENSG00000189334 S100A14 3 
ENSG00000166482 MFAP4 3 
ENSG00000157502 MUM1L1 3 
ENSG00000070019 GUCY2C 3 
ENSG00000185222 WBP5 3 
ENSG00000103241 FOXF1 3 
ENSG00000164318 EGFLAM 3 
ENSG00000125872 LRRN4 3 
ENSG00000100079 LGALS2 3 
ENSG00000077616 NAALAD2 3 
ENSG00000132386 SERPINF1 3 
ENSG00000046604 DSG2 3 
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ENSG00000164825 DEFB1 3 
ENSG00000105989 WNT2 3 
ENSG00000174482 LINGO2 3 
ENSG00000100196 KDELR3 3 
ENSG00000167874 TMEM88 3 
ENSG00000119888 EPCAM 3 
ENSG00000188176 SMTNL2 3 
ENSG00000176788 BASP1 3 
ENSG00000168952 STXBP6 3 
ENSG00000013588 GPRC5A 3 
ENSG00000136026 CKAP4 3 
ENSG00000167434 CA4 3 
ENSG00000186377 CYP4X1 3 
ENSG00000152049 KCNE4 3 
ENSG00000079257 LXN 3 
ENSG00000166394 CYB5R2 3 
ENSG00000139926 FRMD6 3 
ENSG00000183722 LHFP 3 
ENSG00000143867 OSR1 3 
ENSG00000163132 MSX1 3 
ENSG00000138119 MYOF 3 
ENSG00000173376 NDNF 3 
ENSG00000164484 TMEM200A 3 
ENSG00000167755 KLK6 3 
ENSG00000172458 IL17D 3 
ENSG00000180340 FZD2 3 
ENSG00000187123 LYPD6 3 
ENSG00000171951 SCG2 3 
ENSG00000148344 PTGES 3 
ENSG00000179178 TMEM125 3 
ENSG00000152661 GJA1 3 
ENSG00000134258 VTCN1 3 
ENSG00000174099 MSRB3 3 
ENSG00000153822 KCNJ16 3 
ENSG00000112852 PCDHB2 3 
ENSG00000147655 RSPO2 3 
ENSG00000107317 PTGDS 3 
ENSG00000169583 CLIC3 3 
ENSG00000103888 CEMIP 3 
ENSG00000184005 ST6GALNAC3 3 
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ENSG00000151693 ASAP2 3 
ENSG00000180447 GAS1 3 
ENSG00000147003 TMEM27 3 
ENSG00000086548 CEACAM6 3 
ENSG00000164932 CTHRC1 3 
ENSG00000183160 TMEM119 3 
ENSG00000107485 GATA3 3 
ENSG00000081051 AFP 3 
ENSG00000155465 SLC7A7 3 
ENSG00000147257 GPC3 3 
ENSG00000112964 GHR 3 
ENSG00000171812 COL8A2 3 
ENSG00000176907 C8orf4 3 
ENSG00000184347 SLIT3 3 
ENSG00000174807 CD248 3 
ENSG00000168461 RAB31 3 
ENSG00000139278 GLIPR1 3 
ENSG00000071282 LMCD1 3 
ENSG00000181541 MAB21L2 3 
ENSG00000129116 PALLD 3 
ENSG00000198108 CHSY3 3 
ENSG00000164946 FREM1 3 
ENSG00000163017 ACTG2 3 
ENSG00000137573 SULF1 3 
ENSG00000124107 SLPI 3 
ENSG00000108797 CNTNAP1 3 
ENSG00000084207 GSTP1 3 
ENSG00000062038 CDH3 3 
ENSG00000185565 LSAMP 3 
ENSG00000118271 TTR 3 
ENSG00000171004 HS6ST2 3 
ENSG00000203857 HSD3B1 3 
ENSG00000135736 CCDC102A 3 
ENSG00000203857 HSD3B1 3 
ENSG00000167617 CDC42EP5 3 
ENSG00000163520 FBLN2 3 
ENSG00000144619 CNTN4 3 
ENSG00000109099 PMP22 3 
ENSG00000170425 ADORA2B 3 
ENSG00000142156 COL6A1 3 
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ENSG00000113140 SPARC 3 
ENSG00000136193 SCRN1 3 
ENSG00000159251 ACTC1 3 
ENSG00000015413 DPEP1 3 
ENSG00000128591 FLNC 3 
ENSG00000167695 FAM57A 3 
ENSG00000142552 RCN3 3 
ENSG00000116017 ARID3A 3 
ENSG00000118495 PLAGL1 3 
ENSG00000154856 APCDD1 3 
ENSG00000165794 SLC39A2 3 
ENSG00000118503 TNFAIP3 3 
ENSG00000135549 PKIB 3 
ENSG00000146374 RSPO3 3 
ENSG00000011465 DCN 3 
ENSG00000184838 PRR16 3 
ENSG00000049130 KITLG 3 
ENSG00000166165 CKB 3 
ENSG00000147883 CDKN2B 3 
ENSG00000079931 MOXD1 3 
ENSG00000167642 SPINT2 3 
ENSG00000125266 EFNB2 3 
ENSG00000156510 HKDC1 3 
ENSG00000166923 GREM1 3 
ENSG00000130176 CNN1 3 
ENSG00000198832   3 
ENSG00000142173 COL6A2 3 
ENSG00000120820 GLT8D2 3 
ENSG00000007384 RHBDF1 3 
ENSG00000113739 STC2 3 
ENSG00000070404 FSTL3 3 
ENSG00000131459 GFPT2 3 
ENSG00000146674 IGFBP3 3 
ENSG00000115380 EFEMP1 3 
ENSG00000251493 FOXD1 3 
ENSG00000132031 MATN3 3 
ENSG00000108821 COL1A1 3 
ENSG00000130508 PXDN 3 
ENSG00000005884 ITGA3 3 
ENSG00000182534 MXRA7 3 
  219 
ENSG00000141756 FKBP10 3 
ENSG00000171345 KRT19 3 
ENSG00000037965 HOXC8 3 
ENSG00000067057 PFKP 3 
ENSG00000121297 TSHZ3 3 
ENSG00000079689 SCGN 3 
ENSG00000078401 EDN1 3 
ENSG00000120149 MSX2 3 
ENSG00000069011 PITX1 3 
ENSG00000145824 CXCL14 3 
ENSG00000135052 GOLM1 3 
ENSG00000118971 CCND2 3 
ENSG00000145681 HAPLN1 3 
ENSG00000038427 VCAN 3 
ENSG00000164251 F2RL1 3 
ENSG00000110195 FOLR1 3 
ENSG00000164294 GPX8 3 
ENSG00000133661 SFTPD 3 
ENSG00000087303 NID2 3 
ENSG00000163947 ARHGEF3 3 
ENSG00000114251 WNT5A 3 
ENSG00000116991 SIPA1L2 3 
ENSG00000100842 EFS 3 
ENSG00000145555 MYO10 3 
ENSG00000040731 CDH10 3 
ENSG00000160207 HSF2BP 3 
ENSG00000091986 CCDC80 3 
ENSG00000019549 SNAI2 3 
ENSG00000099960 SLC7A4 3 
ENSG00000163430 FSTL1 3 
ENSG00000154734 ADAMTS1 3 
ENSG00000183844 FAM3B 3 
ENSG00000159212 CLIC6 3 
ENSG00000050438 SLC4A8 3 
ENSG00000135480 KRT7 3 
ENSG00000110811 LEPREL2 3 
ENSG00000103175 WFDC1 3 
ENSG00000112562 SMOC2 3 
ENSG00000184697 CLDN6 3 
ENSG00000112818 MEP1A 3 
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ENSG00000146072 TNFRSF21 3 
ENSG00000112655 PTK7 3 
ENSG00000132205 EMILIN2 3 
ENSG00000150938 CRIM1 3 
ENSG00000161896 IP6K3 3 
ENSG00000006747 SCIN 3 
ENSG00000113657 DPYSL3 3 
ENSG00000113083 LOX 3 
ENSG00000064692 SNCAIP 3 
ENSG00000132915 PDE6A 3 
ENSG00000135046 ANXA1 3 
ENSG00000148677 ANKRD1 3 
ENSG00000175315 CST6 3 
ENSG00000172638 EFEMP2 3 
ENSG00000138193 PLCE1 3 
ENSG00000169129 AFAP1L2 3 
ENSG00000165868 HSPA12A 3 
ENSG00000169594 BNC1 3 
ENSG00000141526 SLC16A3 3 
ENSG00000091136 LAMB1 3 
ENSG00000166863 TAC3 3 
ENSG00000114270 COL7A1 3 
ENSG00000204262 COL5A2 3 
ENSG00000168542 COL3A1 3 
ENSG00000115602 IL1RL1 3 
ENSG00000115604 IL18R1 3 
ENSG00000173559 NABP1 3 
ENSG00000119900 OGFRL1 3 
ENSG00000135919 SERPINE2 3 
ENSG00000145730 PAM 3 
ENSG00000118194 TNNT2 3 
ENSG00000167535 CACNB3 3 
ENSG00000150556 LYPD6B 3 
ENSG00000077943 ITGA8 3 
ENSG00000130635 COL5A1 3 
ENSG00000050555 LAMC3 3 
ENSG00000162998 FRZB 3 
ENSG00000198648 STK39 3 
ENSG00000149090 PAMR1 3 
ENSG00000106348 IMPDH1 3 
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ENSG00000166147 FBN1 3 
ENSG00000166963 MAP1A 3 
ENSG00000166145 SPINT1 3 
ENSG00000115008 IL1A 3 
ENSG00000171033 PKIA 3 
ENSG00000104435 STMN2 3 
ENSG00000101198 NKAIN4 3 
ENSG00000133110 POSTN 3 
ENSG00000116774 OLFML3 3 
ENSG00000203857 HSD3B1 3 
ENSG00000164125 FAM198B 3 
ENSG00000164124 TMEM144 3 
ENSG00000060718 COL11A1 3 
ENSG00000164093 PITX2 3 
ENSG00000108947 EFNB3 3 
ENSG00000117525 F3 3 
ENSG00000079112 CDH17 3 
ENSG00000204291 COL15A1 3 
ENSG00000165124 SVEP1 3 
ENSG00000182752 PAPPA 3 
ENSG00000173068 BNC2 3 
ENSG00000136859 ANGPTL2 3 
ENSG00000162493 PDPN 3 
ENSG00000116157 GPX7 3 
ENSG00000142583 SLC2A5 3 
ENSG00000157005 SST 3 
ENSG00000095752 IL11 3 
ENSG00000162576 MXRA8 3 
ENSG00000007062 PROM1 3 
ENSG00000168824   3 
ENSG00000197712 FAM114A1 3 
ENSG00000163288 GABRB1 3 
ENSG00000069702 TGFBR3 3 
ENSG00000145287 PLAC8 3 
ENSG00000163624 CDS1 3 
ENSG00000138772 ANXA3 3 
ENSG00000240583 AQP1 3 
ENSG00000078098 FAP 3 
ENSG00000165556 CDX2 3 
ENSG00000164692 COL1A2 3 
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ENSG00000105825 TFPI2 3 
ENSG00000122585 NPY 3 
ENSG00000105928 DFNA5 3 
ENSG00000105894 PTN 3 
ENSG00000119630 PGF 3 
ENSG00000177875 CCDC184 3 
ENSG00000163637 PRICKLE2 3 
ENSG00000163638 ADAMTS9 3 
ENSG00000156711 MAPK13 3 
ENSG00000197614 MFAP5 3 
ENSG00000173391 OLR1 3 
ENSG00000111339 ART4 3 
ENSG00000139055 ERP27 3 
ENSG00000198759 EGFL6 3 
ENSG00000121361 KCNJ8 3 
ENSG00000123096 SSPN 3 
ENSG00000111319 SCNN1A 3 
ENSG00000104044 OCA2 3 
ENSG00000086991 NOX4 3 
ENSG00000140545 MFGE8 3 
ENSG00000197702 PARVA 3 
ENSG00000140682 TGFB1I1 3 
ENSG00000052344 PRSS8 3 
ENSG00000104415 WISP1 3 
ENSG00000102034 ELF4 3 
ENSG00000102243 VGLL1 3 
ENSG00000089472 HEPH 3 
ENSG00000102359 SRPX2 3 
ENSG00000188153 COL4A5 3 
ENSG00000130224 LRCH2 3 
ENSG00000079215 SLC1A3 3 
ENSG00000133135 RNF128 3 
ENSG00000020181 GPR124 3 
ENSG00000187498 COL4A1 3 
ENSG00000134871 COL4A2 3 
ENSG00000150630 VEGFC 3 
ENSG00000104368 PLAT 3 
ENSG00000168615 ADAM9 3 
ENSG00000145147 SLIT2 3 
ENSG00000218336 TENM3 3 
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ENSG00000104213 PDGFRL 3 
ENSG00000164106 SCRG1 3 
ENSG00000164120 HPGD 3 
ENSG00000140937 CDH11 3 
ENSG00000103196 CRISPLD2 3 
ENSG00000140945 CDH13 3 
ENSG00000103064 SLC7A6 3 
ENSG00000154127 UBASH3B 3 
ENSG00000166250 CLMP 3 
ENSG00000109846 CRYAB 3 
ENSG00000182985 CADM1 3 
ENSG00000110244 APOA4 3 
ENSG00000118137 APOA1 3 
ENSG00000065911 MTHFD2 3 
ENSG00000112175 BMP5 3 
ENSG00000182718 ANXA2 3 
ENSG00000140465 CYP1A1 3 
ENSG00000111799 COL12A1 3 
ENSG00000129038 LOXL1 3 
ENSG00000137269 LRRC1 3 
ENSG00000174498 IGDCC3 3 
ENSG00000158258 CLSTN2 3 
ENSG00000114113 RBP2 3 
ENSG00000073756 PTGS2 3 
ENSG00000153558 FBXL2 3 
ENSG00000164764 SBSPON 3 
ENSG00000101680 LAMA1 3 
ENSG00000103742 IGDCC4 3 
ENSG00000173546 CSPG4 3 
ENSG00000107165 TYRP1 3 
ENSG00000126947 ARMCX1 3 
ENSG00000146250 PRSS35 3 
ENSG00000182636 NDN 3 
ENSG00000171564 FGB 3 
ENSG00000164116 GUCY1A3 3 
ENSG00000135750 KCNK1 3 
ENSG00000099994 SUSD2 3 
ENSG00000166173 LARP6 3 
ENSG00000118407 FILIP1 3 
ENSG00000077942 FBLN1 3 
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ENSG00000169116 PARM1 3 
ENSG00000197635 DPP4 3 
ENSG00000101955 SRPX 3 
ENSG00000206538 VGLL3 3 
ENSG00000183036 PCP4 3 
 
 
Table 10-2: Metagenes from NMF analysis on mouse liver development data 
Ensembl_ID Symbol Metagene  
ENSMUSG00000035540 Gc 1 
ENSMUSG00000036216 Leap2 1 
ENSMUSG00000036381 P2ry14 1 
ENSMUSG00000037053 Azgp1 1 
ENSMUSG00000037798 Mat1a 1 
ENSMUSG00000037942 Crp 1 
ENSMUSG00000038641 Akr1d1 1 
ENSMUSG00000038656 Cyp3a16 1 
ENSMUSG00000038656 Cyp3a16 1 
ENSMUSG00000038656 Cyp3a16 1 
ENSMUSG00000039476 Prrx2 2 
ENSMUSG00000040134 Rdh7 1 
ENSMUSG00000040809 Chil3 1 
ENSMUSG00000041660 Bbox1 1 
ENSMUSG00000042118 Bhmt2 1 
ENSMUSG00000044206 Vsig4 2 
ENSMUSG00000010601 Apol7a 1 
ENSMUSG00000010601 Apol7a 1 
ENSMUSG00000010601 Apol7a 1 
ENSMUSG00000010601 Apol7a 1 
ENSMUSG00000044749 Abca6 1 
ENSMUSG00000045179 Sox3 2 
ENSMUSG00000048217 Nags 1 
ENSMUSG00000052131 Akr1b7 1 
ENSMUSG00000052595 A1cf 1 
ENSMUSG00000052974 Cyp2f2 1 
ENSMUSG00000054417 Cyp3a44 1 
ENSMUSG00000054417 Cyp3a44 1 
ENSMUSG00000054417 Cyp3a44 1 
ENSMUSG00000054630 Ugt2b5 1 
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ENSMUSG00000054630 Ugt2b5 1 
ENSMUSG00000055782 Abcd2 1 
ENSMUSG00000056035 Cyp3a11 1 
ENSMUSG00000056035 Cyp3a11 1 
ENSMUSG00000056035 Cyp3a11 1 
ENSMUSG00000057037 Cfhr1 1 
ENSMUSG00000015970 Chdh 1 
ENSMUSG00000057425 Ugt2b37 1 
ENSMUSG00000057425 Ugt2b37 1 
ENSMUSG00000058207 Serpina3k 1 
ENSMUSG00000058207 Serpina3k 1 
ENSMUSG00000060407 Cyp2a12 1 
ENSMUSG00000060407 Cyp2a12 1 
ENSMUSG00000062410 Hsd3b3 1 
ENSMUSG00000062410 Hsd3b3 1 
ENSMUSG00000019232 Etnppl 1 
ENSMUSG00000069805 Fbp1 1 
ENSMUSG00000070704 Ugt2b36 1 
ENSMUSG00000070704 Ugt2b36 1 
ENSMUSG00000072601 Ear1 1 
ENSMUSG00000072601 Ear1 1 
ENSMUSG00000019987 Arg1 1 
ENSMUSG00000020010 Vnn3 1 
ENSMUSG00000074207 Adh1 1 
ENSMUSG00000074207 Adh1 1 
ENSMUSG00000020072 Pbld1 1 
ENSMUSG00000074637 Sox2 2 
ENSMUSG00000075334 Rprm 2 
ENSMUSG00000078650 G6pc 1 
ENSMUSG00000079012 Serpina3m 2 
ENSMUSG00000079012 Serpina3m 2 
ENSMUSG00000020641 Rsad2 1 
ENSMUSG00000020884 Asgr1 1 
ENSMUSG00000021091 Serpina3n 1 
ENSMUSG00000021091 Serpina3n 1 
ENSMUSG00000021135 Slc10a1 1 
ENSMUSG00000021210 Akr1c6 1 
ENSMUSG00000021210 Akr1c6 1 
ENSMUSG00000021210 Akr1c6 1 
ENSMUSG00000021390 Ogn 1 
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ENSMUSG00000021506 Pitx1 2 
ENSMUSG00000021508 Cxcl14 2 
ENSMUSG00000021922 Itih4 1 
ENSMUSG00000021999 Cpb2 1 
ENSMUSG00000022445 Cyp2d26 1 
ENSMUSG00000022512 Cldn1 1 
ENSMUSG00000022868 Ahsg 1 
ENSMUSG00000022871 Fetub 1 
ENSMUSG00000024863 Mbl2 1 
ENSMUSG00000025003 Cyp2c39 1 
ENSMUSG00000025003 Cyp2c39 1 
ENSMUSG00000025003 Cyp2c39 1 
ENSMUSG00000025194 Abcc2 1 
ENSMUSG00000025478 Dpysl4 2 
ENSMUSG00000025479 Cyp2e1 1 
ENSMUSG00000003053 Cyp2c29 1 
ENSMUSG00000003053 Cyp2c29 1 
ENSMUSG00000003053 Cyp2c29 1 
ENSMUSG00000025911 Adhfe1 1 
ENSMUSG00000025991 Cps1 1 
ENSMUSG00000026368 F13b 1 
ENSMUSG00000026542 Apcs 1 
ENSMUSG00000026822 Lcn2 1 
ENSMUSG00000027048 Abcb11 1 
ENSMUSG00000000049 Apoh 1 
ENSMUSG00000027261 Hao1 1 
ENSMUSG00000003617 Cp 1 
ENSMUSG00000027761 Aadac 1 
ENSMUSG00000027870 Hao2 1 
ENSMUSG00000028553 Angptl3 1 
ENSMUSG00000028715 Cyp4a14 1 
ENSMUSG00000028715 Cyp4a14 1 
ENSMUSG00000029368 Alb 1 
ENSMUSG00000029445 Hpd 1 
ENSMUSG00000029556 Hnf1a 1 
ENSMUSG00000029630 Cyp3a25 1 
ENSMUSG00000029630 Cyp3a25 1 
ENSMUSG00000029630 Cyp3a25 1 
ENSMUSG00000029656 C8b 1 
ENSMUSG00000029727 Cyp3a13 1 
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ENSMUSG00000030111 A2m 1 
ENSMUSG00000004885 Crabp2 2 
ENSMUSG00000030236 Slco1b2 1 
ENSMUSG00000030236 Slco1b2 1 
ENSMUSG00000030244 Gys2 1 
ENSMUSG00000030382 Slc27a5 1 
ENSMUSG00000030413 Pglyrp1 1 
ENSMUSG00000030909 Anks4b 1 
ENSMUSG00000031138 F9 1 
ENSMUSG00000031173 Otc 1 
ENSMUSG00000031271 Serpina7 1 
ENSMUSG00000031594 Fgl1 1 
ENSMUSG00000031640 Klkb1 1 
ENSMUSG00000031645 F11 1 
ENSMUSG00000031722 Hp 1 
ENSMUSG00000031722 Hp 1 
ENSMUSG00000032081 Apoc3 1 
ENSMUSG00000032291 Crabp1 2 
ENSMUSG00000033533 Acsm1 1 
ENSMUSG00000033715 Akr1c14 1 
ENSMUSG00000033715 Akr1c14 1 
ENSMUSG00000033715 Akr1c14 1 
ENSMUSG00000034435 Tmem30b 1 
ENSMUSG00000096852 Cyp2d12 1 
 
 
Table 10-3: Differential expression analysis using SAM on HLCs and mature cells 
(E19.5, PHH) 
Gene 
Name 
Fold 
Change 
q-
value(%) 
ARG1 19.476484 0 
ADH1A 17.694997 0 
APCS 17.035175 0 
GC 15.791466 0 
FETUB 14.363967 0 
ADH1C 14.036458 0 
AZGP1 14.035046 0 
CYP2C9 13.929656 0 
HPR 13.095323 0 
ITIH4 12.987485 0 
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F9 12.696935 0 
HAMP 12.495787 0 
ITIH3 12.132906 0 
RARRES2 11.829739 0 
CYP2C9 11.723588 0 
CYP2C9 11.567727 0 
FBP1 11.267267 0 
CYP8B1 11.098447 0 
KLKB1 10.890199 0 
CFHR2 10.693478 0 
SLCO1B1 10.692924 0 
CYP2C9 10.240908 0 
HAO1 10.194564 0 
G6PC 10.074021 0 
BAAT 9.9903307 0 
C4BPA 9.9514221 0 
F11 9.8224018 0 
CYP3A4 9.7875974 0 
LRG1 9.3539386 0 
SLCO1B3 8.9833948 0 
C3 8.7114759 0 
CYP3A5 8.6479512 0 
CRP 8.603505 0 
CYP3A4 8.5868513 0 
SEC14L4 8.462595 0 
MT1G 8.3981339 0 
C8A 8.3685927 0 
C8G 8.1502165 0 
AKR1C4 7.9824454 0 
CYP3A4 7.7964322 0 
AQP9 7.7606928 0 
AKR1C4 7.699717 0 
BHMT2 7.66797 0 
MBL2 7.6673511 0 
ETNPPL 7.6374664 0 
CYP2C19 7.5933779 0 
CYP3A4 7.5844231 0 
THRSP 7.5609523 0 
SLC2A2 7.5479197 0 
CPB2 7.5173972 0 
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UGT2B15 7.4916742 0 
CYP4A22 7.3322409 0 
CYP4A11 7.3322409 0 
AGXT 7.3186786 0 
HFE2 7.2941923 0 
CYP2D6 6.9804188 0 
F12 6.977067 0 
AKR1C4 6.830319 0 
CYP2C19 6.8180732 0 
MT1M 6.8036695 0 
RDH16 6.7900646 0 
SLC27A5 6.5930516 0 
CYP4A22 6.4774698 0 
CYP4A11 6.4774698 0 
PAH 6.4511817 0 
MT1F 6.4198348 0 
IGFALS 6.37437 0 
CYP2C19 6.368176 0 
AKR1C1 6.1601392 0 
CYP2D6 6.1250017 0 
UGT2B15 5.9965232 0 
CYP4A11 5.9212385 0 
CYP4A22 5.9212385 0 
CYP2C19 5.9135061 0 
AKR1C1 5.9103627 0 
IGFBP1 5.8699256 0 
HAO2 5.8604568 0 
ABCG5 5.8573298 0 
UPB1 5.6787492 0 
CYP2D6 5.615751 0 
LDHD 5.5948737 0 
CYP2D6 5.5853906 0 
APOA5 5.5714422 0 
AOX1 5.5522439 0 
CYP2J2 5.5331258 0 
MASP2 5.4683543 0 
NAT8 5.3984581 0 
SLC17A2 5.3482406 0 
UGT2B15 5.2699503 0 
AKR1C4 5.1879656 0 
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NR1I2 5.1743157 0 
UGT2B15 5.1706553 0 
CYP4F2 5.1631661 0 
CYP2C8 5.1569698 0 
HGFAC 5.0527051 0 
LPA 5.0428147 0 
ONECUT1 5.0363388 0 
CYP4F12 5.0319708 0 
CYP2D6 4.9414974 0 
ABCA6 4.9184354 0 
AKR1C1 4.8803929 0 
GLS2 4.8477262 0 
UGT2B15 4.8466351 0 
HABP2 4.8361336 0 
UGT2B15 4.7937836 0 
C2 4.7359731 0 
AKR1C4 4.7129475 0 
CYP4F2 4.7102656 0 
TAT 4.7032425 0 
ABCB11 4.6918663 0 
VNN1 4.6077168 0 
F13B 4.571373 0 
ONECUT2 4.5543219 0 
CYP2C8 4.5194386 0 
RTP3 4.4910449 0 
CYP4F12 4.4880117 0 
RDH16 4.4414993 0 
PEMT 4.402901 0 
CYP2C8 4.3383354 0 
CSTA 4.3082668 0 
CD14 4.2627324 0 
SLC25A47 4.2280517 0 
ACOT12 4.1566647 0 
CYP39A1 4.1458989 0 
MLXIPL 4.130333 0 
SDS 4.1059429 0 
PAQR9 4.0143963 0 
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Table 10-4: Dynamic differentially expressed genes between human in vitro 
differentiation and mouse development (E9.5 to E15.5) 
Gene Spearman Pearson  Euclidean Foldchange_human Foldchange_mouse 
TPD52L1 -1.00 -1.00 8.20 3.29 2.42 
SOX9 -1.00 -0.97 6.47 3.67 2.69 
CA4 -1.00 -0.99 12.77 5.02 2.93 
COL1A1 -1.00 -1.00 10.53 5.88 1.17 
FOXM1 -1.00 -0.96 6.18 2.56 0.11 
RIN2 -1.00 -1.00 7.20 2.97 1.45 
LAMB1 -1.00 -0.98 8.43 3.27 2.53 
INMT-
FAM188B -0.88 -0.90 8.72 3.39 0.19 
INMT -0.88 -0.90 8.72 3.39 0.19 
ANGPTL2 -1.00 -0.97 6.67 4.64 1.99 
CLEC11A -1.00 -0.99 6.61 2.79 0.74 
MAPK13 -1.00 -1.00 7.06 2.11 1.63 
WISP1 -1.00 -1.00 7.10 4.69 1.85 
SPC25 -1.00 -0.98 6.57 2.61 0.99 
SLC1A3 -1.00 -1.00 6.15 2.94 2.01 
TYRP1 -1.00 -1.00 10.58 4.49 0.64 
FBLN1 -1.00 -1.00 9.12 1.82 3.44 
SCUBE2 -1.00 -0.99 7.18 3.65 1.54 
TLE1 -1.00 -1.00 6.54 2.19 0.65 
RAB25 -1.00 -1.00 9.01 2.63 3.26 
ODC1 -1.00 -1.00 8.15 2.95 0.57 
GATA5 -1.00 -0.95 8.66 3.40 1.18 
BIRC5 -1.00 -1.00 5.88 2.17 0.50 
MMP9 -1.00 -0.99 7.25 2.60 0.97 
GPX3 -1.00 -0.99 7.09 3.20 2.98 
CLDN7 -1.00 -0.99 7.64 2.74 2.99 
SPARC -1.00 -0.98 9.98 6.05 1.12 
P4HA2 -1.00 -0.99 7.01 2.84 1.70 
E2F2 -1.00 -0.98 6.31 2.49 2.25 
DPEP1 -1.00 -1.00 8.17 2.50 2.24 
SOCS2 -0.93 -0.90 9.10 2.58 1.06 
IGF1 -1.00 -0.99 6.02 2.83 1.58 
IGFBP3 -1.00 -0.99 11.78 7.48 2.05 
MTHFD1 -1.00 -0.97 8.03 1.58 2.41 
MSX2 -0.93 -0.89 6.68 3.94 2.89 
CXCL14 -1.00 -1.00 6.81 6.91 3.97 
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VCAN -0.88 -0.91 6.07 2.97 1.74 
NID2 -1.00 -0.99 9.80 7.74 1.52 
WNT5A -1.00 -1.00 8.46 3.83 2.97 
LCP1 -1.00 -0.99 17.44 5.72 1.48 
GPC5 -1.00 -1.00 7.51 4.47 0.46 
CTNND2 -1.00 -1.00 6.89 2.16 2.12 
ZFPM2 -1.00 -1.00 6.43 2.97 2.00 
ANGPT1 -1.00 -1.00 7.69 3.27 2.45 
CDH10 -1.00 -1.00 9.99 5.28 1.36 
COL2A1 -1.00 -0.97 6.11 2.44 4.14 
PPP1R1A -1.00 -1.00 6.18 3.72 2.62 
DGAT1 -1.00 -1.00 7.96 2.41 0.45 
ARC -1.00 -0.98 6.23 0.72 2.14 
SNAI2 -1.00 -1.00 11.54 5.40 3.32 
PROS1 -1.00 -0.97 9.90 3.82 1.11 
CLIC6 -1.00 -1.00 7.55 3.35 2.78 
RCAN1 -1.00 -1.00 6.99 2.50 1.16 
SMOC2 -1.00 -0.98 5.76 3.83 1.81 
CBS -1.00 -1.00 6.81 3.70 2.54 
EPB41L3 -1.00 -1.00 6.69 2.42 2.30 
ANKS1A -1.00 -1.00 5.63 3.29 0.49 
BAMBI -0.94 -0.91 7.82 2.69 1.65 
SYT4 -1.00 -1.00 7.90 4.13 1.21 
BIN1 -1.00 -1.00 5.92 2.70 1.55 
SNCAIP -1.00 -1.00 7.30 4.13 1.47 
PPIC -1.00 -0.99 6.58 2.86 1.56 
ASRGL1 -1.00 -0.98 5.95 2.78 1.64 
SLC1A1 -1.00 -0.97 5.64 2.74 0.60 
HSPA12A -1.00 -0.99 6.38 2.27 1.03 
BNC1 -1.00 -1.00 5.74 3.71 1.79 
PSTPIP2 -1.00 -0.98 6.24 2.44 0.94 
TK1 -1.00 -1.00 6.95 2.81 1.23 
COL3A1 -1.00 -0.98 16.61 7.13 1.79 
IGFBP5 -1.00 -0.99 8.86 4.59 4.06 
RGS1 -1.00 -0.99 5.67 2.87 0.46 
RGS2 -0.95 -0.96 7.16 3.42 1.39 
KIFAP3 -1.00 -1.00 7.62 2.14 2.06 
FRZB -1.00 -0.99 10.57 3.12 2.95 
PAMR1 -0.93 -0.92 5.72 5.80 3.25 
MDK -1.00 -0.99 7.17 1.84 3.30 
  233 
SPINT1 -1.00 -1.00 8.26 2.24 2.98 
BMP2 -1.00 -1.00 9.25 3.00 0.17 
CD93 -1.00 -0.99 7.17 2.58 1.23 
PKIA -1.00 -1.00 7.83 3.79 2.25 
POSTN -1.00 -0.99 9.23 4.44 3.34 
SERPINI1 -1.00 -1.00 5.69 2.22 1.62 
FAM198B -1.00 -0.98 9.51 3.78 2.42 
CCDC109B -1.00 -0.99 7.50 2.35 2.38 
TDO2 -1.00 -1.00 8.92 4.86 1.87 
PDGFC -1.00 -1.00 7.62 3.27 3.12 
PITX2 -1.00 -0.98 11.57 4.54 3.11 
F3 -1.00 -0.99 7.14 3.96 2.14 
COL15A1 -1.00 -1.00 10.76 9.60 1.29 
ALDH4A1 -1.00 -1.00 7.55 1.17 2.87 
SEMA3C -1.00 -0.99 7.56 2.41 2.10 
PCDH7 -1.00 -1.00 6.06 2.39 1.86 
CDX2 -1.00 -1.00 7.90 3.48 2.92 
COL1A2 -1.00 -0.98 11.01 6.08 1.53 
AASS -1.00 -1.00 8.45 1.22 3.42 
ADD2 -1.00 -1.00 6.63 1.92 2.37 
SLCO2B1 -1.00 -0.99 11.48 5.19 1.20 
TSC22D3 -1.00 -1.00 8.46 3.05 1.35 
GPR124 -1.00 -0.98 6.75 5.64 2.43 
VEGFC -1.00 -1.00 8.45 4.85 2.02 
PLAT -1.00 -1.00 7.55 6.14 3.22 
SLIT2 -1.00 -0.98 9.46 3.44 2.84 
SCRG1 -1.00 -1.00 11.93 5.44 1.03 
KLKB1 -1.00 -0.99 9.58 3.62 3.76 
CDH11 -0.85 -0.91 10.09 5.18 2.02 
MT1X -1.00 -1.00 14.69 3.97 5.36 
MT1M -1.00 -0.99 10.16 4.70 4.71 
MT1E -1.00 -0.99 11.41 3.52 4.58 
MT1G -1.00 -1.00 12.88 3.05 4.88 
MT1F -1.00 -1.00 11.62 3.42 4.52 
MT1H -1.00 -1.00 9.08 2.50 4.22 
CRISPLD2 -1.00 -1.00 9.64 5.25 4.16 
CDH13 -1.00 -0.99 5.86 5.25 0.45 
PDGFD -1.00 -1.00 5.64 2.57 1.78 
THY1 -1.00 -1.00 5.90 2.94 1.97 
CADM1 -1.00 -0.99 5.67 2.32 2.47 
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APOA4 -1.00 -0.99 19.40 7.49 2.46 
MNS1 -1.00 -0.98 7.06 2.40 0.84 
DNAJA4 -1.00 -1.00 6.34 0.94 2.38 
TSPAN3 -1.00 -1.00 6.06 1.54 2.21 
LOXL1 -1.00 -0.97 6.86 3.66 1.71 
PLOD2 -1.00 -1.00 6.69 4.38 2.08 
IGDCC3 -0.92 -0.87 8.97 3.94 3.50 
SLCO2A1 -1.00 -1.00 6.53 4.09 2.78 
SBSPON -1.00 -0.92 6.91 5.48 1.19 
RASGRP2 -1.00 -0.99 6.15 0.68 2.03 
CST1 -1.00 -1.00 7.39 8.05 1.13 
PRSS35 -0.99 -0.97 11.30 4.16 2.40 
UCP2 -1.00 -1.00 8.22 1.93 2.59 
DIO1 -1.00 -0.97 14.55 6.13 0.68 
PARM1 -1.00 -1.00 12.20 4.26 2.81 
KANK4 -1.00 -1.00 9.19 4.58 1.77 
FOXA1 -1.00 -0.99 8.92 4.63 1.35 
TGFBI -1.00 -0.99 13.99 6.89 4.48 
SLC51A -1.00 -1.00 11.18 4.11 2.08 
PRTG -1.00 -0.99 7.03 2.90 3.57 
SOSTDC1 -1.00 -0.97 7.06 2.51 2.80 
ALX1 -1.00 -1.00 8.59 1.80 2.73 
NODAL -1.00 -1.00 5.88 4.00 1.31 
HAND1 -1.00 -1.00 14.10 7.00 4.13 
CDKN1C -1.00 -0.96 11.07 3.93 1.35 
CPE -1.00 -1.00 6.76 2.92 1.53 
SPON1 -1.00 -0.95 7.06 3.71 1.89 
SLC19A3 -1.00 -1.00 5.85 2.92 0.62 
RGS4 -0.82 -0.90 6.58 4.28 1.60 
LEFTY2 -1.00 -1.00 10.57 7.26 3.45 
LEFTY1 -1.00 -1.00 12.10 6.50 3.57 
ECHDC3 -1.00 -0.99 6.32 1.65 2.59 
TGFB2 -1.00 -1.00 5.72 2.72 2.15 
PRSS23 -1.00 -1.00 7.36 5.92 1.98 
CITED2 -1.00 -1.00 5.88 1.82 2.17 
GPR176 -1.00 -0.97 7.38 1.46 3.04 
NPNT -1.00 -1.00 8.88 4.84 1.82 
FBXO2 -1.00 -1.00 5.90 3.11 2.37 
AMOT -1.00 -0.98 9.64 4.03 2.36 
KCNJ2 -1.00 -0.99 6.85 3.72 1.30 
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S100A10 -1.00 -1.00 8.96 3.16 1.52 
SLC35F2 -1.00 -0.99 6.09 2.16 2.70 
MFAP4 -1.00 -1.00 9.76 7.62 1.67 
MUM1L1 -1.00 -1.00 11.21 3.73 2.43 
CXXC4 -1.00 -1.00 7.16 2.70 0.99 
SHISA2 -1.00 -0.96 5.76 4.01 3.48 
TMEM88 -1.00 -1.00 8.28 4.20 1.69 
EPCAM -1.00 -1.00 8.01 1.42 3.70 
TSHZ1 -1.00 -1.00 5.77 3.55 2.49 
OSR1 -1.00 -1.00 5.91 4.90 3.03 
NDNF -1.00 -1.00 7.76 4.96 2.27 
FAM110B -1.00 -0.96 5.89 2.86 2.02 
TMEM200A -1.00 -0.99 6.61 4.55 2.47 
FLRT3 -1.00 -1.00 11.71 2.86 3.32 
RSPO2 -1.00 -0.98 5.72 4.60 2.39 
REEP1 -1.00 -1.00 9.03 4.04 0.85 
CTHRC1 -1.00 -1.00 8.53 4.27 2.74 
TMEM119 -1.00 -1.00 7.57 5.02 3.16 
HBZ -1.00 -0.99 7.10 2.84 4.27 
SLIT3 -1.00 -0.99 6.50 3.14 2.46 
CD248 -1.00 -0.98 7.22 6.15 2.98 
MAB21L2 -1.00 -1.00 8.17 2.87 2.09 
GPC6 -1.00 -1.00 6.09 3.08 1.87 
DSC3 -1.00 -0.98 7.70 2.95 1.05 
IFITM1 -1.00 -0.99 6.03 4.57 1.74 
CDH3 -1.00 -0.99 6.32 3.15 2.19 
MYL4 -1.00 -0.98 7.87 2.46 3.26 
AKR1B10 -1.00 -1.00 7.16 2.77 1.39 
HS6ST2 -1.00 -0.99 6.01 3.11 2.34 
CYTL1 -1.00 -1.00 6.76 3.67 0.92 
CDC42EP5 -1.00 -1.00 6.72 6.34 1.10 
IFITM1 -1.00 -0.99 6.51 4.56 1.64 
S1PR3 -0.96 -0.94 6.88 2.46 2.21 
TMEM100 -1.00 -0.99 5.96 3.95 2.50 
CLDN3 -1.00 -0.99 8.73 2.71 1.90 
THBD -1.00 -1.00 11.04 3.04 0.80 
SERPINA3 -0.98 -0.94 5.63 3.15 2.26 
SERPINA3 -0.98 -0.94 5.63 3.15 2.26 
TNNC1 -1.00 -1.00 5.77 3.58 3.10 
KCTD12 -0.94 -0.94 8.17 3.83 2.36 
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TGFBR3 -0.92 -0.89 5.03 6.45 1.87 
 
Table 10-5: Differentially expressed miRNAs during in vitro differentiation 
miRNA D6 D20 FC 
hsa-miR-122-5p 1.116173 11695.98 10478.64 
hsa-miR-122-3p 1.345 2331.818 1733.694 
hsa-miR-194-5p 34.51123 11761.56 340.8037 
hsa-miR-192-5p 65.5152 11588.42 176.8814 
hsa-miR-215-5p 71.58354 6714.885 93.80488 
hsa-miR-126-3p 61.17562 3826.199 62.54451 
hsa-miR-146b-5p 32.51346 1632.775 50.21843 
hsa-miR-660-5p 48.63475 2175.16 44.7244 
hsa-miR-367-3p 2648.167 156.3541 37.16921 
hsa-miR-22-3p 255.7126 8521.853 33.3259 
hsa-miR-99a-5p 241.8919 7184.949 29.70314 
hsa-miR-145-5p 89.83713 2113.623 23.52727 
hsa-miR-4277 53.41646 1162.553 21.76396 
hsa-miR-362-3p 53.32692 1126.184 21.11849 
hsa-miR-100-5p 285.2226 5645.148 19.79208 
hsa-miR-302c-5p 1513.711 322.8364 16.51097 
hsa-miR-148a-3p 756.7924 11612.42 15.34426 
hsa-miR-1271-5p 93.19828 1195.178 12.82403 
hsa-miR-27b-3p 622.1667 7229.333 11.61961 
hsa-miR-335-5p 316.9621 3646.825 11.50555 
hsa-miR-101-3p 318.1882 1137.315 11.47451 
hsa-miR-424-5p 281.3298 3198.852 11.37047 
hsa-miR-148b-3p 249.9862 2716.484 10.86653 
hsa-miR-532-3p 117.6664 1235.765 10.50228 
 
Table 10-6: mRNA-miRNA intensities and interactions for human differentiation 
Gene D6 D20 miRNA Source D6_miRNA D20_miRNA 
miRNA-
mRNA 
Interaction 
COL1A2 7.56 12.89 hsa-miR-367-3p Mirdb 2648.17 156.35 TRUE 
EPB41L3 7.69 9.44 
hsa-miR-1271-
5p Mirdb 93.20 1195.18 FALSE 
FOXA1 5.96 7.60 hsa-miR-4277 Mirdb 53.42 1162.55 FALSE 
PKIA 7.54 7.83 hsa-miR-27b-3p Mirdb 622.17 7229.33 FALSE 
ZFPM2 5.79 6.13 
hsa-miR-148b-
3p Mirdb 249.99 2716.48 FALSE 
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ZFPM2 5.79 6.13 hsa-miR-148a-3p Mirdb 756.79 11612.42 FALSE 
ZFPM2 5.79 6.13 hsa-miR-302c-5p Mirdb 1513.71 322.84 FALSE 
NPNT 4.63 8.93 hsa-miR-101-3p Mirdb 318.19 1137.31 FALSE 
NPNT 4.63 8.93 hsa-miR-362-3p Mirdb 53.33 1126.18 FALSE 
RIN2 6.28 8.44 hsa-miR-145-5p Mirdb 89.84 2113.62 FALSE 
RIN2 6.28 8.44 hsa-miR-101-3p Mirdb 318.19 1137.31 FALSE 
SOSTDC1 4.78 5.81 hsa-miR-367-3p Mirdb 2648.17 156.35 FALSE 
CDH11 8.31 9.94 hsa-miR-101-3p Mirdb 318.19 1137.31 FALSE 
CDH11 8.31 9.94 hsa-miR-4277 Mirdb 53.42 1162.55 FALSE 
CDH11 8.31 9.94 hsa-miR-27b-3p Mirdb 622.17 7229.33 FALSE 
SLC1A1 5.86 7.41 hsa-miR-101-3p Mirdb 318.19 1137.31 FALSE 
SLC1A1 5.86 7.41 
hsa-miR-1271-
5p Mirdb 93.20 1195.18 FALSE 
AMOT 6.42 7.74 hsa-miR-22-3p Mirdb 255.71 8521.85 FALSE 
SYT4 6.17 7.90 hsa-miR-101-3p Mirdb 318.19 1137.31 FALSE 
SYT4 6.17 7.90 hsa-miR-424-5p Mirdb 281.33 3198.85 FALSE 
CDH13 5.41 6.70 hsa-miR-660-5p Mirdb 48.63 2175.16 FALSE 
ALDH4A1 6.52 6.60 hsa-miR-27b-3p Mirdb 622.17 7229.33 FALSE 
PCDH7 5.69 6.32 hsa-miR-367-3p Mirdb 2648.17 156.35 FALSE 
LCP1 4.95 9.45 
hsa-miR-1271-
5p Mirdb 93.20 1195.18 FALSE 
PLOD2 8.44 10.26 
hsa-miR-1271-
5p Mirdb 93.20 1195.18 FALSE 
HAND1 4.66 10.62 hsa-miR-335-5p Mirdb 316.96 3646.82 FALSE 
TMEM100 4.78 6.51 hsa-miR-424-5p Mirdb 281.33 3198.85 FALSE 
KIFAP3 7.79 8.80 hsa-miR-302c-5p Mirdb 1513.71 322.84 FALSE 
FAM110B 6.33 7.00 hsa-miR-367-3p Mirdb 2648.17 156.35 FALSE 
SLIT2 8.16 9.22 hsa-miR-4277 Mirdb 53.42 1162.55 FALSE 
SLIT2 8.16 9.22 hsa-miR-424-5p Mirdb 281.33 3198.85 FALSE 
GPC6 7.87 8.19 hsa-miR-367-3p Mirdb 2648.17 156.35 FALSE 
COL2A1 8.00 6.37 
hsa-miR-148b-
3p Mirdb 249.99 2716.48 FALSE 
COL2A1 8.00 6.37 hsa-miR-148a-3p Mirdb 756.79 11612.42 FALSE 
PRTG 6.00 5.85 
hsa-miR-1271-
5p Mirdb 93.20 1195.18 FALSE 
FLRT3 7.33 8.82 hsa-miR-101-3p Mirdb 318.19 1137.31 FALSE 
FLRT3 7.33 8.82 hsa-miR-27b-3p Mirdb 622.17 7229.33 FALSE 
CDH10 5.75 8.09 hsa-miR-367-3p Mirdb 2648.17 156.35 TRUE 
SPARC 7.56 12.67 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
ODC1 10.68 12.96 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
CADM1 7.65 8.14 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
SOCS2 9.28 8.94 hsa-miR-194-5p MirTarbase 34.51 11761.56 FALSE 
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RGS2 7.56 9.72 hsa-miR-22-3p MirTarbase 255.71 8521.85 FALSE 
SOX9 6.46 6.49 hsa-miR-101-3p MirTarbase 318.19 1137.31 FALSE 
BIRC5 8.80 7.40 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
SERPINA3 4.82 7.47 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CYTL1 5.43 6.91 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CRISPLD2 5.25 9.90 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
SCRG1 7.62 6.81 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
THBD 5.72 6.91 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
TNNC1 7.80 7.19 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
TGFB2 5.05 6.10 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
LOXL1 7.10 8.35 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CDH3 7.08 9.64 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
BMP2 9.49 8.33 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CITED2 8.38 9.25 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
DIO1 3.22 7.68 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
PLAT 5.93 9.47 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
SOX9 6.46 6.49 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CLDN7 6.32 8.66 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CLEC11A 6.81 8.04 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
SMOC2 5.25 8.42 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
COL15A1 4.84 10.21 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CTHRC1 5.70 6.25 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
SOSTDC1 4.78 5.81 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CDKN1C 7.60 11.08 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CST1 7.74 7.11 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
COL3A1 6.32 13.38 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
PPP1R1A 5.89 6.45 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
BNC1 4.82 6.35 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CDH11 8.31 9.94 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
GATA5 4.08 6.39 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
SLC1A1 5.86 7.41 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
FAM198B 4.76 7.83 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CDX2 4.64 6.57 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
BIN1 6.99 8.79 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
IFITM1 12.76 8.60 hsa-miR-335-5p MirTarbase 316.96 3646.82 TRUE 
PROS1 6.40 8.42 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
TPD52L1 6.04 8.08 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CPE 9.53 9.69 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
TSC22D3 6.26 8.55 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
RCAN1 5.83 8.07 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
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RSPO2 4.40 6.01 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
LAMB1 7.60 9.88 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
KCTD12 5.52 7.99 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
WISP1 4.68 6.89 hsa-miR-335-5p MirTarbase 316.96 3646.82 FALSE 
CTHRC1 5.70 6.25 
hsa-miR-148b-
3p MirTarbase 249.99 2716.48 FALSE 
LOXL1 7.10 8.35 
hsa-miR-148b-
3p MirTarbase 249.99 2716.48 FALSE 
SNAI2 6.02 10.05 
hsa-miR-148b-
3p MirTarbase 249.99 2716.48 FALSE 
AKR1B10 5.65 6.25 hsa-miR-145-5p MirTarbase 89.84 2113.62 FALSE 
CLEC11A 6.81 8.04 hsa-miR-122-5p MirTarbase 1.12 11695.98 FALSE 
NODAL 8.88 5.13 hsa-miR-122-5p MirTarbase 1.12 11695.98 TRUE 
THBD 5.72 6.91 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
MT1F 8.95 7.18 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
KCTD12 5.52 7.99 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
ASRGL1 6.74 8.33 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
REEP1 5.39 8.15 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
PRSS23 5.72 8.64 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
FOXA1 5.96 7.60 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
PARM1 5.53 8.20 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
MNS1 6.40 5.94 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
TMEM200A 6.17 7.65 hsa-miR-215-5p MirTarbase 71.58 6714.89 FALSE 
TMEM200A 6.17 7.65 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
THBD 5.72 6.91 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
REEP1 5.39 8.15 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
PCDH7 5.69 6.32 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
ASRGL1 6.74 8.33 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
NPNT 4.63 8.93 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
MT1X 10.65 8.68 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
MNS1 6.40 5.94 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
FOXA1 5.96 7.60 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
MT1F 8.95 7.18 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
PARM1 5.53 8.20 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
PRSS23 5.72 8.64 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
KCTD12 5.52 7.99 hsa-miR-192-5p MirTarbase 65.52 11588.42 FALSE 
BIRC5 8.80 7.40 hsa-miR-101-3p MirTarbase 318.19 1137.31 FALSE 
E2F2 8.09 6.32 hsa-miR-22-3p MirTarbase 255.71 8521.85 FALSE 
S100A10 10.79 12.24 hsa-miR-100-5p MirTarbase 285.22 5645.15 FALSE 
ODC1 10.68 12.96 hsa-miR-100-5p MirTarbase 285.22 5645.15 FALSE 
KCTD12 5.52 7.99 hsa-miR-22-3p MirTarbase 255.71 8521.85 FALSE 
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